<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Research (Wash D C)</journal-id><journal-id journal-id-type="iso-abbrev">Research (Wash D C)</journal-id><journal-id journal-id-type="publisher-id">RESEARCH</journal-id><journal-title-group><journal-title>Research</journal-title></journal-title-group><issn pub-type="epub">2639-5274</issn><publisher><publisher-name>AAAS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7315394</article-id><article-id pub-id-type="doi">10.34133/2020/6925296</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Zichao</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ang</surname><given-names>Melgious Jin Yan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Siew Yin</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yi</surname><given-names>Zhigao</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Goh</surname><given-names>Yi Yiing</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Shuangqian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiaosong</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5433-8611</contrib-id><name><surname>Zhang</surname><given-names>Hongjie</given-names></name><email>hjzhang2019@mail.tsinghua.edu.cn</email><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7004-6408</contrib-id><name><surname>Huang</surname><given-names>Wei</given-names></name><email>iamwhuang@nwpu.edu.cn</email><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2517-5790</contrib-id><name><surname>Liu</surname><given-names>Xiaogang</given-names></name><email>chmlx@nus.edu.sg</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I9">
<sup>9</sup>
</xref><xref ref-type="aff" rid="I10">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Chemistry, National University of Singapore, Singapore 117543, Singapore</aff><aff id="I2">
<sup>2</sup>NUS Graduate School for Integrative Sciences and Engineering, Singapore 117456, Singapore</aff><aff id="I3">
<sup>3</sup>Frontiers Science Center for Flexible Electronics &#x00026; Shaanxi Institute of Flexible Electronics, Northwestern Polytechnical University, Xi'an 710072, China</aff><aff id="I4">
<sup>4</sup>Sports Medical Centre, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, China</aff><aff id="I5">
<sup>5</sup>State Key Laboratory of Rare Earth Resource Utilization, Chang Chun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China</aff><aff id="I6">
<sup>6</sup>Department of Oncology, The Fourth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100048, China</aff><aff id="I7">
<sup>7</sup>Department of Chemistry, Tsinghua University, Beijing 100084, China</aff><aff id="I8">
<sup>8</sup>Key Laboratory of Flexible Electronics &#x00026; Institute of Advanced Materials, Nanjing Tech University, Nanjing 211816, China</aff><aff id="I9">
<sup>9</sup>The N.1 Institute for Health, National University of Singapore, Singapore</aff><aff id="I10">
<sup>10</sup>Joint School of National University of Singapore and Tianjin University, International Campus of Tianjin University, Fuzhou 350807, China</aff><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>6925296</elocation-id><history><date date-type="received"><day>19</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Zichao Luo et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>Exclusive Licensee Science and Technology Review Publishing House. Distributed under a Creative Commons Attribution License (CC BY 4.0).</license-p></license></permissions><abstract><p>The World Health Organization (WHO) has declared the outbreak of 2019 novel coronavirus, known as 2019-nCoV, a pandemic, as the coronavirus has now infected over 2.6 million people globally and caused more than 185,000 fatalities as of April 23, 2020. Coronavirus disease 2019 (COVID-19) causes a respiratory illness with symptoms such as dry cough, fever, sudden loss of smell, and, in more severe cases, difficulty breathing. To date, there is no specific vaccine or treatment proven effective against this viral disease. Early and accurate diagnosis of COVID-19 is thus critical to curbing its spread and improving health outcomes. Reverse transcription-polymerase chain reaction (RT-PCR) is commonly used to detect the presence of COVID-19. Other techniques, such as recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), clustered regularly interspaced short palindromic repeats (CRISPR), and microfluidics, have allowed better disease diagnosis. Here, as part of the effort to expand screening capacity, we review advances and challenges in the rapid detection of COVID-19 by targeting nucleic acids, antigens, or antibodies. We also summarize potential treatments and vaccines against COVID-19 and discuss ongoing clinical trials of interventions to reduce viral progression.</p></abstract><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>21771135</award-id></award-group><award-group><funding-source>National Research Foundation Singapore</funding-source><award-id>NRF-NRFI05-2019-0003</award-id></award-group><award-group><funding-source>Agency for Science, Technology and Research</funding-source><award-id>A1983c0038</award-id><award-id>A1883c0011</award-id></award-group><award-group><funding-source>Ministry of Education - Singapore</funding-source><award-id>MOE2017-T2-2-110</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The recent global outbreak of COVID-19 has led to a public health emergency. As of April 23, 2020, over 2.6 million confirmed cases were reported to WHO from 213 countries and territories [<xref rid="B1" ref-type="bibr">1</xref>]. On January 30, 2020, WHO declared the COVID-19 outbreak as the sixth public health emergency of international concern, following H1N1 (2009), Polio (2014), Ebola in West Africa (2014), Zika (2016), and Ebola (2019) [<xref rid="B2" ref-type="bibr">2</xref>]. The rapid global expansion and rising fatalities have raised grave concerns on the viral spread across the globe. With the rapid increase in the number of confirmed cases, WHO classified the global COVID-19 outbreak as a pandemic on March 11, 2020 [<xref rid="B3" ref-type="bibr">3</xref>]. COVID-19 can spread from person-to-person and animal, and transmission of infection may occur with exposure to symptomatic patients or asymptomatic individuals.</p><p>Coronaviruses (CoVs) (corona: crown-like shape) are enveloped, single-stranded RNA viruses that belong to the order <italic>Nidovirales</italic> in the subfamily <italic>Coronaviridae</italic>. CoVs are divided into four genera: alpha (<italic>&#x003b1;</italic>), beta (<italic>&#x003b2;</italic>), gamma (<italic>&#x003b3;</italic>), and delta (<italic>&#x003b4;</italic>) (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>) [<xref rid="B4" ref-type="bibr">4</xref>]. Alpha- and beta-CoVs infect mammals, while gamma- and delta-CoVs primarily infect birds [<xref rid="B5" ref-type="bibr">5</xref>]. Before December 2019, six types of CoVs had infected humans, including two <italic>&#x003b1;</italic>-CoVs (HCoV-229E and HCoV-NL63) and four <italic>&#x003b2;</italic>-CoVs (HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV). The first two <italic>&#x003b2;</italic>-CoVs (HCoV-OC43 and HCoV-HKU1) mainly cause self-limiting upper respiratory infections, while the other two <italic>&#x003b2;</italic>-CoVs (SARS-CoV and MERS-CoV) are mostly associated with severe respiratory illness [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Full-genome sequence analysis of 2019-nCoV confirms that it is a <italic>&#x003b2;</italic>-CoV, distinct from SARS-CoV and MERS-CoV [<xref rid="B8" ref-type="bibr">8</xref>]. Investigations reveal that 2019-nCoV shares ~80% sequence identity with SARS-CoV while maintaining ~89% nucleotide identity to the SARS-like CoVs (ZC45 and ZXC21) from bats [<xref rid="B9" ref-type="bibr">9</xref>]. A recent report suggests that a bat CoV (RatG13) is 96% identical to 2019-nCoV [<xref rid="B10" ref-type="bibr">10</xref>].</p><p>A typical CoV genome is a single-stranded, positive-sense RNA (+ssRNA) (~30&#x02009;kb) enclosed by a 5&#x02032;-cap and 3&#x02032;-poly-A tail [<xref rid="B11" ref-type="bibr">11</xref>]. The genome size of 2019-nCoV is 29,891 nucleotides, encoding 9860 amino acids, with a G+C content of 38% [<xref rid="B12" ref-type="bibr">12</xref>]. The 2019-nCoV genome contains two flanking untranslated regions (UTRs) on 5&#x02032;- and 3&#x02032;-terminals, one single long open reading frame <italic>1ab</italic> (ORF<italic>1ab</italic>) encoding a polyprotein and at least five other ORFs encoding structural proteins, and eight accessory proteins (<xref ref-type="fig" rid="fig1">Figure 1(c)</xref>). The first ORF (ORF<italic>1a/b</italic>) is about two-thirds of the whole-genome length and encodes the 16 nonstructural proteins (nsp1-16). The other one-third of the genome contains four ORFs encoding the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, whereas other ORFs encode accessory proteins (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref> and (c)). Most of the nonstructural proteins are essential for 2019-nCoV replication, while structural proteins are responsible for virion assembly and viral infection [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. The M and E proteins are required in viral assembly, while the N protein involves RNA genome assembly.</p><p>The S protein, a surface-located trimeric glycoprotein of CoVs, is the primary determinant of CoV tropism, as it binds to the membrane receptor on host cells, mediating viral and cellular membrane fusion [<xref rid="B14" ref-type="bibr">14</xref>]. The S protein of 2019-nCoV reportedly binds to angiotensin-converting enzyme 2 (ACE2), a homolog of ACE on host cell membranes, contributing to 2019-nCoV cell invasion [<xref rid="B15" ref-type="bibr">15</xref>]. Moreover, this particular S protein shows a higher binding affinity to ACE2 than the S protein of SARS-CoV, enabling 2019-nCoV to invade host cells more effectively [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. Recently, a transmembrane glycoprotein, CD147, also known as Basigin or EMMPRIN, has been confirmed as another receptor for binding of the 2019-nCoV S protein, thereby mediating viral invasion [<xref rid="B18" ref-type="bibr">18</xref>].</p><p>The E protein is an integral membrane protein that regulates viral life cycles, including pathogenesis, envelope formation, assembly, and budding [<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>]. Among the four structural proteins, protein E appears to have the highest antigenicity and the most significant potential as an immunogenic target, highlighting the possibility of developing protein E-derived peptides as a 2019-nCoV vaccine [<xref rid="B22" ref-type="bibr">22</xref>]. Systemic studies of proteins S and E have inspired scientists to take creative approaches to design anti-COVID-19 drugs.</p><p>Although some COVID-19 patients show no symptoms, most patients have some common symptoms such as fever, cough, fatigue, sputum production, shortness of breath, sore throat, and headache. In some severe cases, infections can cause pneumonia, severe acute respiratory syndrome, kidney failure, and death. According to the WHO-China joint report [<xref rid="B23" ref-type="bibr">23</xref>], on average, people infected with 2019-nCoV develop mild respiratory symptoms and fever, 5-6 days after infection (mean incubation period, 5-6 days; range, 1-14 days). People over 60 years of age and those with hypertension, diabetes, or cardiovascular diseases are at high risk for severe illness and death. In comparison, children under 19 years appear to be infected minimally by 2019-nCoV (around 2.4% of all reported cases). Based on the Chinese Center for Disease Control and Prevention (China CDC) report (from 72,314 patient records, dated 11 February 2020), among the confirmed cases, 86.6% of patients are 30-79 years of age, 80.9% of patients have mild-to-moderate disease, 13.8% have a severe illness, and 6.1% are critically ill [<xref rid="B24" ref-type="bibr">24</xref>]. Notably, the mortality rate of children under 19 years is 0.2%, while people aged over 80 years have the highest mortality rate of 14.8%.</p><p>Currently, there are no effective antiviral drugs or specific vaccines against COVID-19. Thus, there is an urgent need for rapid detection to prevent further spread, to reduce the intensity of the pandemic, and to slow the increase in cases. Recently, several new technologies, including LAMP-LFA, RPA-LFA, RPA-CRISPR, and other nanomaterial-based IgG/IgM kits, have been adopted for 2019-nCoV detection. A significant number of drug candidates, including chemical drugs, biological drugs, nutritional interventions, and traditional Chinese medicine (TCM), have been proposed for clinical trials after the 2019-nCoV outbreak. In this review, we concentrate on the most significant developments in 2019-nCoV detection and provide an overview of medical treatments and vaccines currently in development to combat and contain the disease.</p></sec><sec id="sec2"><title>2. 2019-nCoV Detection</title><p>According to the <italic>Diagnosis and Treatment Guidelines for COVID</italic>-<italic>19</italic> (7<sup>th</sup> edition), COVID-19 cases can be divided into suspected cases and confirmed cases [<xref rid="B25" ref-type="bibr">25</xref>]. Diagnostic methods for 2019-nCoV are determined by the intrinsic properties of the virus and biomarkers that hosts exhibit after infection. These biomarkers include viral proteins and nucleic acids, as well as antibodies induced in response to viral infection. The most common 2019-nCoV detection methods include viral nucleic acid detection and serum antibody (IgG or IgM) detection. A confirmed case should have at least one of the following criteria: (i) a positive result for 2019-nCoV nucleic acid, using real-time PCR tests from respiratory or blood samples; (ii) a high homogeneity between viral gene sequencing from respiratory or blood samples and known 2019-nCoV; and (iii) serum samples positive for IgM or IgG to 2019-nCoV, or seroconversion in IgG, or a fourfold or more significant increase in IgG antibody titer to 2019-nCoV in the recovery phase than in the acute phase [<xref rid="B25" ref-type="bibr">25</xref>].</p><sec id="sec2.1"><title>2.1. Nucleic Acid Targeting</title><sec id="sec2.1.1"><title>2.1.1. High-Throughput Sequencing (2<sup>nd</sup>-Generation Sequencing)</title><p>High-throughput sequencing (HTS) technology contains various strategies that depend on a combination of library preparation, sequencing and mapping, genome alignment, and data analysis [<xref rid="B26" ref-type="bibr">26</xref>] (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>). Unlike the 1977 Sanger sequencing method (1<sup>st</sup>-generation sequencing) [<xref rid="B27" ref-type="bibr">27</xref>], 2<sup>nd</sup>-generation sequencing has been widely applied in genome sequencing, transcriptional profiling (RNA-seq) disease mapping, and population genetic studies. The whole-genome nucleotide sequence of 2019-nCoV was identified and compared with the full-length genome sequence of coronavirus from bats [<xref rid="B10" ref-type="bibr">10</xref>] through HTS. HTS-based technology is also applied to detect 2019-nCoV. For example, Wang et al. developed a HTS method based on nanopore target sequencing (NTS) by harnessing the benefits of target amplification and long-reads for real-time nanopore sequencing [<xref rid="B28" ref-type="bibr">28</xref>].</p><p>This NTS strategy detects 2019-nCoV with higher sensitivity (100-fold) than standard qPCR, simultaneously with other respiratory viruses within 6-10&#x02009;h. Moreover, all targeted regions can be identified by NTS in higher copies of samples (1000-3000 copies/mL) within 10&#x02009;min, indicating the potential for rapid detection of an outbreak in the clinic. For 1&#x02009;h sequencing data, reads mapped to 2019-nCoV differed remarkably from those of negative controls in all targeted regions at concentrations ranging from 10 to 3000 copies/mL. Importantly, NTS can identify mutated nucleic acids. However, the NTS platform cannot readily detect highly degraded nucleic acid fragments that are less than 200 base pairs in length [<xref rid="B29" ref-type="bibr">29</xref>]. Moreover, the strategy requires tedious sample preparation and lengthy turnaround time.</p><p>Although HTS technology provides fast, low-cost DNA sequencing, it is not suitable for detection in clinics. On the other hand, the HTS strategy may be suitable for amplicon sequencing or de novo sequencing of a whole genome [<xref rid="B30" ref-type="bibr">30</xref>].</p></sec><sec id="sec2.1.2"><title>2.1.2. Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)</title><p>RT-PCR is considered the gold standard to detect nucleic acids extracted from 2019-nCoV specimens qualitatively. Positive results indicate infection with 2019-nCoV. RT-PCR is an advanced technique for coronavirus detection because of its optimized sensitivity, specificity, and simplicity for quantitative assay [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. It provides accurate and reliable identification for confirmed and suspected cases. There are many commercial 2019-nCoV detecting kits with oligonucleotide primers and probes (SYBR Green or TaqMan chemistries) for detecting double genes of 2019-nCoV (nucleocapsid N gene and ORF<italic>1ab</italic>/E/ORF<italic>1b</italic>/S gene). This strategy usually requires four steps: sample collection (respiratory swabs), sample preparation (RNA isolation), one-step qRT-PCR, and data analysis (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>) [<xref rid="B33" ref-type="bibr">33</xref>]. The evaluation procedure typically lasts 4-6&#x02009;h. Recently, Roche (Indiana, USA) developed two automated cobas&#x000ae; 2019-nCoV test systems: cobas&#x000ae; 6800 and cobas&#x000ae; 8800 (approved in testing patient samples by the US FDA), which can process up to 384 results and 1056 results in an 8-hour shift, respectively [<xref rid="B34" ref-type="bibr">34</xref>]. The tests produce results in about 3.5&#x02009;h and can process up to 4128 results in 24&#x02009;h, boosting screening capacity to help restrain the sudden growing epidemic in the USA. RT-PCR is widely applicable to 2019-nCoV detection in the clinic, but limitations of this technology are obvious, such as high false-negative rate and low sensitivity. False-negative results may occur due to the following factors: first, mutations in the primers and probe-target regions in the 2019-nCoV genome [<xref rid="B32" ref-type="bibr">32</xref>]; second, low viral load present in test specimens, improper extraction of nucleic acid from clinical samples, or inappropriate restrictions on sample collection, transportation, or handling [<xref rid="B31" ref-type="bibr">31</xref>]. Real-time RT-PCR has been adopted as the gold standard diagnostic approach for 2019-nCoV worldwide. However, RT-PCR is time-consuming (4-6&#x02009;h) and requires well-equipped laboratories and skilled technicians, thereby limiting full deployment in developing countries.</p></sec><sec id="sec2.1.3"><title>2.1.3. Reverse Transcription- Isothermal Amplification (RT-IAMP)-Based Detection</title><p>Isothermal amplification technology has been developed to eliminate the need for a high-precision instrument in RT-PCR assays. This approach can amplify DNA at isothermal conditions without a thermocycler [<xref rid="B35" ref-type="bibr">35</xref>]. There are mainly four isothermal amplification technologies for nucleic acid detection: LAMP, RPA, nucleic acid sequence-based amplification (NASBA), and transcription-mediated amplification (TMA) [<xref rid="B36" ref-type="bibr">36</xref>]. In NASBA and TMA assays, input RNA is converted to a double-stranded DNA intermediate with a promoter region. Detection of RNA using DNA polymerase-based amplification requires a reverse transcriptase step. LAMP and RPA do not require thermal or chemical melting with the aid of enzymes. Combined with a visual detection platform, such as a lateral flow assay (LFA) or organic dyes, LAMP and RPA have been widely employed in viral detection kits.</p><p>LAMP is a rapid, one-step amplification technique that amplifies nucleic acids with high sensitivity and specificity at an optimal temperature of 65&#x000b0;C [<xref rid="B37" ref-type="bibr">37</xref>]. LAMP processing comprises three steps: an initial step, a cycling amplification step, and an elongation step (<xref ref-type="fig" rid="fig3">Figure 3(a)</xref>). LAMP employs six primers to amplify targeted genes by creating stem-loop structures that promote new DNA synthesis using a DNA polymerase with strand displacement activity. The two inner primers (FIP, BIP) and two outer primers (F3, B3), along with loop structures (LF, LB), create multiple initiating sites in the growing DNA products, enabling rapid amplification. LAMP is also highly specific since the amplification reaction occurs only when the primers correctly recognize all six regions. A reverse transcriptase step is included in the LAMP reaction to allow RNA targets to be detected [<xref rid="B38" ref-type="bibr">38</xref>].</p><p>RT-LAMP offers improved sensitivity and specificity in screening SARS-CoV, HCoV-NL63, and MERS-CoV compared to conventional real-time RT-PCR [<xref rid="B39" ref-type="bibr">39</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>]. Recently, Yu et al. used a commercial LAMP kit to amplify fragmented ORF<italic>1ab</italic> genes of 2019-nCoV (<xref ref-type="fig" rid="fig3">Figure 3(b)</xref> and (c)) [<xref rid="B42" ref-type="bibr">42</xref>]. They optimized the LAMP system through incubation at 65&#x000b0;C for different periods using a 2019-nCoV-positive RNA sample as the template. Results require a 15&#x02009;min reaction time at 65&#x000b0;C, and detection sensitivity is comparable to that of the TaqMan-based qPCR approach (10 copies). RT-LAMP employs two additional protocols for 2019-nCoV RNA detection. Park et al. performed RT-LAMP at 65&#x000b0;C for 40&#x02009;min to identify the nsp3, S, and N genes of 2019-nCoV using colorimetric detection [<xref rid="B43" ref-type="bibr">43</xref>]. The sensitivity of this RT-LAMP assay was 100 copies of 2019-nCoV RNA. The other RT-LAMP protocol was conducted at 63&#x000b0;C for 30&#x02009;min to detect the ORF<italic>1ab</italic>, E, and N genes simultaneously [<xref rid="B44" ref-type="bibr">44</xref>]. The results confirmed the specific nature of ORF<italic>1ab</italic> and the high sensitivity of the N gene. Based on an analysis of 208 clinical specimens, the sensitivity of this RT-LAMP was similar to conventional RT-PCR, and the specificity was 99%. Interestingly, EI-Tholoth et al. designed a two-stage isothermal amplification procedure by combining RPA (37&#x000b0;C) with LAMP (63&#x000b0;C) to detect synthesized DNA fragments of 2019-nCoV [<xref rid="B45" ref-type="bibr">45</xref>]. The test was performed in closed tubes within 1&#x02009;h using either fluorescence or colorimetric detection. This method has a sensitivity of 100 times better than conventional LAMP and RT-PCR, suggesting a rapid, sensitive, point-of-care test for use at home.</p><p>RPA is an isothermal DNA amplification method that utilizes a specific combination of enzymes and proteins (recombinase, single-strand binding (SSB) protein, and strand-displacing DNA polymerase) to amplify target genes rapidly at a constant low temperature between 25 and 42&#x000b0;C in as little as 15&#x02009;min [<xref rid="B46" ref-type="bibr">46</xref>]. RPA usually requires four steps to achieve DNA amplification: formation of a recombinase-primer complex, strand invasion, D-loop formation (stabilized by SSB, DNA polymerization through the use of strand-displacing DNA polymerase), and DNA amplification (<xref ref-type="fig" rid="fig3">Figure 3(d)</xref>) [<xref rid="B47" ref-type="bibr">47</xref>]. Results of RPA can be detected by agarose gel electrophoresis, quantitatively measured using TwistAmp<sup>&#x02122;</sup> probes, or simply applied in lateral flow assays. Apart from DNA target amplification, RPA formats have been developed for the detection of RNA targets (RT-RPA) by adding a reverse transcriptase enzyme to reaction mixtures [<xref rid="B48" ref-type="bibr">48</xref>]. Because RPA- (RT-RPA-) based detection achieves more rapid and sensitive results and operates efficiently, it has been widely adopted to detect animal and human pathogens, such as hand, foot, and mouth disease (HFMD) virus, human immunodeficiency virus (HIV), bovine coronavirus, or MERS-CoV [<xref rid="B49" ref-type="bibr">49</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>]. Currently, RPA has been applied to detect 2019-nCoV, in combination with other technologies, such as CRISPR or microfluidic technology.</p></sec><sec id="sec2.1.4"><title>2.1.4. Clustered Regularly Interspaced Short Palindromic Repeat- (CRISPR-) Based Detection</title><p>The CRISPR-associated protein 9 (Cas9) system (CRISPR/Cas9) is a revolutionary gene-editing toolbox that can modify target genes with high precision and that can control various types of genetic diseases in preclinical studies [<xref rid="B53" ref-type="bibr">53</xref>&#x02013;<xref rid="B56" ref-type="bibr">56</xref>]. Due to the collateral nucleic acid cleavage activity of Cas effectors, CRISPR/Cas systems have also been widely used in nucleic acid detection with fluorescent and colorimetric signals [<xref rid="B56" ref-type="bibr">56</xref>]. There are mainly two kinds of CRISPR/Cas systems for diagnostics, based on the cutting activity of Cas protein on nucleic acids outside of the gRNA target site: the CRISPR/Cas13a and CRISPR/Cas12a systems.</p><p>The CRISPR/Cas13a system (specific high-sensitivity enzymatic reporter unlocking (SHERLOCK)) was developed by Zhang's group, based on the collateral effect of an RNA-guided and RNA-targeting CRISPR effector, Cas13a (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>) [<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>]. The detection system is highly sensitive and specific because it is capable of single-molecule nucleic acid detection. Subsequently, they developed an enhanced SHERLOCK version 2 (SHERLOCKv2) detection system with a 3.5-fold improvement in detection sensitivity and lateral flow readout. SHERLOCKv2 has been used to detect dengue and Zika virus single-stranded RNA or mutations in clinical samples, showing great potential for multiplexable, portable, rapid detection of nucleic acids [<xref rid="B59" ref-type="bibr">59</xref>]. Recently, they combined RT-RPA technology with the SHERLOCK system (namely CRISPR diagnostics) to detect the S and ORF<italic>1ab</italic> genes of 2019-nCoV (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref> and (c)) [<xref rid="B60" ref-type="bibr">60</xref>]. The CRISPR diagnostics-based test can be conducted in 1 hour and can be read using a dipstick. The analysis is performed at 37&#x000b0;C and 42&#x000b0;C, and its detection sensitivity is ten copies per microliter of input, exhibiting unique advantages, such as high sensitivity, specificity, speed, and suitability for point-of-care testing. However, this approach needs to be validated using real patient samples.</p><p>Unlike the CRISPR/Cas13a system, the CRISPR/Cas12a system is based on the collateral effect of Cas12a on single-stranded DNA (ssDNA). Chen and colleagues combined Cas12a ssDNase activation with RPA technology to create a new approach, named DNA endonuclease-targeted CRISPR trans reporter (DETECTR), with attomolar sensitivity for DNA detection (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>) [<xref rid="B61" ref-type="bibr">61</xref>]. DETECTR was also validated with clinical samples, showing the capacity for rapid, specific detection of human papillomavirus (HPV) [<xref rid="B61" ref-type="bibr">61</xref>]. Recently, DETECTR was investigated to identify the nucleic acid of 2019-nCoV. Lucia et al. applied the DETECTR (CRISPR-Cas12a and RT-RPA) to detect the RNA-dependent RNA polymerase (RdRp), ORF<italic>1b</italic>, and ORF<italic>1ab</italic> genes of 2019-nCoV using synthetic RNA fragments as samples [<xref rid="B62" ref-type="bibr">62</xref>]. Remarkably, all steps of the test were completed in 1&#x02009;h, and results were visible to the unaided eye. The limit of detection for ORF<italic>1ab</italic> was ten copies/<italic>&#x003bc;</italic>L. The advantages of this method are its portability and low cost (~US$2 per reaction). But this proposed approach also needs to be validated with clinical samples before commercialization. Another DETECTR-based 2019-nCoV detection strategy was developed by Chiu's lab [<xref rid="B63" ref-type="bibr">63</xref>]. They employed LAMP, CRISPR/Cas12, and lateral flow assay to detect the E and N genes of 2019-nCoV in clinical samples. This protocol supplied rapid (~30&#x02009;min), low-cost, and accurate (100% specific vs. 90% specific for qRT-PCR) detection of 2019-nCoV in respiratory swab samples. Realistically, CRISPR/Cas-based 2019-nCoV detection technology is highly specific, rapid, and low cost, but the detection strategy also needs to be validated using clinical samples.</p></sec><sec id="sec2.1.5"><title>2.1.5. Microfluidic-Based Detection</title><p>The abovementioned methods are based on relative quantification, because they require external calibration with genetic standards or inner reference DNA templates, resulting in unavoidable errors and other uncertainties. On the contrary, methods that do not need standard curves can provide a quantitative analysis of nucleic acids using absolute quantification of genetic copies. Recently, digital PCR and digital LAMP have been achieved with microelectromechanical and microfluidic technologies [<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>].</p><p>Microfluidic or lab-on-a-chip techniques use microsized channels to process or manipulate fluids. Microfluidics has been widely utilized in various fields, including drug screening, tissue engineering, disease diagnostics, and nucleic acid detection [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>]. Based on its portability and ultralow sample consumption, microfluidics shows significant promises in clinical applications [<xref rid="B68" ref-type="bibr">68</xref>]. Regarding nucleic acid analyses, microfluidic devices aliquot diluted nucleic acid samples into hundreds to millions of discrete nanoliter chambers. The isolated chambers contain only one or zero target molecule according to a Poisson distribution. Consequently, the absolute copy number of target nucleic acid can be calculated from the number of positive and negative reactions, based on the Poisson distribution formulas [<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>]. Both digital PCR and digital LAMP have employed microfluidics for pathogen analysis, which is suitable for COVID-19 detection. For instance, Ottesen and colleagues used digital PCR to amplify and analyze multiple genes on a microfluidic chip [<xref rid="B71" ref-type="bibr">71</xref>]. This chip consisted of parallel chambers and micromechanical valves. The micromechanical valves segmented chambers into independent PCR reactors after the sample flowed into chambers through connection channels. The chip was able to detect several kinds of genes with parallel sample panels. Digital PCR can also be conducted with droplets generated by the microfluidic chip. However, the detection of fluorescent signals in droplets requires special instruments, such as flow cytometers, which may limit its application in point-of-care testing. Additionally, the high temperature in PCR amplification tends to evaporate the reaction liquid (nanoliter or even femtoliter), leading to unacceptable errors. Using airtight devices or high pressure delays liquid evaporation but complicates the devices and increases testing costs.</p><p>Digital LAMP is more compatible with microfluidics than digital PCR because it is executed at a moderate temperature. This simplifies microfluidic devices and reduces testing costs. Many microfluidic devices have been reported for nucleic acid detection using digital LAMP, such as self-digitization chips, self-priming compartmentalization chips, and droplet-generation chips [<xref rid="B72" ref-type="bibr">72</xref>&#x02013;<xref rid="B74" ref-type="bibr">74</xref>]. As an example, Xia et al. designed a mathematical model using the Monte Carlo method according to the theories of Poisson statistics and chemometrics [<xref rid="B70" ref-type="bibr">70</xref>]. The mathematical model illustrated influential factors of the digital LAMP assay, guiding the design and analysis of digital LAMP devices. Based on the established mathematical model, they fabricated a spiral chip with 1200 chambers (9.6&#x02009;nL) for pathogen detection (<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>&#x02013;(c)). This spiral chip operated at 65&#x000b0;C without visible liquid evaporation and achieved a quantitative analysis of nucleic acids over four orders of magnitude in concentration with a detection limit of 87 copies per mL. This portable gadget shows significant promise in future point-of-care testing.</p><p>Microfluidics, combined with enzyme-DNA nanostructures, is also applied to detecting 2019-nCoV. Ho et al. developed a modular detection platform (termed enVision) consisting of an integrated circuit of enzyme-DNA nanostructures for direct and versatile detection of pathogen nucleic acids from infected cells [<xref rid="B75" ref-type="bibr">75</xref>]. Built-in enzymatic cascades in the enVision microfluidic system supply a rapid color readout for detecting HPV. The assay is fast (&#x0003c;2&#x02009;h), sensitive (limit&#x02009;of&#x02009;detection &#x0003c; 10&#x02009;attmol), and readily quantified with smartphones. Recently, they adopted the enVision microfluidic system to detect 2019-nCoV [<xref rid="B76" ref-type="bibr">76</xref>]. Preliminary results showed that the enVision platform is sensitive, accurate, fast (within 0.5-1&#x02009;h), and inexpensive (less than $1 per test kit). This novel platform works at room temperature and does not require a heater or special pumps, and it uses a minimal amount of samples, making it highly portable. However, this platform needs to be further validated with real clinical samples.</p></sec></sec><sec id="sec2.2"><title>2.2. Target Antigen and Antibody</title><p>As mentioned above, the primary diagnostic methods are virological detection involving viral nucleic acids. Another approach to detection is with serological assays that measure antigens or antibodies present in the host. Such testing provides vital information about host exposure to 2019-nCoV and is useful for detection and surveillance purposes. For instance, this method greatly helps medical professionals to determine whether some recovered patients have a higher risk of reinfection. However, the disadvantage is that one should be cautioned that in the early stages of COVID-19 infection, the host's antibodies are often not within the detectable range of serological test kits. Besides, there was no proven evidence on the duration of IgM or IgG antibodies circulating in the host after recovery. It could be merely a short time frame for detection. As such, serological tests should not be solely used for COVID-19 diagnosis.</p><sec id="sec2.2.1"><title>2.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)</title><p>Early diagnosis of 2019-nCoV infection is of utmost importance both for medical teams to manage patients effectively and for policymakers to curb the viral spread. Presently, ELISA in cell culture extracts has proven to be the working &#x0201c;gold standard&#x0201d; for laboratory diagnosis of 2019-nCoV [<xref rid="B77" ref-type="bibr">77</xref>]. ELISA is a plate-based assessment method for detecting and quantifying biomolecules, including peptides, proteins, antibodies, and hormones. ELISA techniques depend on specific antibodies to bind target antigens and a detection system to indicate the presence of antigen binding. In an ELISA, an antigen must be immobilized to a solid surface and then complexed with an antibody that is linked to an enzyme. Detection is accomplished by assessing the conjugated enzyme activity after incubation with a substrate to produce a measurable product [<xref rid="B78" ref-type="bibr">78</xref>]. Recently, coronavirus proteins have been widely used in ELISA to diagnose SARS-CoV or other viruses within the coronavirus family [<xref rid="B79" ref-type="bibr">79</xref>].</p><p>In a bold, novel approach, a team of infectious disease experts in Singapore utilized an ELISA against 2019-nCoV to ascertain that suspected subjects were infected with COVID-19 and discovered the connection between two COVID-19 clusters in the local community [<xref rid="B80" ref-type="bibr">80</xref>]. Using blood samples taken from alleged COVID-19 patients, the researchers detected antibodies targeting the spike protein that prevented the virus from killing cells in laboratory tests. They verified that a couple allegedly infected with COVID-19 had the disease because they had exceedingly elevated levels of virus-specific antibodies in their blood. Interestingly, PCR tests on the couple yielded negative results. Because the couple had recovered from the 2019-nCoV infection, they had no viral genetic materials in their bodies, but the antibodies persisted. There were also other reports of using ELISA to diagnose 2019-nCoV infection [<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>]. Each study confirmed the high reproducibility and specificity of ELISA in diagnosing COVID-19 patients accurately in clinics.</p></sec><sec id="sec2.2.2"><title>2.2.2. IgG/IgM Lateral Flow Assay (LFA)</title><p>Research has established that the presence of immunoglobulin M (IgM) indicates a primary defense against viral infections. This IgM defense occurs before the production of high-affinity and adaptive immunoglobulin G (IgG) that is critical for prolonged immunity and immunological memory [<xref rid="B83" ref-type="bibr">83</xref>]. From a previous study on SARS infections, both IgM and IgG antibodies could be detected in the patient blood after 3-6 days and beyond 8 days, respectively [<xref rid="B84" ref-type="bibr">84</xref>]. Given that 2019-nCoV belongs to the same family of coronaviruses including MERS and SARS, 2019-nCoV should also generate IgM and IgG antibodies in infected humans. Therefore, the detection of IgM and IgG antibodies may provide epidemiologists with crucial information on viral infection of test subjects, allowing them to adjust policies to combat the pandemic more effectively.</p><p>Point-of-care lateral flow immunoassays are performed qualitatively to quickly determine the presence of 2019-nCoV by detecting anti-2019-nCoV IgM and anti-2019-nCoV IgG antibodies in human plasma, serum, or whole blood. A typical device is shown in <xref ref-type="fig" rid="fig6">Figure 6(a)</xref>. Reddish-purple lines in the readout indicate the presence of 2019-nCoV IgM and IgG antibodies in the sample. LFA is based on the lateral chromatographic flow of reagents that bind and interact with the sample. As the sample flows through the test device, starting at the sample pad region, the anti-2019-nCoV IgM and IgG antibodies, if present, bind tightly to 2019-nCoV antigen-labeled gold nanoparticles, located on the conjugated pad. When conjugated products in the sample continue to move up the strip, anti-2019-nCoV IgM antibodies and anti-2019-nCoV IgG antibodies bind to anti-human IgM (M line) or anti-human IgG (G line), respectively. No visible lines can be seen when the specimen does not contain anti-2019-nCoV antibodies because no labeled complexes bind at the test zone. IgG-labeled gold colorimetric nanoparticles serve as the control when they bind to anti-rabbit IgG antibodies at the control line (C) (<xref ref-type="fig" rid="fig6">Figure 6(b)</xref>). LFA has proven useful in detecting 2019-nCoVIgM/IgG antibodies in clinical studies, demonstrating 88.66% test sensitivity and 90.63% specificity in human blood, serum, and plasma samples. Results from six patients are shown in <xref ref-type="fig" rid="fig6">Figure 6(c)</xref>. Common 2019-nCoV detection methods are summarized in <xref rid="tab1" ref-type="table">Table 1</xref>.</p></sec></sec><sec id="sec2.3"><title>2.3. Supplementary Detection Methods</title><p>Various diagnostic techniques have been used to complement RT-PCR and antibody-antigen serological testing. These include chest computed tomography (CT) and transmission electron microscopy (TEM). Each has its place in diagnostic settings and can serve as a complementary diagnostic tool to aid medical investigators in diagnosing 2019-nCoV accurately in suspected COVID-19 patients.</p><sec id="sec2.3.1"><title>2.3.1. Chest Computed Tomography (CT)</title><p>In clinics, medical imaging tools are indispensable and form an essential component of viral diagnosis, as well as for monitoring viral progression [<xref rid="B85" ref-type="bibr">85</xref>]. They have also been used for follow-up in outpatient settings for coronavirus-related pulmonary disorders. Just like both SARS and MERS, pulmonary complications in COVID-19 patients have been observed. Learning from the well-documented SARS and MERS studies, CT imaging results in the acute and chronic periods of COVID-19 are invariant, but not always present [<xref rid="B86" ref-type="bibr">86</xref>&#x02013;<xref rid="B89" ref-type="bibr">89</xref>]. Evidence is found in previous studies on SARS and MERS. The glass opacities observed are not always found in COVID-19 patients. Crucially, preliminary imaging discoveries indicate that COVID-19 yields nonspecific results as well [<xref rid="B90" ref-type="bibr">90</xref>&#x02013;<xref rid="B92" ref-type="bibr">92</xref>]. Radiologists are presently striving to any characteristics specific to COVID-19, although present medical information remains limited. Given the precarious situation, there is a pressing need for alternative, complementary diagnostics. CT is one example. COVID-19 patients often develop &#x0201c;ground glass&#x0201d; lung opacities [<xref rid="B93" ref-type="bibr">93</xref>]. As such, a CT imaging scan can readily identify lung abnormalities in human subjects, thereby enabling early treatment against COVID-19. CT has demonstrated some common imaging characteristics in COVID-19 patients. These features include bilateral, multifocal, ground glass opacities, with a peripheral distribution (<xref ref-type="fig" rid="fig7">Figure 7(a)</xref>) [<xref rid="B93" ref-type="bibr">93</xref>]. Crucially, more than half of 90 patients under study presented multilobar involvement and lesions more prominently in the lower lobes of their lungs. Given its feasibility and ease of use, CT has become an essential tool for the 2019-nCoV infection diagnosis. From a radiological perspective, the advantages of using CT imaging could expedite the rate of diagnosis. It also supports the current shortage and heavily reliant on technical know-how during RT-PCR testings. Nonetheless, one limitation is that it should be cautiously utilized as a diagnostic approach because there are no proven, evidence-based clinical benefits of using CT. It could also cause false securities if results are negative. Other limitations include requirements of relatively high-dose CT scans and long-term, continuous usage, which can altogether be logistically challenging and deplete additional medical resources.</p></sec><sec id="sec2.3.2"><title>2.3.2. Transmission Electron Microscopy (TEM)</title><p>Transmission electron microscopy (TEM) has been used for many years and has had a profound impact on our understanding of illnesses, including viral infections. The thousandfold enhanced resolution provided by TEM enables investigators to visualize viral morphology and to classify viruses into families [<xref rid="B94" ref-type="bibr">94</xref>].</p><p>Mechanistically, TEM operates based on interactions between electrons emitted from a source and materials under examination. In the present context, it is usually 2019-nCoV in a cellular sample [<xref rid="B95" ref-type="bibr">95</xref>]. The detector collects a multitude of signals from transmitted electrons, before processing them to reveal viral morphology and location within cells [<xref rid="B96" ref-type="bibr">96</xref>]. Typical specimen preparation for TEM includes sample fixation, embedding, sectioning, staining, and loading onto the TEM copper grids [<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>]. 2019-nCoV sampling typically uses supernatants from patient airway epithelial cells. Infected cells are fixed and dehydrated before embedding in resin. A negatively stained, film-coated grid for examination is similarly prepared for contrast enhancement. 2019-nCoV virus particles seen with TEM are shown [<xref rid="B97" ref-type="bibr">97</xref>] (<xref ref-type="fig" rid="fig7">Figure 7(b)</xref>). TEM enables microbiologists to rapidly diagnose patients with a single examination of a single tissue sample.</p></sec></sec></sec><sec id="sec3"><title>3. Medical Treatment</title><p>There are three general approaches to develop potential antiviral treatments of the human coronavirus. Firstly, standard assays may be used to evaluate existing broad-spectrum antiviral drugs. Secondly, chemical libraries containing existing compounds or databases may be screened. Thirdly, specific, new medications based on the genome and biophysical understanding of 2019-nCoV can be designed and optimized. Therefore, this section will discuss some of the potential 2019-nCoV therapeutics obtained through these general approaches. Besides chemical and biologic drugs commonly used in antiviral therapies, we further elaborate on how nanomaterials, nutritional interventions, traditional Chinese medicine, and stem cell therapy can be potentially used for treatment or as an adjuvant to reduce the mortality and morbidity rate of 2019-nCoV patients. Finally, to end this section, we highlight vaccines as a key therapeutic option to eradicate COVID-19 through herd immunity without getting the disease.</p><sec id="sec3.1"><title>3.1. Chemical Drugs</title><p>There are currently no approved antiviral drugs to treat COVID-19, and patients must depend upon their immune systems to combat the infection. A full-fledged treatment plan has yet to emerge, and both academia and pharmaceutical companies are racing to develop new treatments and vaccines to address COVID-19. Research into the cellular and molecular pathogenesis of 2019-nCoV has provided essential insights with the hope of developing viable therapies. While researchers are working on cures or preventive measures for COVID-19 [<xref rid="B99" ref-type="bibr">99</xref>], a more robust, efficient, and economical way to tackle the disease is to repurpose existing drugs into a viable therapeutic strategy. Drug repurposing, also termed drug repositioning, refers to the process of discovering new therapeutic applications for existing drugs. It offers various advantages over traditional de novo drug discovery, i.e., reduced cost and drug development time, established drug characteristics, and, most importantly, established safe dosages for human use [<xref rid="B100" ref-type="bibr">100</xref>]. Repurposed drugs often negate the need for phase 1 clinical trials and can be used immediately [<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>]. At present, repurposed drugs are the only option available at treatment centers for COVID-19 patients. As COVID-19 is a viral infection, the most obvious choices for repurposed drugs come from known antiviral drugs [<xref rid="B102" ref-type="bibr">102</xref>]. Antiviral creation strategies focus on two approaches: targeting viruses or targeting host cell factors. In this section, we will review antiviral drugs prescribed or proposed against COVID-19 based on the antiviral drug creation strategies.</p><sec id="sec3.1.1"><title>3.1.1. Entry Inhibitors</title><p>When an infection occurs, the virus gains entry into a host cell by attaching itself to the host cell surface (<xref ref-type="fig" rid="fig8">Figure 8</xref>) [<xref rid="B103" ref-type="bibr">103</xref>]. This relies on numerous interactions between the virion surface and the specific proteins on the cell membrane. In general, these surface proteins have other functions but are serendipitously recognized by the virus as entry receptors [<xref rid="B103" ref-type="bibr">103</xref>]. Molecules that prevent such recognition, either by competitive binding or by downregulating the receptors, are known as viral entry inhibitors (<xref ref-type="fig" rid="fig9">Figure 9(a)</xref>). These inhibitors are valuable as therapeutics since blocking infection early in the life cycle reduces cellular and tissue damage associated with viral replication and production of viral progeny.</p><p>As mentioned above, coronavirus particles comprise four structural proteins: the S, E, M, and N proteins [<xref rid="B104" ref-type="bibr">104</xref>&#x02013;<xref rid="B107" ref-type="bibr">107</xref>]. The S protein is the most crucial in viral attachment, fusion, and entry [<xref rid="B108" ref-type="bibr">108</xref>]. It comprises two subunits. S1 facilitates attachment to the host cell receptor, while S2 mediates membrane fusion of the virion and the host cell. As mentioned above, viruses have specific attachment sites. SARS-CoV recognizes ACE2 as its host receptor, while MERS-CoV recognizes dipeptidyl peptidase 4 [<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>]. Like SARS-CoV, 2019-nCoV also targets host ACE2 [<xref rid="B111" ref-type="bibr">111</xref>&#x02013;<xref rid="B113" ref-type="bibr">113</xref>]. Biophysical and structural analysis indicates that the 2019-nCoV S protein binds ACE2 with higher affinity than the SARS-CoV S protein [<xref rid="B16" ref-type="bibr">16</xref>]. Therefore, it is vital to target ACE2 for the development of viral entry inhibitors.</p><p>To the best of our knowledge, not much is known about ACE2-specific inhibitors that are commercially available or under commercial development [<xref rid="B114" ref-type="bibr">114</xref>]. However, ACE2 stimulators have been used in the treatment of hypertension, cardiac diseases, and diabetes mellitus to regulate the renin-angiotensin system [<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>]. There are also ACE inhibitors known for treating the diseases mentioned, but these lack inhibitory activity toward ACE2 due to their distinct substrate-binding pockets [<xref rid="B116" ref-type="bibr">116</xref>&#x02013;<xref rid="B119" ref-type="bibr">119</xref>]. In brief, there are concerns that both ACE2 stimulators and ACE inhibitors can increase the expression of ACE2, which in turn may increase susceptibility to viral host cell entry [<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>]. Much work needs to be done on ACE2-targeting drugs, and controversial issues that lie beyond the treatment pathway need to be addressed soon.</p><p>A small antiviral molecule, umifenovir, has entry inhibitory effects on the influenza virus. Umifenovir targets hemagglutinin for its anti-influenza virus effect [<xref rid="B122" ref-type="bibr">122</xref>&#x02013;<xref rid="B124" ref-type="bibr">124</xref>]. Hemagglutinin, a viral cell surface protein, facilitates infection by undergoing a conformational change when the virus binds to host cells [<xref rid="B122" ref-type="bibr">122</xref>]. Umifenovir interacts with hemagglutinin to stabilize it against low pH-induced conformational change via the formation of an extensive network of noncovalent interactions that prevent hemagglutinin-mediated membrane fusion [<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B124" ref-type="bibr">124</xref>]. It also interacts with phospholipids by altering membrane fluidity [<xref rid="B125" ref-type="bibr">125</xref>], which is vital for the fusion process. This is most likely due to umifenovir's molecular interactions (bearing both the H donor and acceptor groups) with the interfacial region of the lipid bilayer by competing for the hydrogen bonding of phospholipid C=O groups with water molecules [<xref rid="B126" ref-type="bibr">126</xref>]. This renders lipid bilayers of host cells less prone to viral fusion [<xref rid="B125" ref-type="bibr">125</xref>]. No studies have shown that umifenovir is effective in inhibiting SARS-CoV or 2019-nCoV. Wang et al. reported that 4 patients with mild/severe COVID-19 recovered after prescription of combined lopinavir/ritonavir, arbidol (umifenovir), and Shufeng Jiedu Capsule (a traditional Chinese medicine) [<xref rid="B127" ref-type="bibr">127</xref>]. On the other hand, Dong et al. found in an <italic>in vitro</italic> study that arbidol may effectively inhibit 2019-nCoV infection at a concentration of 10-30&#x02009;<italic>&#x003bc;</italic>M [<xref rid="B128" ref-type="bibr">128</xref>].</p><p>Chloroquine, also a small molecule, is a quinine analog used to prevent and treat malaria. Similar to umifenovir, chloroquine exhibits its inhibitory effect on influenza by pH stabilization. Chloroquine is a weak base and becomes protonated intracellularly in a manner described by the Henderson-Hasselbalch law [<xref rid="B129" ref-type="bibr">129</xref>]. It can raise lysosomal pH to facilitate autophagy intracellularly [<xref rid="B130" ref-type="bibr">130</xref>&#x02013;<xref rid="B132" ref-type="bibr">132</xref>]. Chloroquine also alters the signaling pathway of enzymes, causing enzyme glycosylation, ultimately inhibiting viral replication in host cells [<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>]. Liu et al. claimed that chloroquine could inhibit SARS-CoV entry by changing glycosylation of the ACE2 receptor and S protein [<xref rid="B135" ref-type="bibr">135</xref>]. Chloroquine's effective inhibition of SARS-CoV was demonstrated <italic>in vitro</italic> on primate cells and human rectal cells [<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>]. Hydroxychloroquine is a derivative of chloroquine with an additional hydroxyl group. These two chloroquines share similar structures and mechanisms. Both have shown <italic>in vitro</italic> antiviral activities toward 2019-nCoV [<xref rid="B138" ref-type="bibr">138</xref>&#x02013;<xref rid="B140" ref-type="bibr">140</xref>]. Hydroxychloroquine was more effective than chloroquine in inhibiting 2019-nCoV <italic>in vitro</italic> on primate cells [<xref rid="B141" ref-type="bibr">141</xref>]. Until now, chloroquine has shown apparent efficiency and safety against 2019-nCoV in clinical trials conducted in China [<xref rid="B139" ref-type="bibr">139</xref>]. Currently, chloroquine or hydroxychloroquine has been administered to hospitalized 2019-nCoV patients on an uncontrolled basis in various countries, including China and the USA [<xref rid="B42" ref-type="bibr">42</xref>]. However, it must be noted that chloroquine and hydroxychloroquine cause ocular toxicity [<xref rid="B142" ref-type="bibr">142</xref>]. Hydroxychloroquine is reportedly less toxic than chloroquine, making it more attractive as a prescription drug [<xref rid="B135" ref-type="bibr">135</xref>, <xref rid="B143" ref-type="bibr">143</xref>]. Nevertheless, more investigation and clinical trials are needed to evaluate further their efficacy and safety in treating 2019-nCoV.</p></sec><sec id="sec3.1.2"><title>3.1.2. Protease Inhibitors</title><p>Proteases are essential enzymes that regulate cell life processes such as cell growth and death, blood clotting, inflammation, fertilization, and infection [<xref rid="B103" ref-type="bibr">103</xref>]. Viral entry into host cells requires S protein priming by host proteases, which subsequently enables the fusion of viral and cellular membranes [<xref rid="B113" ref-type="bibr">113</xref>]. Membrane fusion enables the release of the viral genome into the host cytoplasm, initiating RNA translation into protein. Most viruses also encode their proteases to protect viral proteins by modulating host cell responses. While proteases are vital for cell life processes, they have become promising targets for antiviral therapeutic agents. Protease inhibitors prevent viral replication by binding selectively to viral proteases or blocking proteolytic cleavage of protein precursors necessary for the production of infectious particles [<xref rid="B144" ref-type="bibr">144</xref>]. It is noteworthy that protease inhibitors were a major therapeutic breakthrough of antiviral drug design in the mid-1990s for the treatment of HIV. Most HIV protease inhibitors have found prominent clinical use (<xref ref-type="fig" rid="fig9">Figure 9(b)</xref>).</p><p>Coronavirus S proteins can be primed by a multitude of proteases [<xref rid="B145" ref-type="bibr">145</xref>]. Hoffmann et al. demonstrated that the S protein of 2019-nCoV could be primed by serine protease TMRPSS2 [<xref rid="B113" ref-type="bibr">113</xref>]. Similarly, both SARS-CoV and MERS-CoV can be activated by other TMPRSS family members [<xref rid="B145" ref-type="bibr">145</xref>]. TMPRSS family proteases are widely expressed in the respiratory tract [<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B146" ref-type="bibr">146</xref>], which is likely the reason that coronaviruses cause acute respiratory distress syndrome. Upon successful priming, the viral genome encoding RNA and several nonstructural proteins, including coronavirus main protease (3CLpro), papain-like protease (PLpro), and RdRp, are released [<xref rid="B147" ref-type="bibr">147</xref>&#x02013;<xref rid="B149" ref-type="bibr">149</xref>]. The single-stranded positive RNA is translated into viral polyproteins by ribosomes in the host cell cytoplasm. The polyproteins are then cleaved into effector proteins by viral proteases: 3CLpro and PLpro. PLpro also acts as a deubiquitinase that may remove specific host cell proteins (e.g., interferon regulatory factor 3 (IRF3) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-<italic>&#x003ba;</italic>B)), thus weakening the immune system [<xref rid="B147" ref-type="bibr">147</xref>, <xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B150" ref-type="bibr">150</xref>]. Both host and viral proteases are essential therapeutic targets in the case of COVID-19.</p><p>Camostat mesylate is a small molecule that has shown an excellent therapeutic effect for chronic pancreatitis treatment by targeting proteases [<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>]. Camostat mesylate primarily inhibits enzymatic autodigestion of the pancreas [<xref rid="B153" ref-type="bibr">153</xref>]. <italic>In vivo</italic> studies on rats with pancreatic fibrosis showed that camostat mesylate inhibits inflammation, cytokine expression, and fibrosis in the pancreas [<xref rid="B154" ref-type="bibr">154</xref>]. It has an additional clinical benefit for pancreatic pain by preventing enzyme-evoked activation of pain receptors [<xref rid="B155" ref-type="bibr">155</xref>]. As mentioned above, the TMPRSS family, especially TMRPSS2, is most likely the protease targeted by a coronavirus. Camostat mesylate inhibits TMPRSS2 activity on primate cells <italic>in vitro</italic>, completely blocking membrane fusion between the host cell and the viral MERS-CoV particle [<xref rid="B156" ref-type="bibr">156</xref>]. Zhou et al. claimed that camostat mesylate displays an inhibitory effect in mice for SARS-CoV infection [<xref rid="B152" ref-type="bibr">152</xref>]. Recent research by Hoffmann et al. showed a promising <italic>in vitro</italic> inhibitory effect of this serine protease inhibitor in SARS-CoV and 2019-nCoV on human lung cells, showing potential as a viable option for COVID-19 treatment [<xref rid="B113" ref-type="bibr">113</xref>]. Unfortunately, <italic>in vitro</italic> and <italic>in vivo</italic> data for camostat mesylate against coronaviruses are limited. More investigation is required to evaluate camostat mesylate as a potential therapeutic against COVID-19.</p><p>Lopinavir-ritonavir is a coformulated antiretroviral drug with excellent efficacy against HIV-1. The lopinavir has a core molecular structure identical to ritonavir. The 5-thiazolyl end group and 2-isopropylthiazolyl group in ritonavir are replaced by the phenoxyacetyl group and a modified valine, respectively, in which the amino terminus has six-membered cyclic urea attached. In brief, lopinavir is a potent protease inhibitor developed from ritonavir with high specificity for HIV-1 protease [<xref rid="B103" ref-type="bibr">103</xref>]. It represents a higher proportion of the coformulation. Lopinavir contains a hydroxyethylene scaffold mimicking a standard peptide bond cleavable by HIV-1 protease [<xref rid="B157" ref-type="bibr">157</xref>]. This results in the production of noncontagious viral particles. On the other hand, ritonavir binds to HIV-1 protease, interrupting the maturation and production of viral particles [<xref rid="B158" ref-type="bibr">158</xref>]. A clinical study from Hong Kong has shown that the combination of lopinavir-ritonavir and ribavirin treatment for 152 patients against SARS-CoV had an overall favourable clinical response [<xref rid="B159" ref-type="bibr">159</xref>]. It has been demonstrated that lopinavir-ritonavir targets 3CLpro of 2019-nCoV and further indicated that 3CLpro might also be the targets of protease inhibitors for other coronaviruses [<xref rid="B160" ref-type="bibr">160</xref>]. Regrettably, a recent clinical trial using lopinavir-ritonavir in Wuhan, China, reported that 199 hospitalized adult patients infected with 2019-nCoV did not benefit from the treatment [<xref rid="B161" ref-type="bibr">161</xref>]. Given such conflicting clinical data, physicians must carefully weigh lopinavir-ritonavir as a COVID-19 treatment.</p><p>Darunavir is another antiretroviral protease inhibitor drug effective against HIV-1. Darunavir is designed for multidrug-resistant HIV-1 protease variants, due to its molecular structure, which introduces more hydrogen bonds compared to conventional antiretroviral medicines. In general, changes in van der Waals and hydrogen bonding interactions between inhibitors and proteases affect the potency of antiretroviral drugs [<xref rid="B162" ref-type="bibr">162</xref>]. Aside from enzymatic inhibition, darunavir inhibits protease dimerization [<xref rid="B163" ref-type="bibr">163</xref>]. The dimerization of HIV protease is essential for the acquisition of its proteolytic activity for the maturation of viral particles [<xref rid="B163" ref-type="bibr">163</xref>]. Lin et al. claimed that darunavir inhibits 2019-nCoV. The group has used molecular modeling to evaluate darunavir binding to 3CLpro and PLpro proteases and found targeted activity against the latter [<xref rid="B164" ref-type="bibr">164</xref>]. Nevertheless, the therapeutic effect of darunavir in COVID-19 clinical cases remains untested [<xref rid="B164" ref-type="bibr">164</xref>]. This may be in part due to potential side effects, such as liver damage and severe skin rashes [<xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B165" ref-type="bibr">165</xref>]. These contraindications must be carefully evaluated if darunavir is to be considered a potential therapeutic agent for COVID-19.</p></sec><sec id="sec3.1.3"><title>3.1.3. Replication Inhibitors</title><p>Polymerases are enzymes essential for viral replication to produce viral progeny. Viral DNA and RNA polymerases are responsible for duplicating the viral genome and facilitating transcription and replication [<xref rid="B103" ref-type="bibr">103</xref>]. Replication inhibitors (<xref ref-type="fig" rid="fig9">Figure 9(c)</xref>) interfere with the production of viral particles by blocking enzymatic activity, ultimately causing chain termination during viral DNA or RNA replication [<xref rid="B166" ref-type="bibr">166</xref>]. There are four types of viral polymerases in viruses: RNA-dependent RNA polymerases, RdRp, DNA-dependent RNA polymerases, and DNA-dependent DNA polymerases.</p><p>In the section Protease Inhibitors, we mentioned that RdRp is released upon successful priming. RdRp is a necessary polymerase that catalyzes the replication of RNA from an RNA template for coronaviruses [<xref rid="B167" ref-type="bibr">167</xref>]. Release of RdRp from the virus initiates the synthesis of a full negative-strand RNA template to be used by RdRp to replicate more viral genomic RNA, which eventually turns host cells into virus factories [<xref rid="B147" ref-type="bibr">147</xref>]. Therefore, RdRp is an attractive therapeutic target to prevent host cells from producing viruses.</p><p>Ribavirin is a synthetic guanosine nucleoside analog that mimics purines, including inosine and adenosine, and ribavirin has been used in the treatment of respiratory syncytial virus [<xref rid="B168" ref-type="bibr">168</xref>]. It has only one ring at the heterocyclic base, compared with guanine's two rings. Notably, ribavirin has a ribose sugar moiety with a hydroxyl group at the 2&#x02032;-carbon position, enabling preferential activity in RNA-related metabolism [<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>]. Ribavirin inhibits cellular enzyme and inosine monophosphate dehydrogenase involved in purine nucleotide biosynthesis [<xref rid="B170" ref-type="bibr">170</xref>, <xref rid="B171" ref-type="bibr">171</xref>]. Ribavirin is also known for its inhibitory effect on viruses by forcing viral genome replication to become catastrophically error-prone. It is likely that as a nucleoside analog, ribavirin is incorporated by RdRp into the newly synthesized viral genome, where it induces mutagenesis [<xref rid="B170" ref-type="bibr">170</xref>, <xref rid="B172" ref-type="bibr">172</xref>]. Although ribavirin has proven effective against viral infections, its mechanism of action has not been firmly established, and there are several proposed mechanisms of action that require further validation [<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B173" ref-type="bibr">173</xref>]. Ribavirin was initially used in treating SARS; however, ribavirin treatment lacked an <italic>in vitro</italic> antiviral effect and caused adverse side effects including anemia, hypoxemia, and decreased hemoglobin levels [<xref rid="B174" ref-type="bibr">174</xref>]. However, ribavirin was used as the primary treatment during the MERS outbreak [<xref rid="B175" ref-type="bibr">175</xref>]. In general, clinical studies of ribavirin treatment for SARS and MERS did not show strong evidence of efficacy against these coronaviruses [<xref rid="B176" ref-type="bibr">176</xref>&#x02013;<xref rid="B178" ref-type="bibr">178</xref>]. There have been no studies of ribavirin's efficacy against COVID-19. Therefore, the use of ribavirin remains controversial and requires more investigation for a better understanding of its mechanism of action, efficacy, and toxicity, even though it is a widely available drug.</p><p>Favipiravir is a synthetic guanine analog frequently used for influenza treatment [<xref rid="B179" ref-type="bibr">179</xref>]. Structurally, favipiravir is closely related to ribavirin, in which it shares the same carboxamide moiety [<xref rid="B180" ref-type="bibr">180</xref>]. While ribavirin interacts with the viral polymerase directly, favipiravir must be phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5&#x02032;-triphosphate (RTP) [<xref rid="B181" ref-type="bibr">181</xref>, <xref rid="B182" ref-type="bibr">182</xref>]. The viral polymerase mistakenly recognizes favipiravir-RTP for a purine nucleotide, thereby disrupting viral genome replication [<xref rid="B181" ref-type="bibr">181</xref>, <xref rid="B182" ref-type="bibr">182</xref>]. Favipiravir has not been used against SARS and MERS previously, but interestingly, it has been shown to reduce viral infection of 2019-nCoV [<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B183" ref-type="bibr">183</xref>]. In a clinical study involving 80 patients infected with 2019-nCoV, conducted in Shenzhen, China, favipiravir showed better efficacy than lopinavir-ritonavir in terms of disease progression and viral clearance [<xref rid="B183" ref-type="bibr">183</xref>]. Another clinical study involving 240 patients with COVID-19 conducted in Hubei Province, China, also demonstrated that those treated with favipiravir had a higher recovery rate compared to those treated with umifenovir (preprint) [<xref rid="B184" ref-type="bibr">184</xref>]. More clinical data are needed to validate favipiravir's efficacy and safety in 2019-nCoV treatment.</p><p>Remdesivir is a trial synthetic adenosine analog that has not yet been clinically approved [<xref rid="B185" ref-type="bibr">185</xref>]. It was synthesized and developed by Gilead Science in 2017 for Ebola virus infection [<xref rid="B186" ref-type="bibr">186</xref>]. Remdesivir needs to be metabolized into its active form, GS-441524, to initiate its activity. The active form of remdesivir inhibits viral RNA polymerase and evades proofreading by viral exonuclease, causing an interruption in viral RNA production [<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B186" ref-type="bibr">186</xref>]. It has been demonstrated that remdesivir is effective against MERS-CoV infection <italic>in vivo</italic> and 2019-nCoV <italic>in vitro</italic> [<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B187" ref-type="bibr">187</xref>], showing great potential as a therapeutic agent for 2019-nCoV. The drug is currently being validated in clinical trials [<xref rid="B188" ref-type="bibr">188</xref>]. Given that antiviral drugs have previously demonstrated reasonable inhibition of coronaviruses and therapeutic efficacy against coronavirus outbreaks, umifenovir, chloroquine, hydroxychloroquine, lopinavir-ritonavir, and ribavirin have been recommended in the latest guidelines for diagnosis and treatment of COVID-19, updated on 17 February 2020 [<xref rid="B189" ref-type="bibr">189</xref>].</p><p>Recent studies also demonstrated that some antibiotics potentially inhibit 2019-nCoV replication. Anderson et al. (preprint) recently developed the first bat genome-wide RNA interference (RNAi) and CRISPR libraries and identified MTHFDI as the critical host factor for viral infections [<xref rid="B190" ref-type="bibr">190</xref>]. MTHFDI is a trifunctional enzyme involved in the one-carbon (C1) metabolic pathway, participating in the cellular production of purine, dTMP, and methyl groups [<xref rid="B191" ref-type="bibr">191</xref>]. Anderson et al. demonstrated that purine synthesis activity of MTHFDI is an essential activity for viral replication, making MTHFDI a potential target for developing antiviral drugs [<xref rid="B190" ref-type="bibr">190</xref>]. They further explained that an MTHFD1 inhibitor, carolacton, restricts replication of influenza virus, mumps virus, Melaka virus, Zika virus, and, most importantly, 2019-nCoV [<xref rid="B190" ref-type="bibr">190</xref>]. Carolacton is a secondary metabolite derived from the mycobacterium <italic>Sorangium cellulosum</italic>. It is a macrolide ketocarbonic acid. Carolacton has been studied as an antibacterial compound against biofilms of pathogenic <italic>Streptococcus mutans</italic> and growth of pathogen <italic>Streptococcus pneumoniae</italic> [<xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B193" ref-type="bibr">193</xref>]. It has no toxic effect against eukaryotic cells [<xref rid="B194" ref-type="bibr">194</xref>]. It has recently been identified as a potent inhibitor of MTHFDI, and its mechanism of action is presumably due to the ability of carolacton to bind with MTHFDI [<xref rid="B194" ref-type="bibr">194</xref>]. More research is needed to validate the mechanism of action, efficacy, and safety of carolacton as a possible treatment for COVID-19. On the other hand, ivermectin is originally a medication used to treat parasite infestation. It comprises different analogs of avermectin: 22,23-dihydroavermectin B1a and 22,23-dihydroavermectin B1b, at a ratio of 4&#x02009;:&#x02009;1 [<xref rid="B195" ref-type="bibr">195</xref>]. They are macrolide antibiotics isolated from the fungus <italic>Streptomyces avermitilis</italic>. It has reportedly stopped HIV-I proliferation by inhibiting interaction of the retroviral integrase protein with adapter protein (importin), responsible for the nuclear protein import cycle [<xref rid="B196" ref-type="bibr">196</xref>]. Caly et al. reported that ivermectin successfully inhibited 2019-nCoV <italic>in vitro</italic> but the mechanism of action is unclear [<xref rid="B197" ref-type="bibr">197</xref>]. Since ivermectin is an approved drug, it shows great potential as a therapeutic agent for COVID-19. <italic>In vivo</italic> work or clinical trials need to be done to confirm its efficacy and safety for treatment against COVID-19. Potential drugs for COVID-19 are summarized in <xref rid="tab2" ref-type="table">Table 2</xref>.</p></sec></sec><sec id="sec3.2"><title>3.2. Nanodrug Delivery System</title><p>Nanomaterials have recently been utilized for the treatment of diseases such as cancer [<xref rid="B198" ref-type="bibr">198</xref>&#x02013;<xref rid="B200" ref-type="bibr">200</xref>] and various types of infections [<xref rid="B201" ref-type="bibr">201</xref>, <xref rid="B202" ref-type="bibr">202</xref>]. The ease of modification of surface properties, large surface area [<xref rid="B203" ref-type="bibr">203</xref>], and multivalent interactions with targets [<xref rid="B204" ref-type="bibr">204</xref>] imbues nanomaterials with massive potential as highly efficacious COVID-19 therapeutic options. However, to the best of our knowledge, no nanoparticle treatment option has been applied to COVID-19. Nonetheless, results obtained from nanoparticle research against other viruses have shown promising potential. For example, Fujimori et al. utilized a CuI nanoparticle to treat H1N1 influenza through the generation of reactive oxygen species (ROS) that inactivate the virus [<xref rid="B205" ref-type="bibr">205</xref>]. Silver nanoparticles also show much promise in treating COVID-19 with their broad antiviral properties against a multitude of viruses, including HIV, hepatitis B virus, herpes simplex virus, respiratory syncytial virus, and monkeypox virus [<xref rid="B206" ref-type="bibr">206</xref>]. The broad antiviral properties of silver nanoparticles and the generality of ROS inactivation suggest that these nanoparticles can be utilized therapeutically without any modifications. Nanoparticles could also be used for drug delivery. Recently, Herold and Sander demonstrated the use of pulmonary surfactant-biomimetic nanoparticles to encapsulate a stimulator of interferon gene (STING) agonist, 2&#x02032;,3&#x02032;-cyclic guanosine monophosphate-adenosine monophosphate, as an adjuvant in a variety of influenza vaccines [<xref rid="B207" ref-type="bibr">207</xref>]. Using nanoparticles as a delivery agent, immune cells were activated without excessive inflammation in the lung. This could provide a considerable benefit for use in COVID-19 vaccines in the future, but as the field is still relatively new, especially in medicinal applications, safety should remain a key consideration in the adoption of nanoparticles in humans.</p></sec><sec id="sec3.3"><title>3.3. Biologic Drugs</title><p>In addition to chemical medicines, another vital form of therapy for COVID-19 may be the use of biologics. Currently, interferon-<italic>&#x003b1;</italic>2b nebulization of 100,000 to 400,000&#x02009;IU/kg twice a day for 5 to 7 days is one of the main treatments for COVID-19 in children, and it has demonstrated efficacy in reducing the viral load during early stages of infection [<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B209" ref-type="bibr">209</xref>]. Another promising biologic drug is convalescent plasma, the plasma of patients who have recovered from COVID-19 [<xref rid="B210" ref-type="bibr">210</xref>, <xref rid="B211" ref-type="bibr">211</xref>]. Antibodies in the donated plasma could confer temporary, passive immunity against COVID-19, allowing patients time to develop active immunity. Clinical trials are currently ongoing [<xref rid="B212" ref-type="bibr">212</xref>, <xref rid="B213" ref-type="bibr">213</xref>], and preliminary results announced from the Chinese hospitals have been promising.</p><p>On the other hand, human monoclonal antibodies or their fragments developed in the lab have shown encouraging results as well. Tian et al. confirmed the binding of a human monoclonal antibody CR3022 to the receptor-binding domain (RBD) of 2019-nCoV with high affinity [<xref rid="B214" ref-type="bibr">214</xref>], highlighting the therapeutic potential of CR3022 toward COVID-19, though further <italic>in vitro</italic> and <italic>in vivo</italic> studies are required before it could be used clinically.</p></sec><sec id="sec3.4"><title>3.4. Nutritional Interventions</title><p>Another supportive treatment for COVID-19 involves dietary interventions. Various research studies have shown supplementation of multiple vitamins and minerals such as vitamins A, C, and D and zinc can reduce the severity of respiratory infections [<xref rid="B215" ref-type="bibr">215</xref>&#x02013;<xref rid="B221" ref-type="bibr">221</xref>]. However, most of these studies targeted children below the age of 5 who were suffering from malnourishment or preexisting diseases. Therefore, vitamin and mineral supplementation may offer more significant benefits to COVID-19 patients in developing countries. Moreover, aggressive supplementation of calories and protein in nutritionally at-risk patients has shown significant benefits in reducing mortality [<xref rid="B222" ref-type="bibr">222</xref>]. Using a modified Nutrition Risk in Critically Ill (mNUTRIC) score, Kalaiselvan and coworkers demonstrated that 42.5% of mechanically ventilated patients have high nutritional risks (mNUTRIC&#x02009;score &#x02265; 5), accompanied by long intensive care unit (ICU) stays and high mortality rates [<xref rid="B223" ref-type="bibr">223</xref>].</p><p>An estimated 5% of COVID-19 patients require ICU care, and of these critically ill patients, most need mechanical ventilation [<xref rid="B224" ref-type="bibr">224</xref>, <xref rid="B225" ref-type="bibr">225</xref>]. Therefore, nutritional intervention using aggressive calorie and protein supplementation may provide substantial benefits to a significant number of critically ill patients. Evidence of such benefits may be provided by the clinical trial (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04274322">NCT04274322</ext-link>) that is expected to end in July 2020.</p></sec><sec id="sec3.5"><title>3.5. Traditional Chinese Medicine</title><p>Traditional Chinese medicine (TCM) is considered a prospective supplementary treatment of COVID-19, due to its impressive performance in treating SARS in 2003 [<xref rid="B226" ref-type="bibr">226</xref>]. First, TCM shows a generalized antiviral effect through direct inhibition of viruses and control of inflammation. For example, Weng et al. reported that the <italic>Smabucus Formosana Nakai</italic> (a traditional medicinal herb) ethanol stem extract displayed strong anti-HCoV-NL63 activity [<xref rid="B227" ref-type="bibr">227</xref>]. Moreover, TCM can alleviate damage induced by inflammatory reactions and immune responses initiated by viral infections. Single and combined Chinese medicines could mitigate the cytokine storm by clearing the heat and toxicity in the body. For instance, TCM approaches were adopted to prevent and treat SARS in 2003 and H1N1 influenza in 2009 [<xref rid="B228" ref-type="bibr">228</xref>]. As of February 17, 2020, over 85.2% of total confirmed cases (over 60,000 cases) had been treated with TCM, showing that TCM yields excellent outcomes. Notably, in a trial of 102 cases with mild symptoms, TCM achieved remarkable therapeutic effects, demonstrated by faster clinical symptom disappearance and reduction of fever, shorter disease course, higher cure rate (by 33%), and lower rate of moderate-to-severe cases [<xref rid="B229" ref-type="bibr">229</xref>]. To date, the National Health Commission (NHC) of the People's Republic of China has published seven editions of the guidelines for diagnosis and treatment of COVID-19 [<xref rid="B25" ref-type="bibr">25</xref>]. Since the fourth version, a list of TCM prescriptions (including TCM soup and TCM capsules) has been recommended for patients based on the stage of the disease and their symptoms [<xref rid="B230" ref-type="bibr">230</xref>].</p><p>According to the 7<sup>th</sup> edition of the guidelines, there are three kinds of TCM prescriptions recommended for different stages of patients: the medical observation period, the clinical treatment period, and critical condition (details in <xref rid="tab3" ref-type="table">Table 3</xref>) [<xref rid="B25" ref-type="bibr">25</xref>]. Among TCM recipes, the Qing Fei Pai Du Decoction is strongly recommended for treatment of COVID-19 by the NHC of the People's Republic of China, because it gave a cure rate of over 90% of COVID-19 patients in a clinical trial involving 701 confirmed cases [<xref rid="B231" ref-type="bibr">231</xref>]. Another TCM recipe, Xue Bi Jing Injection is specifically recommended for treating critically ill COVID-19 patients, because it suppresses severe sepsis, according to the China Food and Drug Administration. It also promoted significant improvement in cases of severe community-acquired pneumonia (CAP) [<xref rid="B232" ref-type="bibr">232</xref>]. Therefore, TCM could be an alternative prophylactic approach to COVID-19 and a supplementary treatment in combination with western medicine to cure COVID-19.</p></sec><sec id="sec3.6"><title>3.6. Stem Cell Therapy</title><p>Stem cell therapy is a promising treatment strategy for degenerative diseases, including Huntington's disease, Parkinson's and Alzheimer's diseases, and chronic diseases such as cardiac failure and diabetes [<xref rid="B233" ref-type="bibr">233</xref>]. A clinical study showed that transplantation of mesenchymal stem cells (MSCs) significantly lowered the mortality of patients with H7N9-induced acute respiratory distress syndrome (ARDS), with no harmful effects [<xref rid="B234" ref-type="bibr">234</xref>]. As H7N9 and 2019-nCoV share similar genome structures and corresponding infection mechanisms, as well as related clinical symptoms (lung failure), MSC-based therapy could be a possible alternative for treating COVID-19. Currently, stem cell-based therapy for COVID-19 is being conducted by different hospitals in China. Doctors from Baoshan Hospital (Yunnan province, China) used human umbilical cord mesenchymal stem cells (hUCMSCs) to treat a 65-year-old critically ill woman with COVID-19. Two days after the 3rd injections of stem cells, the woman recovered, and the throat swab test for COVID-19 turned negative [<xref rid="B235" ref-type="bibr">235</xref>]. Another clinical trial involving stem cell therapy was conducted in seven confirmed COVID-19 patients in different clinical stages in Beijing Youan Hospital (Beijing, China). Two to four days after intravenous transplantation of CE2<sup>&#x02212;</sup> MSCs, all symptoms such as high fever, weakness, and shortness of breath disappeared in all seven patients without observed adverse effects, indicating that MSCs can cure or significantly improve functional outcomes [<xref rid="B236" ref-type="bibr">236</xref>]. There are at least 12 other trials using stem cells to treat COVID-19 in China, according to the WHO report.</p></sec><sec id="sec3.7"><title>3.7. Other Treatments</title><p>Vaccines are another promising treatment to prevent or cure specific viruses. Currently, there is no effective vaccine against 2019-nCoV. Fortunately, two COVID-19 vaccines are undergoing clinical trials. The first is Moderna's mRNA-1273, an mRNA vaccine, which started at KPWHRI in Seattle, USA, on March 16, 2020 [<xref rid="B237" ref-type="bibr">237</xref>]. It targets the spike protein of 2019-nCoV. The other vaccine, Ad5-nCoV (a recombinant novel coronavirus disease vaccine (adenovirus type 5 vector)), was conducted at Tongji Hospital in Wuhan, China, on March 16, 2020 [<xref rid="B238" ref-type="bibr">238</xref>]. The trial was jointly developed and administered by CanSino Biologics Inc. and the Academy of Military Medical Sciences. Ad5-nCoV, a genetically engineered vaccine, expresses the 2019-nCoV S protein using replication-defective adenovirus type 5 as an expression vector, thereby inducing a virus-specific immune response to prevent COVID-19. There are also several other types of COVID-19 vaccines, including deoptimized live attenuated vaccines, protein vaccine, DNA vaccine, RNA vaccine, and subunit vaccine, all of which are in the preclinical stage (<xref rid="tab4" ref-type="table">Table 4</xref>) [<xref rid="B239" ref-type="bibr">239</xref>]. Notably, there is a new microneedle array (MNA) approach based on delivering coronavirus S1 subunit vaccines against COVID-19. Expedited by prior experience in developing vaccines against MERS, this approach was developed within 4 weeks and enabled long-term induction of potent virus-specific antibody responses. Significantly, the MNA work can be extended to other emerging infectious diseases. However, these will require further clinical studies for efficacy and safety, which requires more time.</p><p>According to the 7<sup>th</sup> edition of the diagnostic criteria [<xref rid="B25" ref-type="bibr">25</xref>], patients severely or critically ill with COVID-19 should receive comprehensive antiviral treatment, including lopinavir/ritonavir, arbidol, or Shufeng Jiedu Capsule. Meanwhile, they also need additional treatments, according to their symptoms, including respiratory support (oxygen therapy, high-flow nasal cannulas, or noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation- (ECMO-) based therapy), circulatory support, or continuous renal replacement therapy. The main therapeutic approaches proposed for COVID-19 are summarized in <xref rid="tab5" ref-type="table">Table 5</xref>.</p></sec></sec><sec id="sec4"><title>4. Control and Prevention of COVID-19</title><p>As the most recent pandemic, COVID-19 induces much fear. It is highly infectious and is transmitted asymptomatically. As such, our best options to slow and prevent transmission are to understand the origin of 2019-nCoV, its transmission route, and associated disease pathways and systems. Generally, a pathogen must remain viable outside the host to allow for environmental spread [<xref rid="B240" ref-type="bibr">240</xref>]. Collective effects of many biotic and abiotic factors determine the period that the pathogen can survive [<xref rid="B240" ref-type="bibr">240</xref>]. As of now, COVID-19 is thought to be transmitted directly from person-to-person through liquid (droplets) and, more importantly, transmitted indirectly via contact with contaminated surfaces. 2019-nCoV remains viable for a fairly long period outside the human body (up to 72 hours) and is more stable on plastic and stainless steel than on copper and cardboard [<xref rid="B241" ref-type="bibr">241</xref>]. Therefore, aerosol and fomite transmission of 2019-nCoV is possible, as the virus lingers among particles or fibers, in airborne liquid droplets, and on surfaces, in some cases for days [<xref rid="B241" ref-type="bibr">241</xref>]. Although there are currently insufficient data on the inactivation of environmental 2019-nCoV, data from other coronaviruses can be used as a reference. However, it should be noted that biocidal agents may only limit the survival of coronavirus in critical environments and have no efficacy for infected patients.</p><p>Given the high transmissibility of COVID-19, its propensity for asymptomatic transmission, and its persistent nature, confirmed patients could only be quarantined and treated in adequately equipped facilities. This also applies to anyone who has come into contact with these patients. As such, contact tracing is still a mainstay for disease control. Confirmation can be achieved only when specific diagnostic methods have been employed. Chest CT imaging is useful as an initial evaluation for COVID-19, as CT confirmation is often possible even before symptoms appear; therefore, it is recommended for suspected COVID-19 cases [<xref rid="B242" ref-type="bibr">242</xref>]. Once the primary diagnosis reveals abnormal chest CT findings, a nucleic acid test should be performed to confirm whether a patient is infected. Once a person is confirmed positive, tests such as C-reactive protein (CRP), complete blood count, urinalysis, biochemical indicators (i.e., liver enzymes, myocardial enzymes, and renal function), blood coagulation function, arterial blood gas analysis, and cytokine levels should be performed to monitor the patient's condition [<xref rid="B189" ref-type="bibr">189</xref>]. Chest CT should be performed as a follow-up to treatment as well [<xref rid="B242" ref-type="bibr">242</xref>]. The currently adopted procedure in identifying potential COVID-19 cases in China is summarized in <xref ref-type="fig" rid="fig10">Figure 10</xref>.</p><p>On a community scale and beyond, strict controls over human traffic are essential to limiting disease transmission. By establishing lockdowns, China has been able to bring the crisis under control. Other nations are now following the Chinese's approach in restricting movement of residents within their borders. As evidenced globally, social distancing is essential to halt the spread of COVID-19. On the other hand, individuals have the responsibilities to follow the guidelines given by the authorities, to practice good hygiene, and to behave responsibly. COVID-19, like the past epidemics, does not recognize political boundaries, ethnicity, or gender. The disease has challenged the economic and medical infrastructure of the entire globe. As evidenced by events of the past few months, the impact of the outbreak depends upon how well we are prepared to face such a challenge. Only with time will we be able to fully evaluate the measures that are being taken against COVID-19 today.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>Previous coronavirus epidemics like SARS and MERS have expedited the process of finding useful diagnostic and therapies against 2019-nCoV. It is of paramount importance for all countries to share essential information about 2019-nCoV to mitigate its spread. Because of this strategic approach, research has been mobilized to rapidly develop diagnostic methods and worldwide implementation to minimize the impact of the pandemic. Practical diagnostic tests have aided management and contact tracing of COVID-19 cases in hotspot areas. In this regard, molecular virological techniques have assisted the scientific community in characterizing infectious agents for years. These include qRT-PCR, isothermal amplification, and CRISPR technology.</p><p>On the other hand, serological assays for antibodies and antigens present essential tools to obtain valuable information about prior exposure to 2019-nCoV and the prevalence of infection. These include ELISA and LFA technologies. Serological screening also enables novel vaccines to be assessed and supports the design of functional vaccine approaches. Other approaches, including chest computed tomography (CT) and transmission electron microscopy (TEM), can boost existing detection approaches. Notably, there has been a marked increase in the use of both CT and TEM to detect 2019-nCoV and other coronaviruses. These complimentary tools reveal the progression of suspected infection, which cannot be accomplished by conventional diagnostic means. Nonetheless, there is a pressing need for continuous development of rapid, accurate diagnostic devices and strategies to characterize unknown respiratory pathogens.</p><p>Despite these signs of progress, the present data suggest that current public health policies and improved diagnostic measures alone may not be sufficient to eradicate COVID-19 in the short term. Efficacious and novel treatments are desperately required. Presently, large numbers of ongoing clinical trials of various drugs may succeed in minimizing morbidity and mortality. We have highlighted several of them in this review. Some are highly promising, while others may require more time to demonstrate usefulness. While some drug candidates appear promising and have been used in treating COVID-19 patients in desperation, it does not necessarily mean that they are proven safe and efficacious in the long run. As such, stringent criteria must be established by health regulatory agencies. However, in the long term, vaccines and prophylactics may be required to curb the spread of 2019-nCoV.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the Singapore Ministry of Education (MOE2017-T2-2-110); Agency for Science, Technology and Research (A&#x02217;STAR) (A1883c0011 and A1983c0038); National Research Foundation, Prime Minister's Office, Singapore, under the NRF Investigatorship programme (Award No. NRF-NRFI05-2019-0003); and National Natural Science Foundation of China (21771135).</p></ack><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="other"><collab>WHO</collab><source><italic toggle="yes">Coronavirus disease (COVID-19) outbreak situation</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="other"><collab>WHO</collab><source><italic toggle="yes">2019-nCoV outbreak is an emergency of international concern</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.euro.who.int/en/health-topics/health-emergencies/international-healthregulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern">http://www.euro.who.int/en/health-topics/health-emergencies/international-healthregulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern</ext-link></comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><collab>WHO</collab><source><italic toggle="yes">WHO Director-General's opening remarks at the media briefing on COVID-19</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link></comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P. C.</given-names></name><name><surname>Lau</surname><given-names>S. K.</given-names></name><name><surname>Yip</surname><given-names>C. C.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group><article-title>More and more coronaviruses: human coronavirus HKU1</article-title><source><italic toggle="yes">Viruses</italic></source><year>2009</year><volume>1</volume><issue>1</issue><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.3390/v1010057</pub-id><pub-id pub-id-type="other">2-s2.0-79957636922</pub-id><?supplied-pmid 21994538?><pub-id pub-id-type="pmid">21994538</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P. C.</given-names></name><name><surname>Lau</surname><given-names>S. K.</given-names></name><name><surname>Lam</surname><given-names>C. S.</given-names></name><etal/></person-group><article-title>Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>7</issue><fpage>3995</fpage><lpage>4008</lpage><pub-id pub-id-type="doi">10.1128/JVI.06540-11</pub-id><pub-id pub-id-type="other">2-s2.0-84861307149</pub-id><?supplied-pmid 22278237?><pub-id pub-id-type="pmid">22278237</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name><surname>Lau</surname><given-names>S. K. P.</given-names></name><name><surname>Chu</surname><given-names>C. M.</given-names></name><etal/></person-group><article-title>Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2005</year><volume>79</volume><issue>2</issue><fpage>884</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.2.884-895.2005</pub-id><pub-id pub-id-type="other">2-s2.0-19944427959</pub-id><?supplied-pmid 15613317?><pub-id pub-id-type="pmid">15613317</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>S. T.</given-names></name><name><surname>Poon</surname><given-names>L. L.</given-names></name><etal/></person-group><article-title>Coronavirus as a possible cause of severe acute respiratory syndrome</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2003</year><volume>361</volume><issue>9366</issue><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13077-2</pub-id><pub-id pub-id-type="other">2-s2.0-0242717589</pub-id><?supplied-pmid 12711465?><pub-id pub-id-type="pmid">12711465</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2020</year><volume>382</volume><issue>8</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L. E.</given-names></name><name><surname>Menachery</surname><given-names>V. D.</given-names></name></person-group><article-title>Return of the coronavirus: 2019-nCoV</article-title><source><italic toggle="yes">Viruses</italic></source><year>2020</year><volume>12</volume><issue>2</issue><fpage>p. 135</fpage><pub-id pub-id-type="doi">10.3390/v12020135</pub-id><?supplied-pmid 31991541?><pub-id pub-id-type="pmid">31991541</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name><name><surname>Wang</surname><given-names>X. G.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source><italic toggle="yes">Nature</italic></source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><?supplied-pmid 32015507?><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2020</year><volume>27</volume><issue>3</issue><fpage>325</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id><?supplied-pmid 32035028?><pub-id pub-id-type="pmid">32035028</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F.-W.</given-names></name><name><surname>Kok</surname><given-names>K. H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source><italic toggle="yes">Emerging Microbes &#x00026; Infections</italic></source><year>2020</year><volume>9</volume><issue>1</issue><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id><?supplied-pmid 31987001?><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2020</year><volume>92</volume><issue>4</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><?supplied-pmid 31967327?><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><etal/></person-group><source><italic toggle="yes">ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism</italic></source><year>2020</year><publisher-name>medRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.02.05.20020545</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>Z.</given-names></name></person-group><article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title><source><italic toggle="yes">Frontiers of Medicine</italic></source><year>2020</year><volume>14</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/s11684-020-0754-0</pub-id><pub-id pub-id-type="pmid">32170560</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K. S.</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source><italic toggle="yes">Science</italic></source><year>2020</year><volume>367</volume><issue>6483</issue><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name></person-group><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source><italic toggle="yes">Science</italic></source><year>2020</year><volume>367</volume><issue>6485</issue><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><?supplied-pmid 32132184?><pub-id pub-id-type="pmid">32132184</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>Y.-S.</given-names></name><etal/></person-group><source><italic toggle="yes">SARS-CoV-2 invades host cells via a novel route: CD147-spike protein</italic></source><year>2020</year><publisher-name>bioRxiv</publisher-name></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatagopalan</surname><given-names>P.</given-names></name><name><surname>Daskalova</surname><given-names>S. M.</given-names></name><name><surname>Lopez</surname><given-names>L. A.</given-names></name><name><surname>Dolezal</surname><given-names>K. A.</given-names></name><name><surname>Hogue</surname><given-names>B. G.</given-names></name></person-group><article-title>Coronavirus envelope (E) protein remains at the site of assembly</article-title><source><italic toggle="yes">Virology</italic></source><year>2015</year><volume>478</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.02.005</pub-id><pub-id pub-id-type="other">2-s2.0-84923658914</pub-id><pub-id pub-id-type="pmid">25726972</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto-Torres</surname><given-names>J. L.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name><name><surname>&#x000c1;lvarez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein</article-title><source><italic toggle="yes">Virology</italic></source><year>2011</year><volume>415</volume><issue>2</issue><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2011.03.029</pub-id><pub-id pub-id-type="other">2-s2.0-79957734900</pub-id><pub-id pub-id-type="pmid">21524776</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruch</surname><given-names>T. R.</given-names></name><name><surname>Machamer</surname><given-names>C. E.</given-names></name></person-group><article-title>A single polar residue and distinct membrane topologies impact the function of the infectious bronchitis coronavirus E protein</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2012</year><volume>8</volume><issue>5, article e1002674</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1002674</pub-id><pub-id pub-id-type="other">2-s2.0-84858971773</pub-id><?supplied-pmid 22570613?><pub-id pub-id-type="pmid">22570613</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Abdelmageed</surname><given-names>M. I.</given-names></name><name><surname>Abdelmoneim</surname><given-names>A. H.</given-names></name><name><surname>Mustafa</surname><given-names>M. I.</given-names></name><etal/></person-group><source><italic toggle="yes">Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: an immunoinformatics approach</italic></source><year>2020</year><publisher-name>BioRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.02.04.934232</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="gov"><collab>WHO</collab><source><italic toggle="yes">Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf">https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf</ext-link></comment></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surveillances</surname><given-names>V.</given-names></name></person-group><article-title>The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020</article-title><source><italic toggle="yes">China CDC Weekly</italic></source><year>2020</year><volume>2</volume><fpage>113</fpage><lpage>122</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="other"><collab>National Health Committee of the People's Republic of China</collab><source><italic toggle="yes">Diagnosis and treatment guidelines for COVID-19</italic></source><comment>April 2020, <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml">http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml</ext-link></comment></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobel</surname><given-names>E. J.</given-names></name><name><surname>Yu</surname><given-names>A. M.</given-names></name><name><surname>Lucks</surname><given-names>J. B.</given-names></name></person-group><article-title>High-throughput determination of RNA structures</article-title><source><italic toggle="yes">Nature Reviews Genetics</italic></source><year>2018</year><volume>19</volume><issue>10</issue><fpage>615</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/s41576-018-0034-x</pub-id><pub-id pub-id-type="other">2-s2.0-85050914269</pub-id><?supplied-pmid 30054568?><pub-id pub-id-type="pmid">30054568</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanger</surname><given-names>F.</given-names></name><name><surname>Nicklen</surname><given-names>S.</given-names></name><name><surname>Coulson</surname><given-names>A. R.</given-names></name></person-group><article-title>DNA sequencing with chain-terminating inhibitors</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1977</year><volume>74</volume><issue>12</issue><fpage>5463</fpage><lpage>5467</lpage><pub-id pub-id-type="doi">10.1073/pnas.74.12.5463</pub-id><pub-id pub-id-type="other">2-s2.0-0017681196</pub-id><?supplied-pmid 271968?><pub-id pub-id-type="pmid">271968</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><etal/></person-group><source><italic toggle="yes">Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses</italic></source><year>2020</year><publisher-name>MedRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.03.04.20029538</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Weiss</surname><given-names>Z. R.</given-names></name><name><surname>Williams</surname><given-names>Z.</given-names></name></person-group><article-title>Rapid multiplex small DNA sequencing on the MinION nanopore sequencing platform</article-title><source><italic toggle="yes">G3: Genes, Genomes, Genetics</italic></source><year>2018</year><volume>8</volume><issue>5</issue><fpage>1649</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1534/g3.118.200087</pub-id><pub-id pub-id-type="other">2-s2.0-85046660441</pub-id><?supplied-pmid 29540443?><pub-id pub-id-type="pmid">29540443</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>R. H.</given-names></name><name><surname>Anslan</surname><given-names>S.</given-names></name><name><surname>Bahram</surname><given-names>M.</given-names></name><name><surname>Wurzbacher</surname><given-names>C.</given-names></name><name><surname>Baldrian</surname><given-names>P.</given-names></name><name><surname>Tedersoo</surname><given-names>L.</given-names></name></person-group><article-title>Mycobiome diversity: high-throughput sequencing and identification of fungi</article-title><source><italic toggle="yes">Nature Reviews Microbiology</italic></source><year>2019</year><volume>17</volume><issue>2</issue><fpage>95</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0116-y</pub-id><pub-id pub-id-type="other">2-s2.0-85056715661</pub-id><?supplied-pmid 30442909?><pub-id pub-id-type="pmid">30442909</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Recent advances and perspectives of nucleic acid detection for coronavirus</article-title><source><italic toggle="yes">Journal of Pharmaceutical Analysis</italic></source><year>2020</year><volume>10</volume><issue>2</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.02.010</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahamtan</surname><given-names>A.</given-names></name><name><surname>Ardebili</surname><given-names>A.</given-names></name></person-group><article-title>Real-time RT-PCR in COVID-19 detection: issues affecting the results</article-title><source><italic toggle="yes">Expert Review of Molecular Diagnostics</italic></source><year>2020</year><volume>20</volume><issue>5</issue><fpage>453</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1080/14737159.2020.1757437</pub-id><?supplied-pmid 32297805?><pub-id pub-id-type="pmid">32297805</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>T.</given-names></name><name><surname>Hands</surname><given-names>R. E.</given-names></name><name><surname>Bustin</surname><given-names>S. A.</given-names></name></person-group><article-title>Quantification of mRNA using real-time RT-PCR</article-title><source><italic toggle="yes">Nature Protocols</italic></source><year>2006</year><volume>1</volume><issue>3</issue><fpage>1559</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.236</pub-id><pub-id pub-id-type="other">2-s2.0-33847643776</pub-id><?supplied-pmid 17406449?><pub-id pub-id-type="pmid">17406449</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="other"><collab>Roche's cobas</collab><source><italic toggle="yes">SARS-CoV-2 test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.roche.com/media/releases/med-cor-2020-03-13.htm">https://www.roche.com/media/releases/med-cor-2020-03-13.htm</ext-link></comment></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>P.</given-names></name><name><surname>Ghaemi</surname><given-names>A.</given-names></name></person-group><article-title>Nucleic acid isothermal amplification technologies&#x02014;a review</article-title><source><italic toggle="yes">Nucleosides, Nucleotides and Nucleic Acids</italic></source><year>2008</year><volume>27</volume><issue>3</issue><fpage>224</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1080/15257770701845204</pub-id><pub-id pub-id-type="other">2-s2.0-38949113780</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craw</surname><given-names>P.</given-names></name><name><surname>Balachandran</surname><given-names>W.</given-names></name></person-group><article-title>Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review</article-title><source><italic toggle="yes">Lab on a Chip</italic></source><year>2012</year><volume>12</volume><issue>14</issue><fpage>2469</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1039/c2lc40100b</pub-id><pub-id pub-id-type="other">2-s2.0-84862894848</pub-id><?supplied-pmid 22592150?><pub-id pub-id-type="pmid">22592150</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>Y.</given-names></name><name><surname>Notomi</surname><given-names>T.</given-names></name></person-group><article-title>Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost- effective diagnostic method for infectious diseases</article-title><source><italic toggle="yes">Journal of Infection and Chemotherapy</italic></source><year>2009</year><volume>15</volume><issue>2</issue><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s10156-009-0669-9</pub-id><pub-id pub-id-type="other">2-s2.0-65349100762</pub-id><?supplied-pmid 19396514?><pub-id pub-id-type="pmid">19396514</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Ying</surname><given-names>Q.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Development and application of reverse transcription loop-mediated isothermal amplification for detecting live Shewanella putrefaciens in preserved fish sample</article-title><source><italic toggle="yes">Journal of Food Science</italic></source><year>2012</year><volume>77</volume><issue>4</issue><fpage>M226</fpage><lpage>M230</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3841.2012.02636.x</pub-id><pub-id pub-id-type="other">2-s2.0-84859962423</pub-id><?supplied-pmid 22515249?><pub-id pub-id-type="pmid">22515249</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>E.</given-names></name><name><surname>Chung</surname><given-names>D. R.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>E. S.</given-names></name></person-group><article-title>A simple and multiplex loop-mediated isothermal amplification (LAMP) assay for rapid detection of SARS-CoV</article-title><source><italic toggle="yes">BioChip Journal</italic></source><year>2019</year><volume>13</volume><issue>4</issue><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1007/s13206-019-3404-3</pub-id><?supplied-pmid 32226589?><pub-id pub-id-type="pmid">32226589</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A rapid and specific assay for the detection of MERS-CoV</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2018</year><volume>9</volume><fpage>p. 1101</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.01101</pub-id><pub-id pub-id-type="other">2-s2.0-85047835322</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Milewska</surname><given-names>A.</given-names></name><name><surname>Potempa</surname><given-names>J.</given-names></name></person-group><article-title>Development of loop-mediated isothermal amplification assay for detection of human coronavirus-NL63</article-title><source><italic toggle="yes">Journal of Virological Methods</italic></source><year>2011</year><volume>175</volume><issue>1</issue><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2011.04.024</pub-id><pub-id pub-id-type="other">2-s2.0-79958012975</pub-id><?supplied-pmid 21545810?><pub-id pub-id-type="pmid">21545810</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Hao</surname><given-names>X.</given-names></name><etal/></person-group><source><italic toggle="yes">Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO</italic></source><year>2020</year><publisher-name>MedRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.02.20.20025874</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>G.-S.</given-names></name><name><surname>Ku</surname><given-names>K.</given-names></name><name><surname>Baek</surname><given-names>S. H.</given-names></name><etal/></person-group><article-title>Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2</article-title><source><italic toggle="yes">The Journal of Molecular Diagnostics</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jmoldx.2020.03.006</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Dang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><source><italic toggle="yes">Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method</italic></source><year>2020</year><publisher-name>MedRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.03.02.20030130</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>El-Tholoth</surname><given-names>M.</given-names></name><name><surname>Bau</surname><given-names>H. H.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><source><italic toggle="yes">A Single and Two-Stage, Closed-Tube, Molecular test for the 2019 novel coronavirus (COVID-19) at home, clinic, and points of entry</italic></source><year>2020</year><publisher-name>ChemRxiv</publisher-name><pub-id pub-id-type="doi">10.26434/chemrxiv.11860137.v1</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babu</surname><given-names>B.</given-names></name><name><surname>Ochoa-Corona</surname><given-names>F. M.</given-names></name><name><surname>Paret</surname><given-names>M. L.</given-names></name></person-group><article-title>Recombinase polymerase amplification applied to plant virus detection and potential implications</article-title><source><italic toggle="yes">Analytical Biochemistry</italic></source><year>2018</year><volume>546</volume><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2018.01.021</pub-id><pub-id pub-id-type="other">2-s2.0-85041549828</pub-id><?supplied-pmid 29408177?><pub-id pub-id-type="pmid">29408177</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobato</surname><given-names>I. M.</given-names></name><name><surname>O'Sullivan</surname><given-names>C. K.</given-names></name></person-group><article-title>Recombinase polymerase amplification: basics, applications and recent advances</article-title><source><italic toggle="yes">Trac Trends in Analytical Chemistry</italic></source><year>2018</year><volume>98</volume><fpage>19</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.trac.2017.10.015</pub-id><pub-id pub-id-type="other">2-s2.0-85033399606</pub-id><?supplied-pmid 32287544?><pub-id pub-id-type="pmid">32287544</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el Wahed</surname><given-names>A. A.</given-names></name><name><surname>el-Deeb</surname><given-names>A.</given-names></name><name><surname>el-Tholoth</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A portable reverse transcription recombinase polymerase amplification assay for rapid detection of foot-and-mouth disease virus</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>8, article e71642</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0071642</pub-id><pub-id pub-id-type="other">2-s2.0-84882638205</pub-id><?supplied-pmid 23977101?><pub-id pub-id-type="pmid">23977101</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>D. S.</given-names></name><name><surname>Lehman</surname><given-names>D. A.</given-names></name><name><surname>Lillis</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification</article-title><source><italic toggle="yes">MBio</italic></source><year>2013</year><volume>4</volume><issue>2</issue><pub-id pub-id-type="doi">10.1128/mbio.00135-13</pub-id><pub-id pub-id-type="other">2-s2.0-84880077457</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amer</surname><given-names>H. M.</given-names></name><name><surname>Abd el Wahed</surname><given-names>A.</given-names></name><name><surname>Shalaby</surname><given-names>M. A.</given-names></name><name><surname>Almajhdi</surname><given-names>F. N.</given-names></name><name><surname>Hufert</surname><given-names>F. T.</given-names></name><name><surname>Weidmann</surname><given-names>M.</given-names></name></person-group><article-title>A new approach for diagnosis of bovine coronavirus using a reverse transcription recombinase polymerase amplification assay</article-title><source><italic toggle="yes">Journal of Virological Methods</italic></source><year>2013</year><volume>193</volume><issue>2</issue><fpage>337</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2013.06.027</pub-id><pub-id pub-id-type="other">2-s2.0-84880738024</pub-id><?supplied-pmid 23811231?><pub-id pub-id-type="pmid">23811231</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Wahed</surname><given-names>A. A.</given-names></name><name><surname>Patel</surname><given-names>P.</given-names></name><name><surname>Heidenreich</surname><given-names>D.</given-names></name><name><surname>Hufert</surname><given-names>F. T.</given-names></name><name><surname>Weidmann</surname><given-names>M.</given-names></name></person-group><article-title>Reverse transcription recombinase polymerase amplification assay for the detection of Middle East respiratory syndrome coronavirus</article-title><source><italic toggle="yes">PLoS Currents</italic></source><year>2013</year><volume>5</volume><pub-id pub-id-type="doi">10.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>X. N.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Development of a reverse transcription recombinase-aided amplification assay for the detection of coxsackievirus A10 and coxsackievirus A6 RNA</article-title><source><italic toggle="yes">Archives of Virology</italic></source><year>2018</year><volume>163</volume><issue>6</issue><fpage>1455</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1007/s00705-018-3734-9</pub-id><pub-id pub-id-type="other">2-s2.0-85041920159</pub-id><?supplied-pmid 29429036?><pub-id pub-id-type="pmid">29429036</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Ran</surname><given-names>F. A.</given-names></name><name><surname>Cox</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source><italic toggle="yes">Science</italic></source><year>2013</year><volume>339</volume><issue>6121</issue><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="other">2-s2.0-84873729095</pub-id><?supplied-pmid 23287718?><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>P. D.</given-names></name><name><surname>Lander</surname><given-names>E. S.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Development and applications of CRISPR-Cas9 for genome engineering</article-title><source><italic toggle="yes">Cell</italic></source><year>2014</year><volume>157</volume><issue>6</issue><fpage>1262</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.05.010</pub-id><pub-id pub-id-type="other">2-s2.0-84902096048</pub-id><pub-id pub-id-type="pmid">24906146</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group><article-title>CRISPR gene-editing tested in a person for the first time</article-title><source><italic toggle="yes">Nature</italic></source><year>2016</year><volume>539</volume><issue>7630</issue><fpage>p. 479</fpage><pub-id pub-id-type="doi">10.1038/nature.2016.20988</pub-id><pub-id pub-id-type="other">2-s2.0-85007513300</pub-id><?supplied-pmid 27882996?><pub-id pub-id-type="pmid">27882996</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezaei</surname><given-names>H.</given-names></name><name><surname>khadempar</surname><given-names>S.</given-names></name><name><surname>Farahani</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Harnessing CRISPR/Cas9 technology in cardiovascular disease</article-title><source><italic toggle="yes">Trends in Cardiovascular Medicine</italic></source><year>2020</year><volume>30</volume><issue>2</issue><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2019.03.005</pub-id><pub-id pub-id-type="other">2-s2.0-85063496563</pub-id><?supplied-pmid 30935726?><pub-id pub-id-type="pmid">30935726</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gootenberg</surname><given-names>J. S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O. O.</given-names></name><name><surname>Lee</surname><given-names>J. W.</given-names></name><etal/></person-group><article-title>Nucleic acid detection with CRISPR-Cas13a/C2c2</article-title><source><italic toggle="yes">Science</italic></source><year>2017</year><volume>356</volume><issue>6336</issue><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1126/science.aam9321</pub-id><pub-id pub-id-type="other">2-s2.0-85017652697</pub-id><?supplied-pmid 28408723?><pub-id pub-id-type="pmid">28408723</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>M. J.</given-names></name><name><surname>Koob</surname><given-names>J. G.</given-names></name><name><surname>Gootenberg</surname><given-names>J. S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O. O.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>SHERLOCK: nucleic acid detection with CRISPR nucleases</article-title><source><italic toggle="yes">Nature Protocols</italic></source><year>2019</year><volume>14</volume><issue>10</issue><fpage>2986</fpage><lpage>3012</lpage><pub-id pub-id-type="doi">10.1038/s41596-019-0210-2</pub-id><pub-id pub-id-type="other">2-s2.0-85072718618</pub-id><?supplied-pmid 31548639?><pub-id pub-id-type="pmid">31548639</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gootenberg</surname><given-names>J. S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O. O.</given-names></name><name><surname>Kellner</surname><given-names>M. J.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name><name><surname>Collins</surname><given-names>J. J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6</article-title><source><italic toggle="yes">Science</italic></source><year>2018</year><volume>360</volume><issue>6387</issue><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1126/science.aaq0179</pub-id><pub-id pub-id-type="other">2-s2.0-85042220581</pub-id><?supplied-pmid 29449508?><pub-id pub-id-type="pmid">29449508</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Abudayyeh</surname><given-names>O. O.</given-names></name><name><surname>Jonathan</surname><given-names>S. G.</given-names></name></person-group><source><italic toggle="yes">SHERLOCK, a protocol for detection of COVID-19 using CRISPR diagnostics</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf">https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf</ext-link></comment></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J. S.</given-names></name><name><surname>Ma</surname><given-names>E.</given-names></name><name><surname>Harrington</surname><given-names>L. B.</given-names></name><etal/></person-group><article-title>CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity</article-title><source><italic toggle="yes">Science</italic></source><year>2018</year><volume>360</volume><issue>6387</issue><fpage>436</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1126/science.aar6245</pub-id><pub-id pub-id-type="other">2-s2.0-85042354098</pub-id><?supplied-pmid 29449511?><pub-id pub-id-type="pmid">29449511</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lucia</surname><given-names>C.</given-names></name><name><surname>Federico</surname><given-names>P.-B.</given-names></name><name><surname>Alejandra</surname><given-names>G. C.</given-names></name></person-group><source><italic toggle="yes">An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12</italic></source><year>2020</year><publisher-name>BioRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.02.29.971127</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>J. P.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>CRISPR-Cas12-based detection of SARS-CoV-2</article-title><source><italic toggle="yes">Nature Biotechnology</italic></source><year>2020</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0513-4</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B.</given-names></name><name><surname>Kinzler</surname><given-names>K. W.</given-names></name></person-group><article-title>Digital PCR</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1999</year><volume>96</volume><issue>16</issue><fpage>9236</fpage><lpage>9241</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.16.9236</pub-id><pub-id pub-id-type="other">2-s2.0-0033529765</pub-id><?supplied-pmid 10430926?><pub-id pub-id-type="pmid">10430926</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Kong</surname><given-names>J. E.</given-names></name><name><surname>Ozcan</surname><given-names>A.</given-names></name><name><surname>Di Carlo</surname><given-names>D.</given-names></name></person-group><article-title>Research highlights: digital assays on chip</article-title><source><italic toggle="yes">Lab on a Chip</italic></source><year>2015</year><volume>15</volume><issue>1</issue><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1039/C4LC90119C</pub-id><pub-id pub-id-type="other">2-s2.0-84915763015</pub-id><?supplied-pmid 25410901?><pub-id pub-id-type="pmid">25410901</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittrich</surname><given-names>P. S.</given-names></name><name><surname>Manz</surname><given-names>A.</given-names></name></person-group><article-title>Lab-on-a-chip: microfluidics in drug discovery</article-title><source><italic toggle="yes">Nature Reviews Drug Discovery</italic></source><year>2006</year><volume>5</volume><issue>3</issue><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nrd1985</pub-id><pub-id pub-id-type="other">2-s2.0-33644777646</pub-id><?supplied-pmid 16518374?><pub-id pub-id-type="pmid">16518374</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitesides</surname><given-names>G. M.</given-names></name></person-group><article-title>The origins and the future of microfluidics</article-title><source><italic toggle="yes">Nature</italic></source><year>2006</year><volume>442</volume><issue>7101</issue><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1038/nature05058</pub-id><pub-id pub-id-type="other">2-s2.0-33747117373</pub-id><?supplied-pmid 16871203?><pub-id pub-id-type="pmid">16871203</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sackmann</surname><given-names>E. K.</given-names></name><name><surname>Fulton</surname><given-names>A. L.</given-names></name><name><surname>Beebe</surname><given-names>D. J.</given-names></name></person-group><article-title>The present and future role of microfluidics in biomedical research</article-title><source><italic toggle="yes">Nature</italic></source><year>2014</year><volume>507</volume><issue>7491</issue><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/nature13118</pub-id><pub-id pub-id-type="other">2-s2.0-84896284039</pub-id><?supplied-pmid 24622198?><pub-id pub-id-type="pmid">24622198</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreutz</surname><given-names>J. E.</given-names></name><name><surname>Munson</surname><given-names>T.</given-names></name><name><surname>Huynh</surname><given-names>T.</given-names></name><name><surname>Shen</surname><given-names>F.</given-names></name><name><surname>du</surname><given-names>W.</given-names></name><name><surname>Ismagilov</surname><given-names>R. F.</given-names></name></person-group><article-title>Theoretical design and analysis of multivolume digital assays with wide dynamic range validated experimentally with microfluidic digital PCR</article-title><source><italic toggle="yes">Analytical Chemistry</italic></source><year>2011</year><volume>83</volume><issue>21</issue><fpage>8158</fpage><lpage>8168</lpage><pub-id pub-id-type="doi">10.1021/ac201658s</pub-id><pub-id pub-id-type="other">2-s2.0-80155134181</pub-id><?supplied-pmid 21981344?><pub-id pub-id-type="pmid">21981344</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Monte Carlo modeling-based digital loop-mediated isothermal amplification on a spiral chip for absolute quantification of nucleic acids</article-title><source><italic toggle="yes">Analytical Chemistry</italic></source><year>2017</year><volume>89</volume><issue>6</issue><fpage>3716</fpage><lpage>3723</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.7b00031</pub-id><pub-id pub-id-type="other">2-s2.0-85018995333</pub-id><?supplied-pmid 28211674?><pub-id pub-id-type="pmid">28211674</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottesen</surname><given-names>E. A.</given-names></name><name><surname>Hong</surname><given-names>J. W.</given-names></name><name><surname>Quake</surname><given-names>S. R.</given-names></name><name><surname>Leadbetter</surname><given-names>J. R.</given-names></name></person-group><article-title>Microfluidic digital PCR enables multigene analysis of individual environmental bacteria</article-title><source><italic toggle="yes">Science</italic></source><year>2006</year><volume>314</volume><issue>5804</issue><fpage>1464</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1126/science.1131370</pub-id><pub-id pub-id-type="other">2-s2.0-33845342557</pub-id><?supplied-pmid 17138901?><pub-id pub-id-type="pmid">17138901</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gansen</surname><given-names>A.</given-names></name><name><surname>Herrick</surname><given-names>A. M.</given-names></name><name><surname>Dimov</surname><given-names>I. K.</given-names></name><name><surname>Lee</surname><given-names>L. P.</given-names></name><name><surname>Chiu</surname><given-names>D. T.</given-names></name></person-group><article-title>Digital LAMP in a sample self-digitization (SD) chip</article-title><source><italic toggle="yes">Lab on a Chip</italic></source><year>2012</year><volume>12</volume><issue>12</issue><fpage>2247</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1039/c2lc21247a</pub-id><pub-id pub-id-type="other">2-s2.0-84862164769</pub-id><?supplied-pmid 22399016?><pub-id pub-id-type="pmid">22399016</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Self-priming compartmentalization digital LAMP for point-of-care</article-title><source><italic toggle="yes">Lab on a Chip</italic></source><year>2012</year><volume>12</volume><issue>22</issue><fpage>4755</fpage><lpage>4763</lpage><pub-id pub-id-type="doi">10.1039/c2lc40774d</pub-id><pub-id pub-id-type="other">2-s2.0-84867502612</pub-id><?supplied-pmid 22986619?><pub-id pub-id-type="pmid">22986619</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rane</surname><given-names>T. D.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zec</surname><given-names>H. C.</given-names></name><name><surname>Wang</surname><given-names>T.-H.</given-names></name></person-group><article-title>Microfluidic continuous flow digital loop-mediated isothermal amplification (LAMP)</article-title><source><italic toggle="yes">Lab on a Chip</italic></source><year>2015</year><volume>15</volume><issue>3</issue><fpage>776</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1039/C4LC01158A</pub-id><pub-id pub-id-type="other">2-s2.0-84921627838</pub-id><?supplied-pmid 25431886?><pub-id pub-id-type="pmid">25431886</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>N. R. Y.</given-names></name><name><surname>Lim</surname><given-names>G. S.</given-names></name><name><surname>Sundah</surname><given-names>N. R.</given-names></name><name><surname>Lim</surname><given-names>D.</given-names></name><name><surname>Loh</surname><given-names>T. P.</given-names></name><name><surname>Shao</surname><given-names>H.</given-names></name></person-group><article-title>Visual and modular detection of pathogen nucleic acids with enzyme-DNA molecular complexes</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2018</year><volume>9</volume><issue>1</issue><fpage>3211</fpage><lpage>3238</lpage><pub-id pub-id-type="doi">10.1038/s41467-018-05733-0</pub-id><pub-id pub-id-type="other">2-s2.0-85051647869</pub-id><?supplied-pmid 30104566?><pub-id pub-id-type="pmid">30104566</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="other"><collab>NUSnews</collab><source><italic toggle="yes">NUS scientists work on COVID-19 vaccine trial and rapid test kits</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="http://news.nus.edu.sg/research/nus-scientists-work-covid-19-vaccine-trial-and-rapid-test-kits">http://news.nus.edu.sg/research/nus-scientists-work-covid-19-vaccine-trial-and-rapid-test-kits</ext-link></comment></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>S. K. P.</given-names></name><name><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name><surname>Wong</surname><given-names>B. H. L.</given-names></name><etal/></person-group><article-title>Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in sars patients by enzyme-linked immunosorbent assay</article-title><source><italic toggle="yes">Journal of Clinical Microbiology</italic></source><year>2004</year><volume>42</volume><issue>7</issue><fpage>2884</fpage><lpage>2889</lpage><pub-id pub-id-type="doi">10.1128/JCM.42.7.2884-2889.2004</pub-id><pub-id pub-id-type="other">2-s2.0-3142679423</pub-id><?supplied-pmid 15243033?><pub-id pub-id-type="pmid">15243033</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="other"><source><italic toggle="yes">Rockland Immunochemicals, I. ELISA Assays</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://rockland-inc.com/elisa.aspx">https://rockland-inc.com/elisa.aspx</ext-link></comment></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name><surname>Lau</surname><given-names>S. K. P.</given-names></name><name><surname>Wong</surname><given-names>B. H. L.</given-names></name><etal/></person-group><article-title>Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia</article-title><source><italic toggle="yes">Journal of Clinical Microbiology</italic></source><year>2005</year><volume>43</volume><issue>7</issue><fpage>3054</fpage><lpage>3058</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.7.3054-3058.2005</pub-id><pub-id pub-id-type="other">2-s2.0-22144450335</pub-id><?supplied-pmid 16000415?><pub-id pub-id-type="pmid">16000415</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>N.</given-names></name></person-group><source><italic toggle="yes">Singapore claims first use of antibody test to track coronavirus infections</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.sciencemag.org/news/2020/02/singapore-claims-first-use-antibody-test-track-coronavirus-infections">https://www.sciencemag.org/news/2020/02/singapore-claims-first-use-antibody-test-track-coronavirus-infections</ext-link></comment></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Drabek</surname><given-names>D.</given-names></name><etal/></person-group><source><italic toggle="yes">A human monoclonal antibody blocking SARS-CoV-2 infection</italic></source><year>2020</year><publisher-name>BioRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.03.11.987958</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>du</surname><given-names>R. H.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes</article-title><source><italic toggle="yes">Emerging Microbes &#x00026; Infections</italic></source><year>2020</year><volume>9</volume><issue>1</issue><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1729071</pub-id><?supplied-pmid 32065057?><pub-id pub-id-type="pmid">32065057</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racine</surname><given-names>R.</given-names></name><name><surname>Winslow</surname><given-names>G. M.</given-names></name></person-group><article-title>IgM in microbial infections: taken for granted?</article-title><source><italic toggle="yes">Immunology Letters</italic></source><year>2009</year><volume>125</volume><issue>2</issue><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2009.06.003</pub-id><pub-id pub-id-type="other">2-s2.0-68149178666</pub-id><?supplied-pmid 19539648?><pub-id pub-id-type="pmid">19539648</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25727</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseiny</surname><given-names>M.</given-names></name><name><surname>Kooraki</surname><given-names>S.</given-names></name><name><surname>Gholamrezanezhad</surname><given-names>A.</given-names></name><name><surname>Reddy</surname><given-names>S.</given-names></name><name><surname>Myers</surname><given-names>L.</given-names></name></person-group><article-title>Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome</article-title><source><italic toggle="yes">AJR American Journal of Roentgenology</italic></source><year>2020</year><volume>214</volume><issue>5</issue><fpage>1078</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.2214/AJR.20.22969</pub-id><?supplied-pmid 32108495?><pub-id pub-id-type="pmid">32108495</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketai</surname><given-names>L.</given-names></name><name><surname>Paul</surname><given-names>N. S.</given-names></name><name><surname>Wong</surname><given-names>K. T.</given-names></name></person-group><article-title>Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease</article-title><source><italic toggle="yes">Journal of Thoracic Imaging</italic></source><year>2006</year><volume>21</volume><issue>4</issue><fpage>276</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1097/01.rti.0000213581.14225.f1</pub-id><pub-id pub-id-type="other">2-s2.0-33751197492</pub-id><?supplied-pmid 17110851?><pub-id pub-id-type="pmid">17110851</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>K. M.</given-names></name><name><surname>Lee</surname><given-names>E. Y.</given-names></name><name><surname>Langer</surname><given-names>R. D.</given-names></name><name><surname>Larsson</surname><given-names>S. G.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: what does a radiologist need to know?</article-title><source><italic toggle="yes">American Journal of Roentgenology</italic></source><year>2016</year><volume>206</volume><issue>6</issue><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.2214/AJR.15.15363</pub-id><pub-id pub-id-type="other">2-s2.0-84999074920</pub-id><?supplied-pmid 26998804?><pub-id pub-id-type="pmid">26998804</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>K. M.</given-names></name><name><surname>Lee</surname><given-names>E. Y.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Follow-up chest radiographic findings in patients with MERS-CoV after recovery</article-title><source><italic toggle="yes">Indian Journal of Radiology and Imaging</italic></source><year>2017</year><volume>27</volume><issue>3</issue><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.4103/ijri.IJRI_469_16</pub-id><pub-id pub-id-type="other">2-s2.0-85030165638</pub-id><?supplied-pmid 29089687?><pub-id pub-id-type="pmid">29089687</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>G. E.</given-names></name><name><surname>Wong</surname><given-names>K. T.</given-names></name><name><surname>Tsui</surname><given-names>E. L. H.</given-names></name><etal/></person-group><article-title>Chest radiograph scores as potential prognostic indicators in severe acute respiratory syndrome (SARS)</article-title><source><italic toggle="yes">American Journal of Roentgenology</italic></source><year>2005</year><volume>184</volume><issue>3</issue><fpage>734</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.2214/ajr.184.3.01840734</pub-id><pub-id pub-id-type="other">2-s2.0-16244398642</pub-id><?supplied-pmid 15728590?><pub-id pub-id-type="pmid">15728590</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>M.</given-names></name><name><surname>Bernheim</surname><given-names>A.</given-names></name><name><surname>Mei</surname><given-names>X.</given-names></name><etal/></person-group><article-title>CT imaging features of 2019 novel coronavirus (2019-nCoV)</article-title><source><italic toggle="yes">Radiology</italic></source><year>2020</year><volume>295</volume><issue>1</issue><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020200230</pub-id><?supplied-pmid 32017661?><pub-id pub-id-type="pmid">32017661</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F.-W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K. H.</given-names></name><etal/></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id><?supplied-pmid 31986261?><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Tan</surname><given-names>X. Z.</given-names></name></person-group><article-title>2019 novel coronavirus (2019-nCoV) pneumonia</article-title><source><italic toggle="yes">Radiology</italic></source><year>2020</year><volume>295</volume><issue>1</issue><fpage>p. 19</fpage><pub-id pub-id-type="doi">10.1148/radiol.2020200257</pub-id><?supplied-pmid 32013795?><pub-id pub-id-type="pmid">32013795</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="other"><collab>The Guardian</collab><source><italic toggle="yes">What happens to people's lungs when they get coronavirus?</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.theguardian.com/world/2020/apr/15/what-happens-to-your-lungs-with-coronavirus-covid-19">https://www.theguardian.com/world/2020/apr/15/what-happens-to-your-lungs-with-coronavirus-covid-19</ext-link></comment></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curry</surname><given-names>A.</given-names></name><name><surname>Appleton</surname><given-names>H.</given-names></name><name><surname>Dowsett</surname><given-names>B.</given-names></name></person-group><article-title>Application of transmission electron microscopy to the clinical study of viral and bacterial infections: present and future</article-title><source><italic toggle="yes">Micron</italic></source><year>2006</year><volume>37</volume><issue>2</issue><fpage>91</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.micron.2005.10.001</pub-id><pub-id pub-id-type="other">2-s2.0-30144436798</pub-id><?supplied-pmid 16361103?><pub-id pub-id-type="pmid">16361103</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Probing the nature of upconversion nanocrystals: instrumentation matters</article-title><source><italic toggle="yes">Chemical Society Reviews</italic></source><year>2015</year><volume>44</volume><issue>6</issue><fpage>1479</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1039/C4CS00356J</pub-id><pub-id pub-id-type="other">2-s2.0-84924578339</pub-id><pub-id pub-id-type="pmid">25693872</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Leiro</surname><given-names>R.</given-names></name><name><surname>Scheres</surname><given-names>S. H. W.</given-names></name></person-group><article-title>Unravelling biological macromolecules with cryo-electron microscopy</article-title><source><italic toggle="yes">Nature</italic></source><year>2016</year><volume>537</volume><issue>7620</issue><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nature19948</pub-id><pub-id pub-id-type="other">2-s2.0-84988037279</pub-id><?supplied-pmid 27629640?><pub-id pub-id-type="pmid">27629640</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="other"><collab>Bloomberg</collab><source><italic toggle="yes">Here are the first images of how coronavirus replicates in cells</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.bloomberg.com/news/articles/2020-01-31/here-are-the-first-images-of-how-coronavirus-replicates-in-cells">https://www.bloomberg.com/news/articles/2020-01-31/here-are-the-first-images-of-how-coronavirus-replicates-in-cells</ext-link></comment></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monninger</surname><given-names>M. K.</given-names></name><name><surname>Nguessan</surname><given-names>C. A.</given-names></name><name><surname>Blancett</surname><given-names>C. D.</given-names></name><etal/></person-group><article-title>Preparation of viral samples within biocontainment for ultrastructural analysis: utilization of an innovative processing capsule for negative staining</article-title><source><italic toggle="yes">Journal of Virological Methods</italic></source><year>2016</year><volume>238</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2016.10.005</pub-id><pub-id pub-id-type="other">2-s2.0-84992513161</pub-id><?supplied-pmid 27751950?><pub-id pub-id-type="pmid">27751950</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group><source><italic toggle="yes">Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</italic></source><year>2020</year><publisher-name>BioRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.03.11.983056</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Astin</surname><given-names>J. W.</given-names></name><name><surname>Keerthisinghe</surname><given-names>P.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Sanderson</surname><given-names>L. E.</given-names></name><name><surname>Crosier</surname><given-names>K. E.</given-names></name><name><surname>Hall</surname><given-names>C. J.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Detrich</surname><given-names>H. W.</given-names></name><name><surname>Westerfield</surname><given-names>M.</given-names></name><name><surname>Zon</surname><given-names>L. I.</given-names></name></person-group><article-title>Innate immune cells and bacterial infection in zebrafish</article-title><source><italic toggle="yes">Methods in Cell Biology</italic></source><year>2017</year><volume>138</volume><publisher-name>Academic Press</publisher-name><fpage>31</fpage><lpage>60</lpage></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oprea</surname><given-names>T. I.</given-names></name><name><surname>Bauman</surname><given-names>J. E.</given-names></name><name><surname>Bologa</surname><given-names>C. G.</given-names></name><etal/></person-group><article-title>Drug repurposing from an academic perspective</article-title><source><italic toggle="yes">Drug Discovery Today: Therapeutic Strategies</italic></source><year>2011</year><volume>8</volume><issue>3-4</issue><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.ddstr.2011.10.002</pub-id><pub-id pub-id-type="other">2-s2.0-84862233340</pub-id><?supplied-pmid 22368688?><pub-id pub-id-type="pmid">22368688</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzorno</surname><given-names>A.</given-names></name><name><surname>Padey</surname><given-names>B.</given-names></name><name><surname>Terrier</surname><given-names>O.</given-names></name><name><surname>Rosa-Calatrava</surname><given-names>M.</given-names></name></person-group><article-title>Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2019</year><volume>10</volume><fpage>p. 531</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00531</pub-id><pub-id pub-id-type="other">2-s2.0-85064212427</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vardanyan</surname><given-names>R.</given-names></name><name><surname>Hruby</surname><given-names>V.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Vardanyan</surname><given-names>R.</given-names></name><name><surname>Hruby</surname><given-names>V.</given-names></name></person-group><article-title>Chapter 34 - Antiviral Drugs</article-title><source><italic toggle="yes">Synthesis of Best-Seller Drugs</italic></source><year>2016</year><publisher-name>Academic Press</publisher-name><fpage>687</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-411492-0.00034-1</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine</article-title><source><italic toggle="yes">Cellular &#x00026; Molecular Immunology</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41423-020-0400-4</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fmicb.2020.00298</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Vaccines for the prevention against the threat of MERS-CoV</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2016</year><volume>15</volume><issue>9</issue><fpage>1123</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1167603</pub-id><pub-id pub-id-type="other">2-s2.0-84964068412</pub-id><?supplied-pmid 26985862?><pub-id pub-id-type="pmid">26985862</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Prospects for a MERS-CoV spike vaccine</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2018</year><volume>17</volume><issue>8</issue><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1506702</pub-id><pub-id pub-id-type="other">2-s2.0-85052958867</pub-id><?supplied-pmid 30058403?><pub-id pub-id-type="pmid">30058403</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Millet</surname><given-names>J. K.</given-names></name><name><surname>Licitra</surname><given-names>B. N.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group><article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein</article-title><source><italic toggle="yes">Viruses</italic></source><year>2012</year><volume>4</volume><issue>6</issue><fpage>1011</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.3390/v4061011</pub-id><?supplied-pmid 22816037?><pub-id pub-id-type="pmid">22816037</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M. J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source><italic toggle="yes">Nature</italic></source><year>2003</year><volume>426</volume><issue>6965</issue><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="other">2-s2.0-0344395657</pub-id><?supplied-pmid 14647384?><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V. S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Smits</surname><given-names>S. L.</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source><italic toggle="yes">Nature</italic></source><year>2013</year><volume>495</volume><issue>7440</issue><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nature12005</pub-id><pub-id pub-id-type="other">2-s2.0-84874996988</pub-id><?supplied-pmid 23486063?><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z. J.</given-names></name></person-group><article-title>Structure analysis of the receptor binding of 2019-nCoV</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2020</year><volume>525</volume><issue>1</issue><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.071</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letko</surname><given-names>M.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Munster</surname><given-names>V.</given-names></name></person-group><article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title><source><italic toggle="yes">Nature Microbiology</italic></source><year>2020</year><volume>5</volume><issue>4</issue><fpage>562</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0688-y</pub-id><?supplied-pmid 32094589?><pub-id pub-id-type="pmid">32094589</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source><italic toggle="yes">Cell</italic></source><year>2020</year><volume>181</volume><issue>2</issue><fpage>271</fpage><lpage>280.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huentelman</surname><given-names>M. J.</given-names></name><name><surname>Zubcevic</surname><given-names>J.</given-names></name><name><surname>Hern&#x000e1;ndez Prada</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor</article-title><source><italic toggle="yes">Hypertension</italic></source><year>2004</year><volume>44</volume><issue>6</issue><fpage>903</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000146120.29648.36</pub-id><pub-id pub-id-type="other">2-s2.0-9644258512</pub-id><?supplied-pmid 15492138?><pub-id pub-id-type="pmid">15492138</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qaradakhi</surname><given-names>T.</given-names></name><name><surname>Gadanec</surname><given-names>L. K.</given-names></name><name><surname>McSweeney</surname><given-names>K. R.</given-names></name><etal/></person-group><article-title>The potential actions of angiotensin converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases</article-title><source><italic toggle="yes">Clinical and Experimental Pharmacology and Physiology</italic></source><year>2020</year><volume>47</volume><issue>5</issue><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.13251</pub-id><?supplied-pmid 31901211?><pub-id pub-id-type="pmid">31901211</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamsi-Pasha</surname><given-names>M. A. R.</given-names></name><name><surname>Shao</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>W. H. W.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 as a therapeutic target for heart failure</article-title><source><italic toggle="yes">Current Heart Failure Reports</italic></source><year>2014</year><volume>11</volume><issue>1</issue><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s11897-013-0178-0</pub-id><pub-id pub-id-type="other">2-s2.0-84896730319</pub-id><?supplied-pmid 24293035?><pub-id pub-id-type="pmid">24293035</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasvold</surname><given-names>L. P.</given-names></name><name><surname>Bodeg&#x000e5;rd</surname><given-names>J.</given-names></name><name><surname>Thuresson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients</article-title><source><italic toggle="yes">Journal of human hypertension</italic></source><year>2014</year><volume>28</volume><issue>11</issue><fpage>663</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/jhh.2014.43</pub-id><pub-id pub-id-type="other">2-s2.0-84924269487</pub-id><?supplied-pmid 25211055?><pub-id pub-id-type="pmid">25211055</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>W. B.</given-names></name><name><surname>Wilson</surname><given-names>C.</given-names></name><name><surname>Bakris</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Ace inhibitor use and major cardiovascular outcomes in type 2 diabetes treated with the dpp-4 inhibitor alogliptin</article-title><source><italic toggle="yes">Journal of the American College of Cardiology</italic></source><year>2015</year><volume>65</volume><issue>10, article A1411</issue><pub-id pub-id-type="doi">10.1016/S0735-1097(15)61411-5</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>G. I.</given-names></name><name><surname>Thomas</surname><given-names>D. A.</given-names></name><name><surname>Grant</surname><given-names>P. J.</given-names></name><name><surname>Turner</surname><given-names>A. J.</given-names></name><name><surname>Hooper</surname><given-names>N. M.</given-names></name></person-group><article-title>Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism</article-title><source><italic toggle="yes">Biochemical Journal</italic></source><year>2004</year><volume>383</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1042/BJ20040634</pub-id><pub-id pub-id-type="other">2-s2.0-6344246036</pub-id><?supplied-pmid 15283675?><pub-id pub-id-type="pmid">15283675</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A. B.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor Blockers</article-title><source><italic toggle="yes">The Journal of the American Medical Association</italic></source><year>2020</year><volume>323</volume><issue>18</issue><fpage>1749</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4812</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Karakiulakis</surname><given-names>G.</given-names></name><name><surname>Roth</surname><given-names>M.</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source><italic toggle="yes">The Lancet Respiratory Medicine</italic></source><year>2020</year><volume>8</volume><issue>4, article e21</issue><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id><?supplied-pmid 32171062?><pub-id pub-id-type="pmid">32171062</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadam</surname><given-names>R. U.</given-names></name><name><surname>Wilson</surname><given-names>I. A.</given-names></name></person-group><article-title>Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2017</year><volume>114</volume><issue>2</issue><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1073/pnas.1617020114</pub-id><pub-id pub-id-type="other">2-s2.0-85009380300</pub-id><?supplied-pmid 28003465?><pub-id pub-id-type="pmid">28003465</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z.</given-names></name><name><surname>Lou</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>New small-molecule drug design strategies for fighting resistant influenza A</article-title><source><italic toggle="yes">Acta Pharmaceutica Sinica B</italic></source><year>2015</year><volume>5</volume><issue>5</issue><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2015.07.006</pub-id><pub-id pub-id-type="other">2-s2.0-84947201563</pub-id><?supplied-pmid 26579472?><pub-id pub-id-type="pmid">26579472</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leneva</surname><given-names>I. A.</given-names></name><name><surname>Russell</surname><given-names>R. J.</given-names></name><name><surname>Boriskin</surname><given-names>Y. S.</given-names></name><name><surname>Hay</surname><given-names>A. J.</given-names></name></person-group><article-title>Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2009</year><volume>81</volume><issue>2</issue><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2008.10.009</pub-id><pub-id pub-id-type="other">2-s2.0-58249083139</pub-id><?supplied-pmid 19028526?><pub-id pub-id-type="pmid">19028526</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teissier</surname><given-names>E.</given-names></name><name><surname>Zandomeneghi</surname><given-names>G.</given-names></name><name><surname>Loquet</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2011</year><volume>6</volume><issue>1, article e15874</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0015874</pub-id><pub-id pub-id-type="other">2-s2.0-79551549308</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villala&#x000ed;n</surname><given-names>J.</given-names></name></person-group><article-title>Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes</article-title><source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source><year>2010</year><volume>114</volume><issue>25</issue><fpage>8544</fpage><lpage>8554</lpage><pub-id pub-id-type="doi">10.1021/jp102619w</pub-id><pub-id pub-id-type="other">2-s2.0-77953993735</pub-id><pub-id pub-id-type="pmid">20527735</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment</article-title><source><italic toggle="yes">BioScience Trends</italic></source><year>2020</year><volume>14</volume><issue>1</issue><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.5582/bst.2020.01030</pub-id><?supplied-pmid 32037389?><pub-id pub-id-type="pmid">32037389</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source><italic toggle="yes">Drug Discoveries &#x00026; Therapeutics</italic></source><year>2020</year><volume>14</volume><issue>1</issue><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5582/ddt.2020.01012</pub-id><pub-id pub-id-type="pmid">32147628</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Boelaert</surname><given-names>J. R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name><name><surname>Majori</surname><given-names>G.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: an old drug against today's diseases</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2003</year><volume>3</volume><issue>11</issue><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(03)00806-5</pub-id><pub-id pub-id-type="other">2-s2.0-0242355070</pub-id><?supplied-pmid 14592603?><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>B.</given-names></name><name><surname>Ohkuma</surname><given-names>S.</given-names></name></person-group><article-title>Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages</article-title><source><italic toggle="yes">Journal of Cell Biology</italic></source><year>1981</year><volume>90</volume><issue>3</issue><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1083/jcb.90.3.665</pub-id><pub-id pub-id-type="other">2-s2.0-0019866088</pub-id><?supplied-pmid 6169733?><pub-id pub-id-type="pmid">6169733</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrezenmeier</surname><given-names>E.</given-names></name><name><surname>D&#x000f6;rner</surname><given-names>T.</given-names></name></person-group><article-title>Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</article-title><source><italic toggle="yes">Nature Reviews Rheumatology</italic></source><year>2020</year><volume>16</volume><issue>3</issue><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41584-020-0372-x</pub-id><?supplied-pmid 32034323?><pub-id pub-id-type="pmid">32034323</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauthe</surname><given-names>M.</given-names></name><name><surname>Orhon</surname><given-names>I.</given-names></name><name><surname>Rocchi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion</article-title><source><italic toggle="yes">Autophagy</italic></source><year>2018</year><volume>14</volume><issue>8</issue><fpage>1435</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1080/15548627.2018.1474314</pub-id><pub-id pub-id-type="other">2-s2.0-85050360458</pub-id><?supplied-pmid 29940786?><pub-id pub-id-type="pmid">29940786</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Di Trani</surname><given-names>L.</given-names></name><name><surname>Donatelli</surname><given-names>I.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name></person-group><article-title>New insights into the antiviral effects of chloroquine</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2006</year><volume>6</volume><issue>2</issue><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70361-9</pub-id><pub-id pub-id-type="other">2-s2.0-31344436483</pub-id><?supplied-pmid 16439323?><pub-id pub-id-type="pmid">16439323</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Lucia</surname><given-names>M. B.</given-names></name><name><surname>Rastrelli</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors</article-title><source><italic toggle="yes">JAIDS Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2004</year><volume>35</volume><issue>3</issue><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1097/00126334-200403010-00002</pub-id><pub-id pub-id-type="other">2-s2.0-10744225033</pub-id><?supplied-pmid 15076236?><pub-id pub-id-type="pmid">15076236</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source><italic toggle="yes">Cell Discovery</italic></source><year>2020</year><volume>6</volume><issue>1</issue><fpage>p. 16</fpage><pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>M. J.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Benjannet</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2005</year><volume>2</volume><issue>1</issue><fpage>p. 69</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-2-69</pub-id><pub-id pub-id-type="other">2-s2.0-25444508979</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Ranst</surname><given-names>M. V.</given-names></name></person-group><article-title>In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2004</year><volume>323</volume><issue>1</issue><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.085</pub-id><pub-id pub-id-type="other">2-s2.0-4444275169</pub-id><?supplied-pmid 15351731?><pub-id pub-id-type="pmid">15351731</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source><italic toggle="yes">Cell Research</italic></source><year>2020</year><volume>30</volume><issue>3</issue><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source><italic toggle="yes">BioScience Trends</italic></source><year>2020</year><volume>14</volume><issue>1</issue><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.5582/bst.2020.01047</pub-id><?supplied-pmid 32074550?><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Brouqui</surname><given-names>P.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine as available weapons to fight COVID-19</article-title><source><italic toggle="yes">International Journal of Antimicrobial Agents</italic></source><year>2020</year><volume>55</volume><issue>4, article 105932</issue><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105932</pub-id><?supplied-pmid 32145363?><pub-id pub-id-type="pmid">32145363</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasadhika</surname><given-names>S.</given-names></name><name><surname>Fishman</surname><given-names>G. A.</given-names></name></person-group><article-title>Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures</article-title><source><italic toggle="yes">Eye</italic></source><year>2010</year><volume>24</volume><issue>2</issue><fpage>340</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/eye.2009.65</pub-id><pub-id pub-id-type="other">2-s2.0-77049115207</pub-id><?supplied-pmid 19373270?><pub-id pub-id-type="pmid">19373270</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McChesney</surname><given-names>E. W.</given-names></name></person-group><article-title>Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate</article-title><source><italic toggle="yes">The American Journal of Medicine</italic></source><year>1983</year><volume>75</volume><issue>1</issue><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(83)91265-2</pub-id><pub-id pub-id-type="other">2-s2.0-0020608881</pub-id><pub-id pub-id-type="pmid">6408923</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konvalinka</surname><given-names>J.</given-names></name><name><surname>Kr&#x000e4;usslich</surname><given-names>H.-G.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>B.</given-names></name></person-group><article-title>Retroviral proteases and their roles in virion maturation</article-title><source><italic toggle="yes">Virology</italic></source><year>2015</year><volume>479-480</volume><fpage>403</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.03.021</pub-id><pub-id pub-id-type="other">2-s2.0-84937511797</pub-id><?supplied-pmid 25816761?><pub-id pub-id-type="pmid">25816761</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>J. K.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group><article-title>Host cell proteases: critical determinants of coronavirus tropism and pathogenesis</article-title><source><italic toggle="yes">Virus Research</italic></source><year>2015</year><volume>202</volume><fpage>120</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.11.021</pub-id><pub-id pub-id-type="other">2-s2.0-84930047858</pub-id><?supplied-pmid 25445340?><pub-id pub-id-type="pmid">25445340</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>S.</given-names></name><name><surname>Heurich</surname><given-names>A.</given-names></name><name><surname>Lavender</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2012</year><volume>7</volume><issue>4, article e35876</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0035876</pub-id><pub-id pub-id-type="other">2-s2.0-84860485820</pub-id><?supplied-pmid 22558251?><pub-id pub-id-type="pmid">22558251</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases</article-title><source><italic toggle="yes">ACS Central Science</italic></source><year>2020</year><volume>6</volume><issue>3</issue><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.0c00272</pub-id><?supplied-pmid 32226821?><pub-id pub-id-type="pmid">32226821</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Snijder</surname><given-names>E. J.</given-names></name><name><surname>Gorbalenya</surname><given-names>A. E.</given-names></name></person-group><article-title>Virus-encoded proteinases and proteolytic processing in the Nidovirales</article-title><source><italic toggle="yes">Journal of General Virology</italic></source><year>2000</year><volume>81</volume><issue>4</issue><fpage>853</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-81-4-853</pub-id><pub-id pub-id-type="other">2-s2.0-0034072633</pub-id><pub-id pub-id-type="pmid">10725411</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e1;ez-Santos</surname><given-names>Y. M.</given-names></name><name><surname>St John</surname><given-names>S. E.</given-names></name><name><surname>Mesecar</surname><given-names>A. D.</given-names></name></person-group><article-title>The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2015</year><volume>115</volume><fpage>21</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.12.015</pub-id><pub-id pub-id-type="other">2-s2.0-84983527138</pub-id><?supplied-pmid 25554382?><pub-id pub-id-type="pmid">25554382</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.-W.</given-names></name><name><surname>Cherney</surname><given-names>M. M.</given-names></name><name><surname>Huitema</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Crystal Structures of the Main Peptidase from the SARS Coronavirus Inhibited by a Substrate-like Aza-peptide Epoxide</article-title><source><italic toggle="yes">Journal of Molecular Biology</italic></source><year>2005</year><volume>353</volume><issue>5</issue><fpage>1137</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.09.004</pub-id><pub-id pub-id-type="other">2-s2.0-27144538090</pub-id><?supplied-pmid 16219322?><pub-id pub-id-type="pmid">16219322</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>van der Hoek</surname><given-names>L.</given-names></name><name><surname>Taguchi</surname><given-names>F.</given-names></name><name><surname>Matsuyama</surname><given-names>S.</given-names></name></person-group><article-title>Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>12</issue><fpage>6537</fpage><lpage>6545</lpage><pub-id pub-id-type="doi">10.1128/JVI.00094-12</pub-id><pub-id pub-id-type="other">2-s2.0-84864018547</pub-id><?supplied-pmid 22496216?><pub-id pub-id-type="pmid">22496216</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Vedantham</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Protease inhibitors targeting coronavirus and filovirus entry</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2015</year><volume>116</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id><pub-id pub-id-type="other">2-s2.0-84923219776</pub-id><?supplied-pmid 25666761?><pub-id pub-id-type="pmid">25666761</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashizawa</surname><given-names>N.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Miyake</surname><given-names>T.</given-names></name><name><surname>Shizuku</surname><given-names>T.</given-names></name><name><surname>Imaoka</surname><given-names>T.</given-names></name><name><surname>Kinoshita</surname><given-names>Y.</given-names></name></person-group><article-title>Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?</article-title><source><italic toggle="yes">Journal of Gastroenterology and Hepatology</italic></source><year>2006</year><volume>21</volume><issue>4</issue><fpage>767</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2005.04041.x</pub-id><pub-id pub-id-type="other">2-s2.0-33645864657</pub-id><?supplied-pmid 16677167?><pub-id pub-id-type="pmid">16677167</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibo</surname><given-names>J.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Kawabe</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity</article-title><source><italic toggle="yes">Laboratory Investigation</italic></source><year>2005</year><volume>85</volume><issue>1</issue><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700203</pub-id><pub-id pub-id-type="other">2-s2.0-12344256183</pub-id><?supplied-pmid 15531908?><pub-id pub-id-type="pmid">15531908</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikura</surname><given-names>H.</given-names></name><name><surname>Nishimura</surname><given-names>S.</given-names></name><name><surname>Matsunami</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents</article-title><source><italic toggle="yes">Life Sciences</italic></source><year>2007</year><volume>80</volume><issue>21</issue><fpage>1999</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2007.02.044</pub-id><pub-id pub-id-type="other">2-s2.0-34247100738</pub-id><?supplied-pmid 17433371?><pub-id pub-id-type="pmid">17433371</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Matsuyama</surname><given-names>S.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2013</year><volume>87</volume><issue>23</issue><fpage>12552</fpage><lpage>12561</lpage><pub-id pub-id-type="doi">10.1128/JVI.01890-13</pub-id><pub-id pub-id-type="other">2-s2.0-84887169848</pub-id><?supplied-pmid 24027332?><pub-id pub-id-type="pmid">24027332</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV</article-title><source><italic toggle="yes">International Journal of Antimicrobial Agents</italic></source><year>2009</year><volume>33</volume><issue>4</issue><fpage>307</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2008.10.010</pub-id><pub-id pub-id-type="other">2-s2.0-61449189645</pub-id><?supplied-pmid 19108994?><pub-id pub-id-type="pmid">19108994</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>M. W.</given-names></name><name><surname>Montaner</surname><given-names>J. S. G.</given-names></name></person-group><article-title>Ritonavir-boosted protease inhibitors in HIV therapy</article-title><source><italic toggle="yes">Annals of Medicine</italic></source><year>2011</year><volume>43</volume><issue>5</issue><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.3109/07853890.2011.572905</pub-id><pub-id pub-id-type="other">2-s2.0-79959359682</pub-id><pub-id pub-id-type="pmid">21501034</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C. M.</given-names></name><name><surname>Cheng</surname><given-names>V. C.</given-names></name><name><surname>Hung</surname><given-names>I. F.</given-names></name><etal/></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source><italic toggle="yes">Thorax</italic></source><year>2004</year><volume>59</volume><issue>3</issue><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><pub-id pub-id-type="other">2-s2.0-12144290587</pub-id><?supplied-pmid 14985565?><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.-J.</given-names></name></person-group><article-title>Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines</article-title><source><italic toggle="yes">Journal of Genetics and Genomics</italic></source><year>2020</year><volume>47</volume><issue>2</issue><fpage>119</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.jgg.2020.02.001</pub-id><?supplied-pmid 32173287?><pub-id pub-id-type="pmid">32173287</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe Covid-19</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2020</year><volume>382</volume><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Yi</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2015</year><volume>4, article 6872</volume><pub-id pub-id-type="doi">10.1038/srep06872</pub-id><pub-id pub-id-type="other">2-s2.0-84925245959</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H.</given-names></name><name><surname>Takamune</surname><given-names>N.</given-names></name><name><surname>Nirasawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2014</year><volume>111</volume><issue>33</issue><fpage>12234</fpage><lpage>12239</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400027111</pub-id><pub-id pub-id-type="other">2-s2.0-84906311179</pub-id><?supplied-pmid 25092296?><pub-id pub-id-type="pmid">25092296</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Shen</surname><given-names>R.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name></person-group><source><italic toggle="yes">Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases</italic></source><year>2020</year><publisher-name>bioRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.01.31.929695</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Eckhardt</surname><given-names>B. J.</given-names></name><name><surname>Gulick</surname><given-names>R. M.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Cohen</surname><given-names>J.</given-names></name><name><surname>Powderly</surname><given-names>W. G.</given-names></name><name><surname>Opal</surname><given-names>S. M.</given-names></name></person-group><article-title>Drugs for HIV Infection</article-title><source><italic toggle="yes">Infectious Diseases (Fourth Edition)</italic></source><year>2017</year><publisher-name>Elsevier</publisher-name><fpage>1293</fpage><lpage>1308. e2</lpage><pub-id pub-id-type="doi">10.1016/B978-0-7020-6285-8.00152-0</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magden</surname><given-names>J.</given-names></name><name><surname>K&#x000e4;&#x000e4;ri&#x000e4;inen</surname><given-names>L.</given-names></name><name><surname>Ahola</surname><given-names>T.</given-names></name></person-group><article-title>Inhibitors of virus replication: recent developments and prospects</article-title><source><italic toggle="yes">Applied Microbiology and Biotechnology</italic></source><year>2005</year><volume>66</volume><issue>6</issue><fpage>612</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1007/s00253-004-1783-3</pub-id><pub-id pub-id-type="other">2-s2.0-15244352597</pub-id><?supplied-pmid 15592828?><pub-id pub-id-type="pmid">15592828</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lung</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Y. S.</given-names></name><name><surname>Yang</surname><given-names>Y. H.</given-names></name><etal/></person-group><article-title>The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2020</year><volume>92</volume><issue>6</issue><fpage>693</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1002/jmv.25761</pub-id><pub-id pub-id-type="pmid">32167173</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>E.</given-names></name><name><surname>Ghany</surname><given-names>M. G.</given-names></name><name><surname>Liang</surname><given-names>T. J.</given-names></name></person-group><article-title>The application and mechanism of action of ribavirin in therapy of hepatitis C</article-title><source><italic toggle="yes">Antiviral Chemistry and Chemotherapy</italic></source><year>2012</year><volume>23</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3851/IMP2125</pub-id><pub-id pub-id-type="other">2-s2.0-84867253160</pub-id><?supplied-pmid 22592135?><pub-id pub-id-type="pmid">22592135</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>S.</given-names></name><name><surname>Maag</surname><given-names>D.</given-names></name><name><surname>Arnold</surname><given-names>J. J.</given-names></name><etal/></person-group><article-title>The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2000</year><volume>6</volume><issue>12</issue><fpage>1375</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1038/82191</pub-id><pub-id pub-id-type="other">2-s2.0-0034532953</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulin</surname><given-names>D.</given-names></name><name><surname>Arnold</surname><given-names>J. J.</given-names></name><name><surname>van Laar</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Signatures of nucleotide analog incorporation by an RNA-dependent rna polymerase revealed using high-throughput magnetic tweezers</article-title><source><italic toggle="yes">Cell Reports</italic></source><year>2017</year><volume>21</volume><issue>4</issue><fpage>1063</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.005</pub-id><pub-id pub-id-type="other">2-s2.0-85032002414</pub-id><pub-id pub-id-type="pmid">29069588</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G.</given-names></name><name><surname>King</surname><given-names>S.</given-names></name><name><surname>Knowles</surname><given-names>S.</given-names></name><name><surname>Phillips</surname><given-names>E.</given-names></name></person-group><article-title>Ribavirin in the treatment of SARS: a new trick for an old drug?</article-title><source><italic toggle="yes">CMAJ</italic></source><year>2003</year><volume>168</volume><issue>10</issue><fpage>1289</fpage><lpage>1292</lpage><?supplied-pmid 12743076?><pub-id pub-id-type="pmid">12743076</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>S.</given-names></name><name><surname>Cameron</surname><given-names>C. E.</given-names></name><name><surname>Andino</surname><given-names>R.</given-names></name></person-group><article-title>RNA virus error catastrophe: direct molecular test by using ribavirin</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2001</year><volume>98</volume><issue>12</issue><fpage>6895</fpage><lpage>6900</lpage><pub-id pub-id-type="doi">10.1073/pnas.111085598</pub-id><pub-id pub-id-type="other">2-s2.0-0035811016</pub-id><?supplied-pmid 11371613?><pub-id pub-id-type="pmid">11371613</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Te</surname><given-names>H. S.</given-names></name><name><surname>Randall</surname><given-names>G.</given-names></name><name><surname>Jensen</surname><given-names>D. M.</given-names></name></person-group><article-title>Mechanism of action of ribavirin in the treatment of chronic hepatitis C</article-title><source><italic toggle="yes">Gastroenterology &#x00026; Hepatology</italic></source><year>2007</year><volume>3</volume><issue>3</issue><fpage>218</fpage><lpage>225</lpage><?supplied-pmid 21960835?><pub-id pub-id-type="pmid">21960835</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>D. Y.</given-names></name></person-group><article-title>Pharmacologic treatment of SARS: current knowledge and recommendations</article-title><source><italic toggle="yes">Annals Academy of Medicine</italic></source><year>2007</year><volume>36</volume><fpage>438</fpage><lpage>443</lpage></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyall</surname><given-names>J.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name><name><surname>Kindrachuk</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies</article-title><source><italic toggle="yes">Drugs</italic></source><year>2017</year><volume>77</volume><issue>18</issue><fpage>1935</fpage><lpage>1966</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0830-1</pub-id><pub-id pub-id-type="other">2-s2.0-85034083736</pub-id><pub-id pub-id-type="pmid">29143192</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name><name><surname>Momattin</surname><given-names>H.</given-names></name><name><surname>Dib</surname><given-names>J.</given-names></name><name><surname>Memish</surname><given-names>Z. A.</given-names></name></person-group><article-title>Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study</article-title><source><italic toggle="yes">International Journal of Infectious Diseases</italic></source><year>2014</year><volume>20</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2013.12.003</pub-id><pub-id pub-id-type="other">2-s2.0-84896695450</pub-id><?supplied-pmid 24406736?><pub-id pub-id-type="pmid">24406736</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momattin</surname><given-names>H.</given-names></name><name><surname>Mohammed</surname><given-names>K.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Memish</surname><given-names>Z. A.</given-names></name><name><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name></person-group><article-title>Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS- CoV) &#x02013; possible lessons from a systematic review of SARS-CoV therapy</article-title><source><italic toggle="yes">International Journal of Infectious Diseases</italic></source><year>2013</year><volume>17</volume><issue>10</issue><fpage>e792</fpage><lpage>e798</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2013.07.002</pub-id><pub-id pub-id-type="other">2-s2.0-84883775193</pub-id><?supplied-pmid 23993766?><pub-id pub-id-type="pmid">23993766</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>Y. P.</given-names></name><name><surname>Song</surname><given-names>J. Y.</given-names></name><name><surname>Seo</surname><given-names>Y. B.</given-names></name><name><surname>Choi</surname><given-names>J. P.</given-names></name><name><surname>Shin</surname><given-names>H. S.</given-names></name><name><surname>Rapid Response Team</surname></name></person-group><article-title>Antiviral treatment guidelines for Middle East respiratory syndrome</article-title><source><italic toggle="yes">Infection &#x00026; Chemotherapy</italic></source><year>2015</year><volume>47</volume><issue>3</issue><fpage>212</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.3947/ic.2015.47.3.212</pub-id><pub-id pub-id-type="other">2-s2.0-84945570358</pub-id><?supplied-pmid 26483999?><pub-id pub-id-type="pmid">26483999</pub-id></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelnabi</surname><given-names>R.</given-names></name><name><surname>Morais</surname><given-names>A. T. S. .</given-names></name><name><surname>Leyssen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2017</year><volume>91</volume><issue>12</issue><pub-id pub-id-type="doi">10.1128/jvi.00487-17</pub-id><pub-id pub-id-type="other">2-s2.0-85019750229</pub-id></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettini</surname><given-names>F.</given-names></name><name><surname>Trezza</surname><given-names>A.</given-names></name><name><surname>Spiga</surname><given-names>O.</given-names></name></person-group><article-title>A Focus on Ebola Virus Polymerase</article-title><source><italic toggle="yes">Viral Polymerases</italic></source><year>2019</year><fpage>181</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-815422-9.00007-3</pub-id></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y.</given-names></name><name><surname>Gowen</surname><given-names>B. B.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Shiraki</surname><given-names>K.</given-names></name><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Barnard</surname><given-names>D. L.</given-names></name></person-group><article-title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2013</year><volume>100</volume><issue>2</issue><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.09.015</pub-id><pub-id pub-id-type="other">2-s2.0-84885448756</pub-id><?supplied-pmid 24084488?><pub-id pub-id-type="pmid">24084488</pub-id></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y.</given-names></name><name><surname>Komeno</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source><italic toggle="yes">Proceedings of the Japan Academy, Series B</italic></source><year>2017</year><volume>93</volume><issue>7</issue><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.2183/pjab.93.027</pub-id><pub-id pub-id-type="other">2-s2.0-85026639600</pub-id><?supplied-pmid 28769016?><pub-id pub-id-type="pmid">28769016</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Experimental treatment with favipiravir for COVID-19: an open-label control study</article-title><source><italic toggle="yes">Engineering</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.eng.2020.03.007</pub-id></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group><source><italic toggle="yes">Favipiravir versus arbidol for COVID-19: a randomized clinical trial</italic></source><year>2020</year><publisher-name>medRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.03.17.20037432</pub-id></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>T. K.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Lo</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title><source><italic toggle="yes">Nature</italic></source><year>2016</year><volume>531</volume><issue>7594</issue><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/nature17180</pub-id><pub-id pub-id-type="other">2-s2.0-84982234143</pub-id><?supplied-pmid 26934220?><pub-id pub-id-type="pmid">26934220</pub-id></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name><name><surname>Al-Homoud</surname><given-names>A. H.</given-names></name><name><surname>Memish</surname><given-names>Z. A.</given-names></name></person-group><article-title>Remdesivir as a possible therapeutic option for the COVID-19</article-title><source><italic toggle="yes">Travel Medicine and Infectious Disease</italic></source><year>2020</year><volume>34</volume><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101615</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Leist</surname><given-names>S. R.</given-names></name><etal/></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2020</year><volume>11</volume><issue>1</issue><fpage>p. 222</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id><?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="other"><collab>Centers for Disease Control and Prevention</collab><source><italic toggle="yes">Information for clinicians on therapeutic options for COVID-19 patients</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html</ext-link></comment></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="other"><collab>Chinese Centre for Disease Control and Prevention</collab><source><italic toggle="yes">COVID-19 prevention and control: diagnosis and treatment</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.chinacdc.cn/en/COVID19/202002/P020200310326343385431.pdf">http://www.chinacdc.cn/en/COVID19/202002/P020200310326343385431.pdf</ext-link></comment></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>D. E.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>Q.</given-names></name><etal/></person-group><source><italic toggle="yes">Orthogonal genome-wide screenings in bat cells identify MTHFD1 as a target of broad antiviral therapy</italic></source><year>2020</year><publisher-name>bioRxiv</publisher-name><pub-id pub-id-type="doi">10.1101/2020.03.29.014209</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducker</surname><given-names>G. S.</given-names></name><name><surname>Rabinowitz</surname><given-names>J. D.</given-names></name></person-group><article-title>One-carbon metabolism in health and disease</article-title><source><italic toggle="yes">Cell Metabolism</italic></source><year>2017</year><volume>25</volume><issue>1</issue><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.009</pub-id><pub-id pub-id-type="other">2-s2.0-84994772445</pub-id><?supplied-pmid 27641100?><pub-id pub-id-type="pmid">27641100</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apel</surname><given-names>C.</given-names></name><name><surname>Barg</surname><given-names>A.</given-names></name><name><surname>Rheinberg</surname><given-names>A.</given-names></name><name><surname>Conrads</surname><given-names>G.</given-names></name><name><surname>Wagner-D&#x000f6;bler</surname><given-names>I.</given-names></name></person-group><article-title>Dental composite materials containing carolacton inhibit biofilm growth of <italic>Streptococcus mutans</italic></article-title><source><italic toggle="yes">Dental Materials</italic></source><year>2013</year><volume>29</volume><issue>11</issue><fpage>1188</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1016/j.dental.2013.09.005</pub-id><pub-id pub-id-type="other">2-s2.0-84885957507</pub-id><?supplied-pmid 24094824?><pub-id pub-id-type="pmid">24094824</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donner</surname><given-names>J.</given-names></name><name><surname>Reck</surname><given-names>M.</given-names></name><name><surname>Bunk</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The biofilm inhibitor carolacton enters gram-negative cells: studies using a TolC-deficient strain <italic>of Escherichia coli</italic></article-title><source><italic toggle="yes">mSphere</italic></source><year>2017</year><volume>2</volume><issue>5, article e00375</issue><pub-id pub-id-type="doi">10.1128/mspheredirect.00375-17</pub-id><?supplied-pmid 28959742?><pub-id pub-id-type="pmid">28959742</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunze</surname><given-names>B.</given-names></name><name><surname>Reck</surname><given-names>M.</given-names></name><name><surname>D&#x000f6;tsch</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Damage of <italic>Streptococcus mutans</italic> biofilms by carolacton, a secondary metabolite from the myxobacterium Sorangium cellulosum</article-title><source><italic toggle="yes">BMC Microbiology</italic></source><year>2010</year><volume>10</volume><issue>1</issue><fpage>p. 199</fpage><pub-id pub-id-type="doi">10.1186/1471-2180-10-199</pub-id><pub-id pub-id-type="other">2-s2.0-77954868440</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sainas</surname><given-names>S.</given-names></name><name><surname>Dosio</surname><given-names>F.</given-names></name><name><surname>Boschi</surname><given-names>D.</given-names></name><name><surname>Lolli</surname><given-names>M. L.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Botta</surname><given-names>M.</given-names></name></person-group><article-title>Targeting human onchocerciasis: recent advances beyond ivermectin</article-title><source><italic toggle="yes">Annual Reports in Medicinal Chemistry</italic></source><year>2018</year><volume>51</volume><publisher-loc>Cambridge, MA, USA</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name><name><surname>Sivakumaran</surname><given-names>H.</given-names></name><name><surname>Heaton</surname><given-names>S. M.</given-names></name><name><surname>Harrich</surname><given-names>D.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name></person-group><article-title>Ivermectin is a specific inhibitor of importin <italic>&#x003b1;</italic>/<italic>&#x003b2;</italic>-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus</article-title><source><italic toggle="yes">Biochemical Journal</italic></source><year>2012</year><volume>443</volume><issue>3</issue><fpage>851</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1042/BJ20120150</pub-id><pub-id pub-id-type="other">2-s2.0-84860153620</pub-id><?supplied-pmid 22417684?><pub-id pub-id-type="pmid">22417684</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J. D.</given-names></name><name><surname>Catton</surname><given-names>M. G.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2020</year><volume>178, article 104787</volume><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id></element-citation></ref><ref id="B198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination</article-title><source><italic toggle="yes">ACS Nano</italic></source><year>2018</year><volume>12</volume><issue>6</issue><fpage>5121</fpage><lpage>5129</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b09041</pub-id><pub-id pub-id-type="other">2-s2.0-85047378222</pub-id><?supplied-pmid 29771487?><pub-id pub-id-type="pmid">29771487</pub-id></element-citation></ref><ref id="B199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy</article-title><source><italic toggle="yes">ACS Nano</italic></source><year>2018</year><volume>12</volume><issue>2</issue><fpage>1630</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b08219</pub-id><pub-id pub-id-type="other">2-s2.0-85042718409</pub-id><?supplied-pmid 29346736?><pub-id pub-id-type="pmid">29346736</pub-id></element-citation></ref><ref id="B200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Near-infrared upconversion mesoporous cerium oxide hollow biophotocatalyst for concurrent pH-/H<sub>2</sub>O<sub>2</sub>-responsive O<sub>2</sub>-evolving synergetic cancer therapy</article-title><source><italic toggle="yes">Advanced Materials</italic></source><year>2018</year><volume>30</volume><issue>7, article 1704833</issue><pub-id pub-id-type="doi">10.1002/adma.201704833</pub-id><pub-id pub-id-type="other">2-s2.0-85041959802</pub-id></element-citation></ref><ref id="B201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>Y.-W.</given-names></name><name><surname>Jia</surname><given-names>H.-R.</given-names></name><name><surname>Wu</surname><given-names>F.-G.</given-names></name></person-group><article-title>Near-infrared light-controllable on-demand antibiotics release using thermo- sensitive hydrogel-based drug reservoir for combating bacterial infection</article-title><source><italic toggle="yes">Biomaterials</italic></source><year>2019</year><volume>188</volume><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.09.045</pub-id><pub-id pub-id-type="other">2-s2.0-85056162048</pub-id><?supplied-pmid 30339942?><pub-id pub-id-type="pmid">30339942</pub-id></element-citation></ref><ref id="B202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcandalli</surname><given-names>J.</given-names></name><name><surname>Fiala</surname><given-names>B.</given-names></name><name><surname>Ols</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus</article-title><source><italic toggle="yes">Cell</italic></source><year>2019</year><volume>176</volume><issue>6</issue><fpage>1420</fpage><lpage>1431.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.01.046</pub-id><pub-id pub-id-type="other">2-s2.0-85061724158</pub-id><?supplied-pmid 30849373?><pub-id pub-id-type="pmid">30849373</pub-id></element-citation></ref><ref id="B203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>M.</given-names></name><name><surname>Deshmukh</surname><given-names>S. D.</given-names></name><name><surname>Ingle</surname><given-names>A. P.</given-names></name><name><surname>Gupta</surname><given-names>I. R.</given-names></name><name><surname>Galdiero</surname><given-names>M.</given-names></name><name><surname>Galdiero</surname><given-names>S.</given-names></name></person-group><article-title>Metal nanoparticles: the protective nanoshield against virus infection</article-title><source><italic toggle="yes">Critical Reviews in Microbiology</italic></source><year>2014</year><volume>42</volume><issue>1</issue><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.3109/1040841x.2013.879849</pub-id><pub-id pub-id-type="other">2-s2.0-84959335099</pub-id><?supplied-pmid 24754250?><pub-id pub-id-type="pmid">24754250</pub-id></element-citation></ref><ref id="B204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portney</surname><given-names>N. G.</given-names></name><name><surname>Ozkan</surname><given-names>M.</given-names></name></person-group><article-title>Nano-oncology: drug delivery, imaging, and sensing</article-title><source><italic toggle="yes">Analytical and Bioanalytical Chemistry</italic></source><year>2006</year><volume>384</volume><issue>3</issue><fpage>620</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1007/s00216-005-0247-7</pub-id><pub-id pub-id-type="other">2-s2.0-32544436574</pub-id><?supplied-pmid 16440195?><pub-id pub-id-type="pmid">16440195</pub-id></element-citation></ref><ref id="B205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimori</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Hayata</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Novel antiviral characteristics of nanosized copper(I) iodide particles showing inactivation activity against 2009 pandemic H1N1 influenza virus</article-title><source><italic toggle="yes">Applied and Environmental Microbiology</italic></source><year>2012</year><volume>78</volume><issue>4</issue><fpage>951</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1128/aem.06284-11</pub-id><pub-id pub-id-type="other">2-s2.0-84863115394</pub-id><?supplied-pmid 22156433?><pub-id pub-id-type="pmid">22156433</pub-id></element-citation></ref><ref id="B206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galdiero</surname><given-names>S.</given-names></name><name><surname>Falanga</surname><given-names>A.</given-names></name><name><surname>Vitiello</surname><given-names>M.</given-names></name><name><surname>Cantisani</surname><given-names>M.</given-names></name><name><surname>Marra</surname><given-names>V.</given-names></name><name><surname>Galdiero</surname><given-names>M.</given-names></name></person-group><article-title>Silver nanoparticles as potential antiviral agents</article-title><source><italic toggle="yes">Molecules</italic></source><year>2011</year><volume>16</volume><issue>10</issue><fpage>8894</fpage><lpage>8918</lpage><pub-id pub-id-type="doi">10.3390/molecules16108894</pub-id><pub-id pub-id-type="other">2-s2.0-80054958479</pub-id><?supplied-pmid 22024958?><pub-id pub-id-type="pmid">22024958</pub-id></element-citation></ref><ref id="B207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>S.</given-names></name><name><surname>Sander</surname><given-names>L.-E.</given-names></name></person-group><article-title>Toward a universal flu vaccine</article-title><source><italic toggle="yes">Science</italic></source><year>2020</year><volume>367</volume><issue>6480</issue><fpage>852</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1126/science.aba2754</pub-id><pub-id pub-id-type="pmid">32079760</pub-id></element-citation></ref><ref id="B208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts&#x02019; consensus statement</article-title><source><italic toggle="yes">World Journal of Pediatrics</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1007/s12519-020-00343-7</pub-id></element-citation></ref><ref id="B209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.-M.</given-names></name><name><surname>Fu</surname><given-names>J. F.</given-names></name><name><surname>Shu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus</article-title><source><italic toggle="yes">World Journal of Pediatrics</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1007/s12519-020-00345-5</pub-id></element-citation></ref><ref id="B210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casadevall</surname><given-names>A.</given-names></name><name><surname>Pirofski</surname><given-names>L.</given-names></name></person-group><article-title>The convalescent sera option for containing COVID-19</article-title><source><italic toggle="yes">Journal of Clinical Investigation</italic></source><year>2020</year><volume>130</volume><issue>4</issue><fpage>1545</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1172/JCI138003</pub-id><?supplied-pmid 32167489?><pub-id pub-id-type="pmid">32167489</pub-id></element-citation></ref><ref id="B211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Convalescent plasma as a potential therapy for COVID-19</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2020</year><volume>20</volume><issue>4</issue><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30141-9</pub-id><?supplied-pmid 32113510?><pub-id pub-id-type="pmid">32113510</pub-id></element-citation></ref><ref id="B212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxmen</surname><given-names>A.</given-names></name></person-group><article-title>More than 80 clinical trials launch to test coronavirus treatments</article-title><source><italic toggle="yes">Nature</italic></source><year>2020</year><volume>578</volume><issue>7795</issue><fpage>347</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-00444-3</pub-id><?supplied-pmid 32071447?><pub-id pub-id-type="pmid">32071447</pub-id></element-citation></ref><ref id="B213"><label>213</label><element-citation publication-type="other"><collab>Pharmaceutical, T</collab><source><italic toggle="yes">Takeda initiates development of a plasma-derived therapy for COVID-19</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.takeda.com/newsroom/newsreleases/2020/takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19/">https://www.takeda.com/newsroom/newsreleases/2020/takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19/</ext-link></comment></element-citation></ref><ref id="B214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source><italic toggle="yes">Emerging Microbes &#x00026; Infections</italic></source><year>2020</year><volume>9</volume><issue>1</issue><fpage>382</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1729069</pub-id><?supplied-pmid 32065055?><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="B215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villamor</surname><given-names>E.</given-names></name><name><surname>Mbise</surname><given-names>R.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal infections on child growth</article-title><source><italic toggle="yes">Pediatrics</italic></source><year>2002</year><volume>109</volume><issue>1, article e6</issue><pub-id pub-id-type="doi">10.1542/peds.109.1.e6</pub-id><?supplied-pmid 11773574?><pub-id pub-id-type="pmid">11773574</pub-id></element-citation></ref><ref id="B216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasziou</surname><given-names>P. P.</given-names></name><name><surname>Mackerras</surname><given-names>D. E.</given-names></name></person-group><article-title>Vitamin A supplementation in infectious diseases: a meta-analysis</article-title><source><italic toggle="yes">BMJ</italic></source><year>1993</year><volume>306</volume><issue>6874</issue><fpage>366</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1136/bmj.306.6874.366</pub-id><?supplied-pmid 8461682?><pub-id pub-id-type="pmid">8461682</pub-id></element-citation></ref><ref id="B217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemil&#x000e4;</surname><given-names>H.</given-names></name></person-group><article-title>Vitamin C and SARS coronavirus</article-title><source><italic toggle="yes">Journal of Antimicrobial Chemotherapy</italic></source><year>2003</year><volume>52</volume><issue>6</issue><fpage>1049</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh002</pub-id><pub-id pub-id-type="other">2-s2.0-0346888667</pub-id><?supplied-pmid 14613951?><pub-id pub-id-type="pmid">14613951</pub-id></element-citation></ref><ref id="B218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemil&#x000e4;</surname><given-names>H.</given-names></name></person-group><article-title>Vitamin C intake and susceptibility to pneumonia</article-title><source><italic toggle="yes">The Pediatric Infectious Disease Journal</italic></source><year>1997</year><volume>16</volume><issue>9</issue><fpage>836</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1097/00006454-199709000-00003</pub-id><pub-id pub-id-type="other">2-s2.0-0030869033</pub-id><?supplied-pmid 9306475?><pub-id pub-id-type="pmid">9306475</pub-id></element-citation></ref><ref id="B219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martineau</surname><given-names>A. R.</given-names></name><name><surname>Jolliffe</surname><given-names>D. A.</given-names></name><name><surname>Hooper</surname><given-names>R. L.</given-names></name><etal/></person-group><article-title>Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data</article-title><source><italic toggle="yes">BMJ</italic></source><year>2017</year><volume>356, article i6583</volume><pub-id pub-id-type="doi">10.1136/bmj.i6583</pub-id><pub-id pub-id-type="other">2-s2.0-85013031994</pub-id></element-citation></ref><ref id="B220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>te Velthuis</surname><given-names>A. J. W.</given-names></name><name><surname>van den Worm</surname><given-names>S. H. E.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name><name><surname>Snijder</surname><given-names>E. J.</given-names></name><name><surname>van Hemert</surname><given-names>M. J.</given-names></name></person-group><article-title>Zn<sup>2+</sup> inhibits coronavirus and arterivirus rna polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2010</year><volume>6</volume><issue>11, article e1001176</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1001176</pub-id><pub-id pub-id-type="other">2-s2.0-79251492015</pub-id><?supplied-pmid 21079686?><pub-id pub-id-type="pmid">21079686</pub-id></element-citation></ref><ref id="B221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassi</surname><given-names>Z. S.</given-names></name><name><surname>Moin</surname><given-names>A.</given-names></name><name><surname>Bhutta</surname><given-names>Z. A.</given-names></name><name><surname>Cochrane Acute Respiratory Infections Group</surname></name></person-group><article-title>Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months</article-title><source><italic toggle="yes">Cochrane Database of Systematic Reviews</italic></source><year>2016</year><volume>12, article CD005978</volume><pub-id pub-id-type="doi">10.1002/14651858.cd005978.pub3</pub-id><pub-id pub-id-type="other">2-s2.0-79952198134</pub-id></element-citation></ref><ref id="B222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberda</surname><given-names>C.</given-names></name><name><surname>Gramlich</surname><given-names>L.</given-names></name><name><surname>Jones</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The relationship between nutritional intake and clinical outcomes in critically ill patients: results of an international multicenter observational study</article-title><source><italic toggle="yes">Intensive Care Medicine</italic></source><year>2009</year><volume>35</volume><issue>10</issue><fpage>1728</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1567-4</pub-id><pub-id pub-id-type="other">2-s2.0-72449168374</pub-id><?supplied-pmid 19572118?><pub-id pub-id-type="pmid">19572118</pub-id></element-citation></ref><ref id="B223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalaiselvan</surname><given-names>M.</given-names></name><name><surname>Renuka</surname><given-names>M. K.</given-names></name><name><surname>Arunkumar</surname><given-names>A. S.</given-names></name></person-group><article-title>Use of nutrition risk in critically ill (NUTRIC) score to assess nutritional risk in mechanically ventilated patients: a prospective observational study</article-title><source><italic toggle="yes">Indian Journal of Critical Care Medicine</italic></source><year>2017</year><volume>21</volume><issue>5</issue><fpage>253</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.4103/ijccm.IJCCM_24_17</pub-id><pub-id pub-id-type="other">2-s2.0-85019731669</pub-id><?supplied-pmid 28584426?><pub-id pub-id-type="pmid">28584426</pub-id></element-citation></ref><ref id="B224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title><source><italic toggle="yes">The Lancet Respiratory Medicine</italic></source><year>2020</year><volume>8</volume><issue>5</issue><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id><pub-id pub-id-type="pmid">32105632</pub-id></element-citation></ref><ref id="B225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>McGoogan</surname><given-names>J. M.</given-names></name></person-group><article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China</article-title><source><italic toggle="yes">JAMA</italic></source><year>2020</year><volume>323</volume><issue>13</issue><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id></element-citation></ref><ref id="B226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.-Y.</given-names></name><name><surname>Shin</surname><given-names>H. S.</given-names></name><name><surname>Park</surname><given-names>H.</given-names></name><etal/></person-group><article-title>In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2008</year><volume>41</volume><issue>2</issue><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2007.10.011</pub-id><pub-id pub-id-type="other">2-s2.0-38749113891</pub-id><?supplied-pmid 18036887?><pub-id pub-id-type="pmid">18036887</pub-id></element-citation></ref><ref id="B227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>J.-R.</given-names></name><name><surname>Lin</surname><given-names>C. S.</given-names></name><name><surname>Lai</surname><given-names>H. C.</given-names></name><etal/></person-group><article-title>Antiviral activity of Sambucus FormosanaNakai ethanol extract and related phenolic acid constituents against human coronavirus NL63</article-title><source><italic toggle="yes">Virus Research</italic></source><year>2019</year><volume>273, article 197767</volume><pub-id pub-id-type="doi">10.1016/j.virusres.2019.197767</pub-id><pub-id pub-id-type="other">2-s2.0-85072653742</pub-id></element-citation></ref><ref id="B228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>L.-x.</given-names></name><name><surname>Wu</surname><given-names>Y.-l.</given-names></name><name><surname>Dai</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>S.-c.</given-names></name></person-group><article-title>Antiviral activity of Isatidis Radix derived glucosinolate isomers and their breakdown products against influenza A in vitro/ovo and mechanism of action</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2020</year><volume>251</volume><pub-id pub-id-type="doi">10.1016/j.jep.2020.112550</pub-id></element-citation></ref><ref id="B229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>A.-H.</given-names></name><name><surname>Wang</surname><given-names>X.-J.</given-names></name></person-group><article-title>Traditional Chinese medicine for COVID-19 treatment</article-title><source><italic toggle="yes">Pharmacological Research</italic></source><year>2020</year><volume>155, article 104743</volume><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104743</pub-id></element-citation></ref><ref id="B230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>M. R.</given-names></name><name><surname>Shi</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>Z. H.</given-names></name><name><surname>Zhou</surname><given-names>S. P.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name></person-group><article-title>Application of integrative medicine protocols on treatment of coronavirus disease 2019</article-title><source><italic toggle="yes">Chinese Traditional and Herbal Drugs</italic></source><year>2020</year><volume>51</volume><fpage>878</fpage><lpage>882</lpage></element-citation></ref><ref id="B231"><label>231</label><element-citation publication-type="other"><collab>Publicity Department of the People's Republic of China</collab><source><italic toggle="yes">Press conference of the joint prevention and control mechanism of state council on Feb 17, 2020.</italic></source><comment><ext-link ext-link-type="uri" xlink:href="https://www.nhc.gov.cn/xcs/yqfkdt/202002/f12a62d10c2a48c6895cedf2faea6e1f.shtml">https://www.nhc.gov.cn/xcs/yqfkdt/202002/f12a62d10c2a48c6895cedf2faea6e1f.shtml</ext-link></comment></element-citation></ref><ref id="B232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>C.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial</article-title><source><italic toggle="yes">Critical Care Medicine</italic></source><year>2019</year><volume>47</volume><issue>9</issue><fpage>e735</fpage><lpage>e743</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000003842</pub-id><pub-id pub-id-type="other">2-s2.0-85071355927</pub-id><?supplied-pmid 31162191?><pub-id pub-id-type="pmid">31162191</pub-id></element-citation></ref><ref id="B233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Pham</surname><given-names>P.</given-names></name><name><surname>Phan</surname><given-names>N. K.</given-names></name></person-group><article-title>Welcome to progress in stem cell</article-title><source><italic toggle="yes">Progress in Stem Cell</italic></source><year>2014</year><volume>1</volume><issue>1</issue><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.15419/psc.v1i1.38</pub-id></element-citation></ref><ref id="B234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment</article-title><source><italic toggle="yes">Engineering</italic></source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.eng.2020.02.006</pub-id></element-citation></ref><ref id="B235"><label>235</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><etal/></person-group><source><italic toggle="yes">Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells</italic></source><year>2020</year><publisher-name>ChinaXiv</publisher-name></element-citation></ref><ref id="B236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia</article-title><source><italic toggle="yes">Aging and Disease</italic></source><year>2020</year><volume>11</volume><issue>2</issue><fpage>216</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.14336/AD.2020.0228</pub-id><pub-id pub-id-type="pmid">32257537</pub-id></element-citation></ref><ref id="B237"><label>237</label><element-citation publication-type="other"><collab>National Institutes of Health (NIH)</collab><source><italic toggle="yes">NIH clinical trial of investigational vaccine for COVID-19 begins</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins">https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins</ext-link></comment></element-citation></ref><ref id="B238"><label>238</label><element-citation publication-type="other"><collab>Bioworld</collab><source><italic toggle="yes">China approves first homegrown COVID-19 vaccine to enter clinical trials</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials">https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials</ext-link></comment></element-citation></ref><ref id="B239"><label>239</label><element-citation publication-type="other"><source><italic toggle="yes">DRAFT landscape of COVID-19 candidate vaccines-20 March, 2020</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1">https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1</ext-link></comment></element-citation></ref><ref id="B240"><label>240</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>M. H.</given-names></name><name><surname>Sattar</surname><given-names>S. A.</given-names></name><name><surname>Adegbunrin</surname><given-names>O.</given-names></name><name><surname>Tetro</surname><given-names>J.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Schmidt</surname><given-names>A.</given-names></name><name><surname>Weber</surname><given-names>O.</given-names></name><name><surname>Wolff</surname><given-names>M. H.</given-names></name></person-group><article-title>Environmental survival and microbicide inactivation of coronaviruses</article-title><source><italic toggle="yes">Coronaviruses with Special Emphasis on First Insights Concerning SARS</italic></source><year>2005</year><publisher-loc>Birkh&#x000e4;user Basel</publisher-loc><publisher-name>Birkh&#x000e4;user Advances in Infectious Diseases BAID</publisher-name><fpage>201</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1007/3-7643-7339-3_10</pub-id></element-citation></ref><ref id="B241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Bushmaker</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>D. H.</given-names></name><etal/></person-group><article-title>Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2020</year><volume>382</volume><issue>16</issue><fpage>1564</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id><?supplied-pmid 32182409?><pub-id pub-id-type="pmid">32182409</pub-id></element-citation></ref><ref id="B242"><label>242</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>S.</given-names></name><name><surname>Abedi</surname><given-names>A.</given-names></name><name><surname>Balakrishnan</surname><given-names>S.</given-names></name><name><surname>Gholamrezanezhad</surname><given-names>A.</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients</article-title><source><italic toggle="yes">American Journal of Roentgenology</italic></source><year>2020</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2214/AJR.20.23034</pub-id><?supplied-pmid 32174129?><pub-id pub-id-type="pmid">32174129</pub-id></element-citation></ref><ref id="B243"><label>243</label><element-citation publication-type="other"><source><italic toggle="yes">Key export products for COVID-19 diagnosis &#x00026; treatment</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="http://iq.chineseembassy.org/chn/gdxw/P020200331083539284917.pdf">http://iq.chineseembassy.org/chn/gdxw/P020200331083539284917.pdf</ext-link></comment></element-citation></ref><ref id="B244"><label>244</label><element-citation publication-type="other"><source><italic toggle="yes">University of Nankai develops rapid test kit</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.thestar.com.my/news/regional/2020/02/18/university-of-nankai-develops-rapid-test-kit">https://www.thestar.com.my/news/regional/2020/02/18/university-of-nankai-develops-rapid-test-kit</ext-link></comment></element-citation></ref><ref id="B245"><label>245</label><element-citation publication-type="other"><source><italic toggle="yes">Researchers develop new test kit to detect coronavirus in 15 mins</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://news.cgtn.com/news/2020-03-11/Researchers-develop-new-test-kit-to-detect-coronavirus-in-15-mins-OMjPu5DFEk/index.html">https://news.cgtn.com/news/2020-03-11/Researchers-develop-new-test-kit-to-detect-coronavirus-in-15-mins-OMjPu5DFEk/index.html</ext-link></comment></element-citation></ref><ref id="B246"><label>246</label><element-citation publication-type="other"><source><italic toggle="yes">China approves 29-minute testing kit for new coronavirus</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.chinadaily.com.cn/a/202003/07/WS5e63521aa31012821727d239.html">https://www.chinadaily.com.cn/a/202003/07/WS5e63521aa31012821727d239.html</ext-link></comment></element-citation></ref><ref id="B247"><label>247</label><element-citation publication-type="other"><source><italic toggle="yes">S'pore researchers invent Covid-19 test that can tell if someone's infected in 5 minutes</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://mothership.sg/2020/03/covid-19-test-how-long/">https://mothership.sg/2020/03/covid-19-test-how-long/</ext-link></comment></element-citation></ref><ref id="B248"><label>248</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>J. P.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Fasching</surname><given-names>C. L.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name><name><surname>Chiu</surname><given-names>C. Y.</given-names></name><name><surname>Chen</surname><given-names>J. S.</given-names></name></person-group><source><italic toggle="yes">A protocol for rapid detection of the 2019 novel coronavirus SARS-CoV-2 using CRISPR diagnostics: SARS-CoV-2 DETECTR</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://mammoth.bio/wp-content/uploads/2020/03/Mammoth-Biosciences-A-protocol-for-rapid-detection-of-SARS-CoV-2-using-CRISPR-diagnostics-DETECTR.pdf">https://mammoth.bio/wp-content/uploads/2020/03/Mammoth-Biosciences-A-protocol-for-rapid-detection-of-SARS-CoV-2-using-CRISPR-diagnostics-DETECTR.pdf</ext-link></comment></element-citation></ref><ref id="B249"><label>249</label><element-citation publication-type="other"><collab>Channelnewsasia</collab><source><italic toggle="yes">New COVID-19 test kits used to screen swab samples collected at Singapore checkpoints</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.channelnewsasia.com/news/singapore/covid19-new-test-kits-swab-three-hours-12505658">https://www.channelnewsasia.com/news/singapore/covid19-new-test-kits-swab-three-hours-12505658</ext-link></comment></element-citation></ref><ref id="B250"><label>250</label><element-citation publication-type="other"><collab>Beihang University</collab><source><italic toggle="yes">The development of Beihang University on detecting and preventing of 2019-nCoV</italic></source><year>2020</year><comment><ext-link ext-link-type="uri" xlink:href="https://ygy.buaa.edu.cn/info/1072/2569.htm">https://ygy.buaa.edu.cn/info/1072/2569.htm</ext-link></comment></element-citation></ref><ref id="B251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S. F.</given-names></name><name><surname>Quadeer</surname><given-names>A. A.</given-names></name><name><surname>McKay</surname><given-names>M. R.</given-names></name></person-group><article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</article-title><source><italic toggle="yes">Viruses</italic></source><year>2020</year><volume>12</volume><issue>3</issue><fpage>p. 254</fpage><pub-id pub-id-type="doi">10.3390/v12030254</pub-id><?supplied-pmid 32106567?><pub-id pub-id-type="pmid">32106567</pub-id></element-citation></ref><ref id="B252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Ran</surname><given-names>Q. S.</given-names></name><etal/></person-group><article-title>Efficacy and mechanism of Lianhua Qingwen Capsules(LHQW) on chemotaxis of macrophages in acute lung injury (ALI) animal model</article-title><source><italic toggle="yes">China Journal of Chinese Materia Medica</italic></source><year>2019</year><volume>44</volume><issue>11</issue><fpage>2317</fpage><lpage>2323</lpage><pub-id pub-id-type="doi">10.19540/j.cnki.cjcmm.20190210.001</pub-id><pub-id pub-id-type="other">2-s2.0-85070816004</pub-id><?supplied-pmid 31359658?><pub-id pub-id-type="pmid">31359658</pub-id></element-citation></ref><ref id="B253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2018</year><volume>211</volume><fpage>358</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.10.001</pub-id><pub-id pub-id-type="other">2-s2.0-85031014772</pub-id><?supplied-pmid 28987599?><pub-id pub-id-type="pmid">28987599</pub-id></element-citation></ref><ref id="B254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chi-Yan Cheng</surname><given-names>B.</given-names></name><name><surname>Xie</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name><name><surname>Gao</surname><given-names>X. Y.</given-names></name><name><surname>Luo</surname><given-names>G.</given-names></name></person-group><article-title>Re-Du-Ninginhalation solution exerts suppressive effect on the secretion of inflammatory mediatorsviainhibiting IKK<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic>/I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>/NF-<italic>&#x003ba;</italic>B, MAPKs/AP-1, and TBK1/IRF3 signaling pathways in lipopolysaccharide stimulated RAW 264.7 macrophages</article-title><source><italic toggle="yes">RSC Advances</italic></source><year>2019</year><volume>9</volume><issue>16</issue><fpage>8912</fpage><lpage>8925</lpage><pub-id pub-id-type="doi">10.1039/C9RA00060G</pub-id><pub-id pub-id-type="other">2-s2.0-85063333275</pub-id></element-citation></ref><ref id="B255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>S.</given-names></name><name><surname>Hang</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-<italic>&#x003ba;</italic>B pathways</article-title><source><italic toggle="yes">Acta Pharmaceutica Sinica B</italic></source><year>2016</year><volume>6</volume><issue>3</issue><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2016.02.002</pub-id><pub-id pub-id-type="other">2-s2.0-84971505081</pub-id><?supplied-pmid 27175331?><pub-id pub-id-type="pmid">27175331</pub-id></element-citation></ref><ref id="B256"><label>256</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>H. L.</given-names></name><name><surname>Cai</surname><given-names>L. L.</given-names></name><name><surname>Yan</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>S. J.</given-names></name><name><surname>Mao</surname><given-names>B.</given-names></name></person-group><article-title>Tanreqing injection attenuates lipopolysaccharide-induced airway inflammation through MAPK/NF-<italic>&#x003ba;</italic>B signaling pathways in rats model</article-title><source><italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic></source><year>2016</year><volume>2016</volume><fpage>15</fpage><pub-id pub-id-type="publisher-id">5292346</pub-id><pub-id pub-id-type="doi">10.1155/2016/5292346</pub-id><pub-id pub-id-type="other">2-s2.0-84976351824</pub-id><?supplied-pmid 27366191?><pub-id pub-id-type="pmid">27366191</pub-id></element-citation></ref><ref id="B257"><label>257</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>L. S.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X. Y.</given-names></name><name><surname>Zhong</surname><given-names>H. L.</given-names></name></person-group><article-title>Action mechanism of Shenfu injection by computational system biology analysis</article-title><source><italic toggle="yes">Chinese Journal of Experimental Traditional Medical Formulae</italic></source><year>2015</year><volume>21</volume><fpage>217</fpage><lpage>221</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Biological and genomic structure of 2019-nCoV. (a) Classification of coronavirus genera. (b) Schematic structure of 2019-nCoV. (c) The whole-genome structure of 2019-nCoV.</p></caption><graphic xlink:href="RESEARCH2020-6925296.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>High-throughput sequencing and real-time qRT-PCR-based detection of 2019-nCoV. (a) Four steps of high-throughput sequencing technology. (b) Steps for real-time RT-PCR analysis.</p></caption><graphic xlink:href="RESEARCH2020-6925296.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Isothermal amplification of nucleic acids for detecting 2019-nCoV. (a) The mechanism and process of loop-mediated isothermal amplification technology. (b, c) RT-LAMP combination with SYBR Green for detection of 2019-nCoV. The signal of SYBR Green dye was detected with a gel imaging system (b) and was visible with the naked eye under blue light (c). (d) The mechanism and process of recombinase polymerase amplification technology. Adapted and copyright with permission (b, c) [<xref rid="B42" ref-type="bibr">42</xref>], medRxiv.</p></caption><graphic xlink:href="RESEARCH2020-6925296.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>CRISPR-Cas system-based detection of 2019-nCoV. (a) Mechanism of SHERLOCK and DETECTR for 2019-nCoV detection. (b, c) Typical images of lateral flow readout for CRISPR-based detection at various concentrations [<xref rid="B60" ref-type="bibr">60</xref>].</p></caption><graphic xlink:href="RESEARCH2020-6925296.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Microfluidic-based detection of 2019-nCoV. (a) Design and fabrication of a spiral chip. (b) Operation procedures for sample introduction and partition on the chip. PDMS: polydimethylsiloxane. (c) Raw (upper) and software-extracted images (down) of the chip after nucleic amplification. Adapted and copyright with permission (a&#x02013;c) [<xref rid="B70" ref-type="bibr">70</xref>], American Chemical Society.</p></caption><graphic xlink:href="RESEARCH2020-6925296.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Lateral flow assays for detecting 2019-nCoV antigens or antibodies to 2019-nCoV. (a) Diagram showing LFA-based quick detection of 2019-nCoV in an IgM-IgG combined antibody assay. (b) A diagram showing different test results. (c) Representative assay test showing results from blood of different patients. Patient #13: IgM and IgG positive; #14: IgM weak positive; #15: IgM and IgG negative; #16: IgG weakly positive; #17: IgG positive only; #18: IgM positive only. Adapted and copyright with permission (c) [<xref rid="B84" ref-type="bibr">84</xref>], Wiley.</p></caption><graphic xlink:href="RESEARCH2020-6925296.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Computed tomography and transmission electron microscopy characterizations of 2019-nCoV. (a) Cross-sectional noncontrast enhanced chest CT radiographs of a man's lungs with COVID-19. The figure shows enlarged lesions and increased density of the lesions at the outer edge of the lungs (yellow arrows) [<xref rid="B93" ref-type="bibr">93</xref>]. (b) A TEM image of the 2019-nCoV grown in cells at the University of Hong Kong [<xref rid="B97" ref-type="bibr">97</xref>].</p></caption><graphic xlink:href="RESEARCH2020-6925296.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Proposed schematic of 2019-nCoV replication and potential treatment options targeting the coronavirus replication cycle. ACE2: angiotensin-converting enzyme 2; +: positive-strand RNA; AP: accessory protein; E: envelope protein; ER: endoplasmic reticulum; N: nucleocapsid protein; M: membrane protein; ERGIC: endoplasmic reticulum-Golgi intermediate compartment; S: spike glycoprotein.</p></caption><graphic xlink:href="RESEARCH2020-6925296.008"/></fig><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Chemical structure of drugs used to treat COVID-19. (a) Chemical structures of entry inhibitors. (b) Chemical structures of protease inhibitors. (c) Chemical structures of replication inhibitors.</p></caption><graphic xlink:href="RESEARCH2020-6925296.009"/></fig><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Procedures for identifying COVID-19 cases.</p></caption><graphic xlink:href="RESEARCH2020-6925296.010"/></fig><table-wrap id="tab1" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 1</label><caption><p>Detection methods of 2019-nCoV classified by protein and gene targets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Method</th><th align="center" rowspan="2" colspan="1">Sampling methods</th><th align="center" rowspan="2" colspan="1">Detection time</th><th align="center" rowspan="2" colspan="1">Accuracy/limit of detection</th><th align="center" colspan="5" rowspan="1">Advantages</th><th align="center" rowspan="2" colspan="1">Remarks and Ref.</th></tr><tr><th align="center" rowspan="1" colspan="1">Rapid</th><th align="center" rowspan="1" colspan="1">Low cost</th><th align="center" rowspan="1" colspan="1">Sensitive</th><th align="center" rowspan="1" colspan="1">Portable</th><th align="center" rowspan="1" colspan="1">Visual analysis</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1">Antibody</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IgG/IgM-LFA</td><td align="center" rowspan="1" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">15&#x02009;min</td><td align="center" rowspan="1" colspan="1">92.69%</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Inapplicable to early-stage detection [<xref rid="B243" ref-type="bibr">243</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IgG/IgM-AIE-QD</td><td align="center" rowspan="1" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">15&#x02009;min</td><td align="center" rowspan="1" colspan="1">75%</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Inapplicable to early-stage detection [<xref rid="B244" ref-type="bibr">244</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IgM-colloidal gold-LFA</td><td align="center" rowspan="1" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">15&#x02009;min</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Inapplicable to early-stage detection [<xref rid="B245" ref-type="bibr">245</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IgG/IgM-ELISA or LFA</td><td align="center" rowspan="1" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">29&#x02009;min</td><td align="center" rowspan="1" colspan="1">93.1%</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Inapplicable to early-stage detection [<xref rid="B246" ref-type="bibr">246</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IgG/IgM-colloidal gold-FLA</td><td align="center" rowspan="1" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">15-30&#x02009;min</td><td align="center" rowspan="1" colspan="1">90%</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Inapplicable to early-stage detection<sup>&#x00026;</sup></td></tr><tr><td align="left" colspan="10" rowspan="1">Nucleic acid (whole genome)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nanopore target sequencing</td><td align="center" rowspan="1" colspan="1">Throat swab</td><td align="center" rowspan="1" colspan="1">6-10&#x02009;h</td><td align="center" rowspan="1" colspan="1">&#x0003e;95%, 10 copies/mL</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Monitor mutation but time-consuming and costly [<xref rid="B28" ref-type="bibr">28</xref>]</td></tr><tr><td align="left" colspan="10" rowspan="1">Nucleic acid (N and E genes or ORF<italic>1ab</italic>/RdRp/S)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Real-time RT-PCR</td><td align="center" rowspan="1" colspan="1">Nasopharyngeal or oropharyngeal swab</td><td align="center" rowspan="1" colspan="1">240-360&#x02009;min</td><td align="center" rowspan="1" colspan="1">67%, 3.2 copies/<italic>&#x003bc;</italic>L</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Established standard method but time-consuming and requiring skilled personnel<sup>&#x00026;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RT-LAMP</td><td align="center" rowspan="1" colspan="1">Nasopharyngeal or oropharyngeal swab</td><td align="center" rowspan="1" colspan="1">30&#x02009;min</td><td align="center" rowspan="1" colspan="1">&#x0003e;95%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">A single, simple protocol but with noisy signals<sup>&#x00026;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Close-tube Penn-RAMP (LAMP+RPA)</td><td align="center" rowspan="1" colspan="1">Synthetic RNA</td><td align="center" rowspan="1" colspan="1">100&#x02009;min</td><td align="center" rowspan="1" colspan="1">7 copies per reaction</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Suitable for home screening but requiring clinical validation [<xref rid="B45" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cepat</td><td align="center" rowspan="1" colspan="1">Nasopharyngeal or oropharyngeal swab</td><td align="center" rowspan="1" colspan="1">5-10&#x02009;min</td><td align="center" rowspan="1" colspan="1">99%</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">High specificity but requiring clinical validation [<xref rid="B247" ref-type="bibr">247</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CRISPR-Cas12a/RT-LAMP (DETECTR)</td><td align="center" rowspan="1" colspan="1">Nasopharyngeal/oropharyngeal swab</td><td align="center" rowspan="1" colspan="1">45&#x02009;min</td><td align="center" rowspan="1" colspan="1">10 copies/<italic>&#x003bc;</italic>L input</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Requiring clinical validation [<xref rid="B248" ref-type="bibr">248</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;HTX COVID-19 test kit</td><td align="center" rowspan="1" colspan="1">Nasopharyngeal or oropharyngeal swab</td><td align="center" rowspan="1" colspan="1">180&#x02009;min</td><td align="center" rowspan="1" colspan="1">99%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Severity evaluation possible but requiring clinical validation [<xref rid="B249" ref-type="bibr">249</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;enVision</td><td align="center" rowspan="1" colspan="1">Synthetic RNA</td><td align="center" rowspan="1" colspan="1">30&#x02009;min</td><td align="center" rowspan="1" colspan="1">Not known</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Requiring clinical validation [<xref rid="B76" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CRISPR-Cas13a/RPA-LFA (SHERLOCK)</td><td align="center" rowspan="1" colspan="1">Synthetic RNA</td><td align="center" rowspan="1" colspan="1">&#x0003c;60&#x02009;min</td><td align="center" rowspan="1" colspan="1">10 copies/<italic>&#x003bc;</italic>L input</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Simple but requiring clinical validation [<xref rid="B60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CRISPR-Cas12a/RT-RPA (DETECTR)</td><td align="center" rowspan="1" colspan="1">Synthetic RNA</td><td align="center" rowspan="1" colspan="1">&#x0003c;60&#x02009;min</td><td align="center" rowspan="1" colspan="1">10 copies/<italic>&#x003bc;</italic>L input</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Requiring clinical validation [<xref rid="B62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Multiparameter-chip/RPA</td><td align="center" rowspan="1" colspan="1">Synthetic RNA</td><td align="center" rowspan="1" colspan="1">&#x0003c;60&#x02009;min</td><td align="center" rowspan="1" colspan="1">&#x0003e;90%</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">&#x02714;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02714;</td><td align="center" rowspan="1" colspan="1">Requiring clinical validation [<xref rid="B250" ref-type="bibr">250</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>N/A: not available (an established method used for comparison in this table); &#x00026;: commercial kits; LAMP: loop-mediated isothermal amplification; RPA: recombinase polymerase amplification; FLA: lateral flow assay; CRISPR: clustered regularly interspaced short palindromic repeats; DETECTR: DNA endonuclease-targeted CRISPR trans reporter.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 2</label><caption><p>Potential antiviral drugs for COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Potential therapeutic agents</th><th align="center" rowspan="2" colspan="1">Target of inhibition</th><th align="center" rowspan="2" colspan="1">Indication/purposes</th><th align="center" rowspan="2" colspan="1">Preliminary studies</th><th align="center" colspan="2" rowspan="1">Application for COVID-19</th></tr><tr><th align="center" rowspan="1" colspan="1">Case studies</th><th align="center" rowspan="1" colspan="1">Remarks</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Umifenovir</td><td align="center" rowspan="1" colspan="1">Entry receptor</td><td align="center" rowspan="1" colspan="1">Antiviral drug on influenza; not yet tested for coronaviruses</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Compared with favipiravir (see favipiravir)</td><td align="center" rowspan="1" colspan="1">Currently being evaluated in China</td></tr><tr><td align="left" rowspan="1" colspan="1">Chloroquine, hydroxychloroquine</td><td align="center" rowspan="1" colspan="1">Entry receptor</td><td align="center" rowspan="1" colspan="1">Antiviral drug on malaria; not yet tested for coronaviruses</td><td align="center" rowspan="1" colspan="1">
<italic>In vitro</italic> antiviral activities against 2019-nCoV on primate cells [<xref rid="B135" ref-type="bibr">135</xref>, <xref rid="B138" ref-type="bibr">138</xref>]</td><td align="center" rowspan="1" colspan="1">Ongoing</td><td align="center" rowspan="1" colspan="1">Currently being evaluated in China and the United States</td></tr><tr><td align="left" rowspan="1" colspan="1">Camostat mesylate</td><td align="center" rowspan="1" colspan="1">Host protease</td><td align="center" rowspan="1" colspan="1">Antiviral drug on pancreatic diseases; not yet tested for coronaviruses</td><td align="center" rowspan="1" colspan="1">
<italic>In vitro</italic> antiviral activities against 2019-nCoV in human lung cancer cells [<xref rid="B113" ref-type="bibr">113</xref>]</td><td align="center" rowspan="1" colspan="1">Not known</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">Lopinavir-ritonavir</td><td align="center" rowspan="1" colspan="1">Viral protease</td><td align="center" rowspan="1" colspan="1">Used in combination with ribavirin for SARS and MERS</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">199 hospitalized patients, Wuhan, China (99 lopinavir+ritonavir+100 standard care) [<xref rid="B161" ref-type="bibr">161</xref>]</td><td align="center" rowspan="1" colspan="1">Currently being evaluated in China and the United States. However, found to be ineffective based on preliminary findings</td></tr><tr><td align="left" rowspan="1" colspan="1">Darunavir</td><td align="center" rowspan="1" colspan="1">Viral protease</td><td align="center" rowspan="1" colspan="1">Antiretroviral drug; not yet tested for coronaviruses</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Not known</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribavirin</td><td align="center" rowspan="1" colspan="1">Genome replication</td><td align="center" rowspan="1" colspan="1">Used in combination with lopinavir-ritonavir for SARS and MERS</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Not known</td><td align="center" rowspan="1" colspan="1">Currently being evaluated in China</td></tr><tr><td align="left" rowspan="1" colspan="1">Favipiravir</td><td align="center" rowspan="1" colspan="1">Genome replication</td><td align="center" rowspan="1" colspan="1">Antiviral drug on influenza; not yet tested for coronaviruses</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">240 patients in Hubei province, China (120 favipiravir+120 arbidol) (preprint) [<xref rid="B184" ref-type="bibr">184</xref>]</td><td align="center" rowspan="1" colspan="1">Higher recovery rate compared to those treated with umifenovir (arbidol)</td></tr><tr><td align="left" rowspan="1" colspan="1">Remdesivir</td><td align="center" rowspan="1" colspan="1">Genome replication</td><td align="center" rowspan="1" colspan="1">The new antiviral drug initially developed for Ebola</td><td align="center" rowspan="1" colspan="1">
<italic>In vitro</italic> antiviral activities toward 2019-nCoV on primate cells [<xref rid="B138" ref-type="bibr">138</xref>]</td><td align="center" rowspan="1" colspan="1">Ongoing</td><td align="center" rowspan="1" colspan="1">Under clinical trials</td></tr><tr><td align="left" rowspan="1" colspan="1">Carolacton</td><td align="center" rowspan="1" colspan="1">Genome replication</td><td align="center" rowspan="1" colspan="1">Potential antibacterial compound against biofilm formation of <italic>Streptococcus mutans</italic> and growth of <italic>Streptococcus pneumoniae</italic> [<xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B193" ref-type="bibr">193</xref>]</td><td align="center" rowspan="1" colspan="1">
<italic>In vitro</italic> antiviral activities against bat kidney cells [<xref rid="B190" ref-type="bibr">190</xref>]</td><td align="center" rowspan="1" colspan="1">Not known</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">Ivermectin</td><td align="center" rowspan="1" colspan="1">Genome replication</td><td align="center" rowspan="1" colspan="1">Antiparasitic drug (broad-spectrum).</td><td align="center" rowspan="1" colspan="1">
<italic>In vitro</italic> antiviral activities against 2019-nCoV on primate cells [<xref rid="B197" ref-type="bibr">197</xref>]</td><td align="center" rowspan="1" colspan="1">Not known</td><td align="center" rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><fn><p>N/A: not available. Note: &#x0201c;coronaviruses&#x0201d; only target SARS-CoV and MERS-CoV.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 3</label><caption><p>TCM recommendations by guidelines for diagnosis and treatment of COVID-19 (7<sup>th</sup> edition) [<xref rid="B25" ref-type="bibr">25</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Symptoms</th><th align="center" rowspan="1" colspan="1">Potential TCM</th><th align="center" rowspan="1" colspan="1">Main ingredients (common names)</th><th align="center" rowspan="1" colspan="1">Active ingredients</th><th align="center" rowspan="1" colspan="1">Precaution</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Suspected cases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Fatigue, gastrointestinal discomfort</td><td align="center" rowspan="1" colspan="1">Huo Xiang Zheng Qi Capsule (&#x085ff;&#x09999;&#x06b63;&#x06c14;&#x080f6;&#x056ca;)</td><td align="center" rowspan="1" colspan="1">Patchouli, Indian buead, areca peel, perilla leaf, dahurian angelica root, tangerine peel, platycodon root, largehead Atractylodes rhizome, magnolia bark, pinellia rhizome, licorice</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response. Allergic individuals are prohibited from the treatment. Patients with diseases, i.e., cardiac diseases, liver diseases, kidney diseases, hypertension, and diabetes, and pregnant women should speak to physicians before the treatment</td></tr><tr><td align="left" rowspan="3" colspan="1">&#x02003;Fatigue, fever</td><td align="center" rowspan="1" colspan="1">Lian Hua Qing Wen Capsule (&#x08fde;&#x082b1;&#x06e05;&#x0761f;&#x080f6;&#x056ca;)</td><td align="center" rowspan="1" colspan="1">Forsythia, honeysuckle flower, ephedra, apricot, gypsum, indigowoad root, crown wood-fern, heartleaf houttuynia, patchouli, rhubarb, arctic root, mint, licorice</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response. Not suitable for people with a cold. Not suitable for long-term use. Allergic individuals are prohibited from the treatment. Patients with diseases, i.e., cardiac diseases, liver diseases, kidney diseases, hypertension, and diabetes, and pregnant women should speak to physicians before the treatment</td></tr><tr><td align="center" rowspan="1" colspan="1">Shu Feng Jie Du Capsule (&#x0758f;&#x098ce;&#x089e3;&#x06bd2;&#x080f6;&#x056ca;)</td><td align="center" rowspan="1" colspan="1">Bushy knotweed root, forsythia, indigowoad root, thorowax root, patrinia, verbena leaf, reed root, licorice</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., nausea. Allergic individuals and individuals with allergic constitution are prohibited from the treatment</td></tr><tr><td align="center" rowspan="1" colspan="1">Jin Hua Qing Gan Pill (&#x091d1;&#x082b1;&#x06e05;&#x0611f;&#x04e38;)</td><td align="center" rowspan="1" colspan="1">Honeysuckle flower, gypsum, ephedra, apricot, baical skullcap root, forsythia, fritillaria bulb, anemarrhena rhizome, great burdock achene, wormwood mint, licorice</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Side effects are not known. Pregnant women, allergic individuals, and individuals with allergic constitution are prohibited from the treatment</td></tr><tr><td align="left" colspan="5" rowspan="1">Confirmed cases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mild/general/severe</td><td align="center" rowspan="1" colspan="1">Qing Fei Pai Du Decoction (&#x06e05;&#x080ba;&#x06392;&#x06bd2;&#x06c64;)</td><td align="center" rowspan="1" colspan="1">Ephedra, licorice, apricot, gypsum, cinnamon twig, water plantain rhizome, polyporus, largehead Atractylodes rhizome, Indian buead, thorowax root, baical skullcap root, pinellia rhizome, ginger, tatarian aster root, coltsfoot flower, blackberry lily rhizome, Manchurian wildginger, Chinese yam, immature bitter orange, tangerine peel, patchouli</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Not recommended to be used as a precautionary measure</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Severe</td><td align="center" rowspan="1" colspan="1">Xi Yan Ping Injection (&#x0559c;&#x0708e;&#x05e73;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Andrographis</td><td align="center" rowspan="1" colspan="1">Andrographolide</td><td align="center" rowspan="1" colspan="1">May cause adverse reactions, i.e., skin rash, itchiness, fever, pain, dyspnea, cyanosis, palpitations, and convulsions. Pregnant women and allergic individuals are prohibited from the treatment</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Xing Nao Jing Injection (&#x09192;&#x08111;&#x09759;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Musk, borneol, cape jasmine fruit, turmeric tuber</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., skin rash. Pregnant women are prohibited from the treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Severe/critical</td><td align="center" rowspan="1" colspan="1">Xue Bi Jing Injection (&#x08840;&#x05fc5;&#x051c0;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Safflower, peony root, Szechuan lovage rhizome, red sage root, Chinese angelica root</td><td align="center" rowspan="1" colspan="1">Hydroxysafflor yellow A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., itchiness. Pregnant women are prohibited from the treatment</td></tr><tr><td rowspan="2" colspan="1"/><td align="center" rowspan="1" colspan="1">Re Du Ning Injection (&#x070ed;&#x06bd2;&#x05b81;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Wormwood, honeysuckle flower, cape jasmine fruit</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., dizziness, chest tightness, thirstiness, diarrhea, nausea, vomit, skin rash, and itchiness. Allergic individuals are prohibited from the treatment</td></tr><tr><td align="center" rowspan="1" colspan="1">Tan Re Qing Injection (&#x075f0;&#x070ed;&#x06e05;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Baical skullcap root, bear bile, goat horn, honeysuckle flower, forsythia</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., dizziness, nausea, vomit, itchiness, and skin rash</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Critical</td><td align="center" rowspan="1" colspan="1">Shen Fu Injection (&#x053c2;&#x09644;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Red ginseng, Chinese aconite</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., tachycardia, skin rash, dizziness, headache, hiccup, tremor, dyspnea, nausea, visual abnormality, abnormality in liver function, and urinary retention. Newborns, allergic individuals, and individuals with allergic constitution are prohibited from the treatment</td></tr><tr><td rowspan="4" colspan="1"/><td align="center" rowspan="1" colspan="1">Sheng Mai Injection (&#x0751f;&#x08109;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Red ginseng, Ophiopogon, magnolia berry</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause an autoimmune response, i.e., anaphylactic shock. Newborns, pregnant women, allergic individuals, and individuals with allergic constitution are prohibited from the treatment</td></tr><tr><td align="center" rowspan="1" colspan="1">Shen Mai Injection (&#x053c2;&#x09ea6;&#x06ce8;&#x05c04;&#x06db2;)</td><td align="center" rowspan="1" colspan="1">Red ginseng, Ophiopogon</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause autoimmune response and adverse effect on treated patients, i.e., anaphylactic shock and damage to the body systems. Newborns, pregnant women, allergic individuals, and individuals with allergic constitution are prohibited from the treatment</td></tr><tr><td align="center" rowspan="1" colspan="1">Su He Xiang Pill (&#x082cf;&#x05408;&#x09999;&#x04e38;)</td><td align="center" rowspan="1" colspan="1">Storax, benzoin, borneol, musk, buffalo horn, sandalwood, agarwood, clove, nut grass, costus root, frankincense, long pepper fruit, largehead Atractylodes rhizome, gall nut, Cinnabaris</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Side effects are not known. Pregnant women are prohibited from the treatment</td></tr><tr><td align="center" rowspan="1" colspan="1">An Gong Niu Huang Pill (&#x05b89;&#x05bab;&#x0725b;&#x09ec4;&#x04e38;)</td><td align="center" rowspan="1" colspan="1">Buffalo horn, musk, pearl, realgar, coptis root, Cinnabaris, baical skullcap root, cape jasmine fruit, turmeric tuber, borneol</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">May cause autoimmune responses, i.e., hypothermia. Prescription guidance is unclear</td></tr></tbody></table><table-wrap-foot><fn><p>N/A: not available.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 4</label><caption><p>Summary of 2019-nCoV vaccine developments at different stages [<xref rid="B239" ref-type="bibr">239</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Vaccine name</th><th align="center" rowspan="1" colspan="1">Vaccine type/platform</th><th align="center" rowspan="1" colspan="1">Developer</th><th align="center" rowspan="1" colspan="1">Vaccine name</th><th align="center" rowspan="1" colspan="1">Vaccine type/platform</th><th align="center" rowspan="1" colspan="1">Developer</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ad5-nCoV<sup>&#x02217;&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">DNA/adenovirus type 5 vector</td><td align="center" rowspan="1" colspan="1">CanSino Biological Inc., Beijing Institute of Biotechnology</td><td align="center" rowspan="1" colspan="1">Vaxil Bio COVID-19 vaccine</td><td align="center" rowspan="1" colspan="1">Protein subunit/signal peptide combinations</td><td align="center" rowspan="1" colspan="1">Vaxil Bio</td></tr><tr><td align="left" rowspan="1" colspan="1">INO-4800</td><td align="center" rowspan="1" colspan="1">DNA/DNA plasmid, electroporation device</td><td align="center" rowspan="1" colspan="1">Inovio Pharmaceuticals</td><td align="center" rowspan="1" colspan="1">COVID-19S-Trimer</td><td align="center" rowspan="1" colspan="1">Protein subunit/pandemic adjuvant system</td><td align="center" rowspan="1" colspan="1">Clover Biopharmaceuticals Inc./GSK</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">DNA/S gene</td><td align="center" rowspan="1" colspan="1">Takis/Applied DNA Sciences/Evvivax</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/S protein</td><td align="center" rowspan="1" colspan="1">AJ Vaccine</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">DNA plasmid</td><td align="center" rowspan="1" colspan="1">Zydus Cadila</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/li-Key peptide</td><td align="center" rowspan="1" colspan="1">Generex/EpiVax</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Ad26/MVA boost</td><td align="center" rowspan="1" colspan="1">Janssen Pharmaceutical Companies</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/S protein</td><td align="center" rowspan="1" colspan="1">EpiVax/Univ. of Georgia</td></tr><tr><td align="left" rowspan="1" colspan="1">GV-MVA-VLP/vaccine</td><td align="center" rowspan="1" colspan="1">DNA/nonreplicating viral vector</td><td align="center" rowspan="1" colspan="1">GeoVax/BravoVax</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Protein subunit/S protein (baculovirus production)</td><td align="center" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="left" rowspan="1" colspan="1">ChAdOx-nCoV-19<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">DNA/nonreplicating viral vector</td><td align="center" rowspan="1" colspan="1">University of Oxford</td><td align="center" rowspan="1" colspan="1">N/A<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">Protein subunit/Full-length protein<break/>Matrix-MTM adjuvant</td><td align="center" rowspan="1" colspan="1">Novavax</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">DNA/nonreplicating viral vector, NasoVAX-S gene</td><td align="center" rowspan="1" colspan="1">Altimmune</td><td align="center" rowspan="1" colspan="1">Heat's gp96 based vaccine for COVID-19</td><td align="center" rowspan="1" colspan="1">Protein subunit/Heat's gp96 backbone to express antigen of COVID-19</td><td align="center" rowspan="1" colspan="1">Heat Biologics/Univ. of Miami</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">DNA/nonreplicating viral vector (Ad5 S)</td><td align="center" rowspan="1" colspan="1">Greffex</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/molecular clamp stabilized spike protein</td><td align="center" rowspan="1" colspan="1">University of Queensland/GSK</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">DNA/nonreplicating viral vector (VAAST); oral vaccine platform</td><td align="center" rowspan="1" colspan="1">Vaxart, Inc.</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/molecular clamp stabilized spike protein</td><td align="center" rowspan="1" colspan="1">University of Queensland/GSK</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">DNA vaccine/measles vector (replicating viral vector)</td><td align="center" rowspan="1" colspan="1">Vaxart, Inc.</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/S1 or RBD protein</td><td align="center" rowspan="1" colspan="1">Baylor College of Medicine</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">DNA vaccine/measles vector</td><td align="center" rowspan="1" colspan="1">Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/plant-based coronavirus</td><td align="center" rowspan="1" colspan="1">iBio/CC-Pharming</td></tr><tr><td align="left" rowspan="1" colspan="1">TNX-1800/COVID-19</td><td align="center" rowspan="1" colspan="1">DNA vaccine/horsepox vaccine platform-S gene</td><td align="center" rowspan="1" colspan="1">Tonix Pharma/Southern Research</td><td align="center" rowspan="1" colspan="1">N/A<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">Protein subunit/protein</td><td align="center" rowspan="1" colspan="1">VIDO-InterVac, University of Saskatchewan</td></tr><tr><td align="left" rowspan="1" colspan="1">mRNA-1273<sup>&#x02217;&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">mRNA/novel lipid nanoparticle</td><td align="center" rowspan="1" colspan="1">Moderna/NIAID</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/protein</td><td align="center" rowspan="1" colspan="1">University of Saskatchewan</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">mRNA vaccine/VLP-cocktail (S, M, E, N)/lipid nanoparticle</td><td align="center" rowspan="1" colspan="1">Fudan University/Shanghai JiaoTong University/RNACure Biopharma</td><td align="center" rowspan="1" colspan="1">Live attenuated virus<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">Deoptimized live attenuated vaccines</td><td align="center" rowspan="1" colspan="1">Codagenix/Serum Institute of India</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">mRNA vaccine/lipid nanoparticle/S and S-RBD antigen</td><td align="center" rowspan="1" colspan="1">Fudan University/Shanghai JiaoTong University/RNACure Biopharma</td><td align="center" rowspan="1" colspan="1">VLP Vaccine</td><td align="center" rowspan="1" colspan="1">Plant-derived VLP/four structural of rotavirus (VP2, VP4, VP6, and VP7)</td><td align="center" rowspan="1" colspan="1">Medicago Inc.</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">mRNAvaccine/LUNAR&#x000ae;-nanoparticle nonviral delivery system</td><td align="center" rowspan="1" colspan="1">Arcturus/Duke-NUS</td><td align="center" rowspan="1" colspan="1">Inactivated Vaccine</td><td align="center" rowspan="1" colspan="1">Formalin-inactivated+alum adjuvanted</td><td align="center" rowspan="1" colspan="1">Sinovac</td></tr><tr><td align="left" rowspan="1" colspan="1">BNT162<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">mRNA vaccine</td><td align="center" rowspan="1" colspan="1">BioNTech/Fosun Pharma/Pfizer</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">University of Hong Kong</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Self-amplifying RNA vaccine</td><td align="center" rowspan="1" colspan="1">Imperial College London</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Unknown/IPA's proprietary discovery platforms</td><td align="center" rowspan="1" colspan="1">ImmunoPrecise</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">mRNA</td><td align="center" rowspan="1" colspan="1">CureVac</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">MIGAL Galilee Research Institute</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein subunit/Drosophila S2 insect cell expression system VLPs</td><td align="center" rowspan="1" colspan="1">ExpreS2ion</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">Doherty Institute</td></tr><tr><td align="left" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Protein/S protein</td><td align="center" rowspan="1" colspan="1">WRAIR/USAMRIID</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">Tulane University</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;&#x02217;</sup>In clinical studies. <sup>&#x02217;</sup>Preparing for clinical studies. N/A: not available.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 5</label><caption><p>Summary of main therapeutic approaches proposed for COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Drug names</th><th align="center" rowspan="1" colspan="1">Original indication</th><th align="center" rowspan="1" colspan="1">Mechanism of action</th><th align="center" rowspan="1" colspan="1">Clinical status</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Chemical drugs</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Umifenovir</td><td align="center" rowspan="1" colspan="1">Influenza A &#x00026; B</td><td align="center" rowspan="1" colspan="1">Inhibition of binding of the virus to host cell membrane</td><td align="center" rowspan="1" colspan="1">Phase 4 trials for COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i001.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B122" ref-type="bibr">122</xref>&#x02013;<xref rid="B124" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chloroquine and derivatives</td><td align="center" rowspan="1" colspan="1">Malaria</td><td align="center" rowspan="1" colspan="1">Inhibition of lysosomal activity and signaling pathway in virus</td><td align="center" rowspan="1" colspan="1">Phase 2-3 trials for prophylaxis of COVID-19<break/>Phase 2-4 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i002.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B130" ref-type="bibr">130</xref>&#x02013;<xref rid="B140" ref-type="bibr">140</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lopinavir</td><td align="center" rowspan="1" colspan="1">HIV</td><td align="center" rowspan="1" colspan="1">Proposed inhibition of 3CLpro</td><td align="center" rowspan="1" colspan="1">Phase 2-4 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i003.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ritonavir</td><td align="center" rowspan="1" colspan="1">HIV</td><td align="center" rowspan="1" colspan="1">Proposed inhibition of 3CLpro</td><td align="center" rowspan="1" colspan="1">Phase 2-4 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i004.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Darunavir</td><td align="center" rowspan="1" colspan="1">HIV</td><td align="center" rowspan="1" colspan="1">Inhibition of viral maturation pathways</td><td align="center" rowspan="1" colspan="1">Phase 2-3 trials for the treatment of pneumonia caused by COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i005.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B164" ref-type="bibr">164</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Camostat mesylate</td><td align="center" rowspan="1" colspan="1">Pancreatic inflammation</td><td align="center" rowspan="1" colspan="1">Inhibition of viral entry into host cells</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i006.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Remdesivir</td><td align="center" rowspan="1" colspan="1">Ebola (proposed)</td><td align="center" rowspan="1" colspan="1">Inhibits viral RNA polymerase</td><td align="center" rowspan="1" colspan="1">Phase 3 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i007.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B188" ref-type="bibr">188</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Favipiravir</td><td align="center" rowspan="1" colspan="1">Influenza</td><td align="center" rowspan="1" colspan="1">Inhibits RdRp</td><td align="center" rowspan="1" colspan="1">Phase 3 and randomized trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i008.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B179" ref-type="bibr">179</xref>&#x02013;<xref rid="B182" ref-type="bibr">182</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ribavirin</td><td align="center" rowspan="1" colspan="1">HCV, RSV</td><td align="center" rowspan="1" colspan="1">Inhibition of viral RNA replication &#x00026; increased mutation in viral RNA</td><td align="center" rowspan="1" colspan="1">Phase 2 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i009.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B168" ref-type="bibr">168</xref>&#x02013;<xref rid="B172" ref-type="bibr">172</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Biologics</td><td rowspan="1" colspan="1">&#x02009;</td><td rowspan="1" colspan="1">&#x02009;</td><td rowspan="1" colspan="1">&#x02009;</td><td rowspan="1" colspan="1">&#x02009;</td><td rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;INF-<italic>&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1">HCV, HCL, melanoma</td><td align="center" rowspan="1" colspan="1">Invoking interferon response through exogenous interferons</td><td align="center" rowspan="1" colspan="1">Multiple randomized trials for COVID-19 patients</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i010.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B209" ref-type="bibr">209</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Convalescent plasma</td><td align="center" rowspan="1" colspan="1">Influenza, Ebola, SARS, MERS</td><td align="center" rowspan="1" colspan="1">Suppression of viremia</td><td align="center" rowspan="1" colspan="1">Multiple randomized trials for COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i011.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B212" ref-type="bibr">212</xref>, <xref rid="B213" ref-type="bibr">213</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Human monoclonal antibodies</td><td align="center" rowspan="1" colspan="1">Nil</td><td align="center" rowspan="1" colspan="1">Binding to the receptor-binding domain of COVID-2019</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i012.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B214" ref-type="bibr">214</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;mRNA-1273, Ad5-nCoV</td><td align="center" rowspan="1" colspan="1">Nil</td><td align="center" rowspan="1" colspan="1">Eliciting immune response via host cell-expressed viral protein</td><td align="center" rowspan="1" colspan="1">Phase 1 clinical trials for prevention of COVID-19 infection</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i013.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B237" ref-type="bibr">237</xref>, <xref rid="B238" ref-type="bibr">238</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;B &#x00026; T cell epitopes</td><td align="center" rowspan="1" colspan="1">SARS-CoV</td><td align="center" rowspan="1" colspan="1">Invoke immune targeting of these epitopes</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i014.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B251" ref-type="bibr">251</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MSC</td><td align="center" rowspan="1" colspan="1">Heart disease, Parkinson's disease, lung cancer, type 1 diabetes, stroke</td><td align="center" rowspan="1" colspan="1">Promotes endothelial repair and reduce inflammation through secretion of soluble paracrine factors</td><td align="center" rowspan="1" colspan="1">Phase 0-1 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i015.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B235" ref-type="bibr">235</xref>, <xref rid="B236" ref-type="bibr">236</xref>]</td></tr><tr><td align="left" colspan="6" rowspan="1">TCM/herbal remedies</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lian Hua Qing Wen Capsule</td><td align="center" rowspan="1" colspan="1">Influenza</td><td align="center" rowspan="1" colspan="1">Downregulates MCP-1 which decreases monocytes chemotaxis to infection foci</td><td align="center" rowspan="1" colspan="1">Phase 4 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i016.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B252" ref-type="bibr">252</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Xue Bi Jing Injection</td><td align="center" rowspan="1" colspan="1">Inflammation</td><td align="center" rowspan="1" colspan="1">Inhibition of proinflammatory Th17 cells and reduced inflammatory cytokines TNF-<italic>&#x003b1;</italic> and IL-6</td><td align="center" rowspan="1" colspan="1">Phase 0-4 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i017.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B232" ref-type="bibr">232</xref>, <xref rid="B253" ref-type="bibr">253</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Re Du Ning Injection</td><td align="center" rowspan="1" colspan="1">URTI</td><td align="center" rowspan="1" colspan="1">Suppressing secretion of inflammatory mediators</td><td align="center" rowspan="1" colspan="1">Phase 0 trial for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i018.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B254" ref-type="bibr">254</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Xi Yan Ping Injection</td><td align="center" rowspan="1" colspan="1">HFMD, URTI</td><td align="center" rowspan="1" colspan="1">Inhibition of NF-<italic>&#x003ba;</italic>B and MAPK-mediated inflammatory responses</td><td align="center" rowspan="1" colspan="1">Phase 0 trial for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i019.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B255" ref-type="bibr">255</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tan Re Qing Injection/Capsule</td><td align="center" rowspan="1" colspan="1">URTI, COPD</td><td align="center" rowspan="1" colspan="1">Inhibition of NF-<italic>&#x003ba;</italic>B and MAPK-mediated inflammatory responses</td><td align="center" rowspan="1" colspan="1">Phase 0-4 trials for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i020.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B256" ref-type="bibr">256</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Shen Fu Injection</td><td align="center" rowspan="1" colspan="1">Congestive heart failure, ischemic stroke</td><td align="center" rowspan="1" colspan="1">Affect various immune signaling pathways to have a protective effect against organ damage</td><td align="center" rowspan="1" colspan="1">Phase 4 trial for the treatment of COVID-19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="RESEARCH2020-6925296.tab5.i021.jpg"/>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B257" ref-type="bibr">257</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: 3CLpro: 3C-like protease; COPD: chronic obstructive pulmonary disease; HCL: hairy cell leukemia; HCV: hepatitis C virus; HFMD: hand, foot, and mouth disease; HIV: human immunodeficiency virus; IL-6: interleukin 6; INF-<italic>&#x003b1;</italic>: interferon-alpha; MAPK: mitogen-activated protein kinase; MCP-1: monocyte chemoattractant protein-1; MERS-CoV: Middle East respiratory syndrome-coronavirus; MSC: mesenchymal stem cell; NF-<italic>&#x003ba;</italic>B: nuclear factor kappa-light-chain-enhancer of activated B cells; RdRp: RNA-dependent RNA polymerase; RNA: ribonucleic acid; RSV: respiratory syncytial virus; SARS-CoV: severe acute respiratory syndrome-coronavirus; Th17: T helper 17; TNF-<italic>&#x003b1;</italic>: tumor necrosis factor-alpha; URTI: upper respiratory tract infection.</p></fn></table-wrap-foot></table-wrap></floats-group></article>